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Abstract: Embryonal tumors represent an important group of childhood malignancies. Among them,
medulloblastoma (MB) is a tumor of the central nervous system that arises in the cerebellum, while
neuroblastoma (NB) is an extra cranial solid tumor that originates from the sympathetic nervous system.
Despite intense multimodality therapy, the survival rates for high-risk patients remain very little. There-
fore, novel therapeutic strategies are urgently required. Kinases have drawn much of the attention for the
design of new targeted therapies due to their role in oncogenic transformation. In the present thesis, we
used a loss-of-function kinome-wide RNA interference (RNAi) screen aimed at identifying new kinases
which are critical for promoting drug resistance, a major cause of treatment failure in neuroblastoma.
Several kinases have been identified amongst which the fibroblast growth factor receptor 2 (FGFR2)
represented the most attractive candidate for further validation studies. RNAi mediated silencing of
FGFR2, as well as pharmacological inhibition of the kinase activity of FGFR2, sensitized NB cells to
cisplatin, a commonly used chemotherapy for the treatment of neuroblastoma. Analysis of the expression
of FGFR2 in primary NB revealed that FGFR2, as well as its ligand FGF-2 are consistently expressed,
indicating the presence of an autocrine loop. Moreover, a cDNA microarray analysis comprising data
of over 250 NB samples revealed that FGFR2 over-expression correlates with MYCN amplification and
advanced stage disease, demonstrating for the first time the clinical relevance of FGFR2 in neuroblas-
toma. Receptor tyrosine kinases (RTK) and their downstream signalling cascades have been shown to
play a crucial role in cancer development. In neuroblastoma and medulloblastoma, the phosphoinosi-
tide 3-kinase (PI3K) has been found to have an important role in mediating pro- survival signals from
different growth factor receptors such as IGF-1R or ERBB2. In a further project, we have analyzed
the therapeutic potential of targeting the IGF-1R/PI3K axis in MB and NB with R1507a humanized
monoclonal antibody against the IGF-1R, and PIK75 class IA PI3K inhibitor. Our findings demonstrate
that a subset of NB and MB cell lines were responsive to these agents, particularly when combined with
conventional chemotherapies. However, other agents targeting different RTKs or PI3K have previously
demonstrated to have anti-proliferative effects in preclinical models, but translating the results into a clin-
ical setting has been rather challenging. A better knowledge of the mechanisms of action of the signalling
components downstream of RTKs may contribute to the identification of novel and suitable therapeutic
strategies. In order to gain further insights into the mechanisms underlying the role of the different PI3K
isoforms in MB in cell survival, we analyzed the impact of RNAi-mediated down-regulation of p110￿ and
p110￿ on the global gene expression of MB cells by means of DNA microarrays. By using bioinformatic
tools, a comparative analysis of the sets of genes, which were differentially expressed, revealed c-Myc
as the transcription factor, whose network of genes was mostly deregulated. This transcriptional net-
work included the ￿-subunit of the receptor for the leukemia inhibitory factor (LIFR￿) as target gene,
which was one of the most significantly deregulated genes upon the downregulation of PIK3CA, encoding
for the isoform p110￿. LIFR￿ expression was found elevated in primary MB, in comparison to normal
cerebellum. Targeting the LIFR￿ by RNAi or by a neutralizing antibody significantly impaired MB cell
proliferation. Being a downstream effector of the well characterized oncogenes PIK3CA and MYC in
MB, LIFR represents an interesting target gene for further analysis. All together, the results obtained
in this thesis provide insights into the role of kinase signalling in neuroblastoma and medulloblastoma.
Further validations and clinical-oriented studies will hopefully contribute to the improvement of the
therapeutic strategies for the treatment of these young patients. ZUSAMMENFASSUNG Embryonale
Tumoren entstehen durch Entartung unreifer Zellen während der embryonalen Organ- und Gewebeen-
twicklung. Zu diesen zählen Medulloblastome (MB), bösartige Tumore des zentralen Nervensystems, die
im Kleinhirn entstehen, und Neuroblastome (NB), extrakranielle solide Tumore des unreifen sympathis-
chen Nervensystems. Die Behandlung solcher Tumore besteht aus der operativen Tumorentfernung und
einer Kombination aus intensiver Chemo- und Strahlentherapie. Trotz dieser aggressiven therapeutis-
chen Ansätze sind die Überlebensraten für Hochrisiko-Patienten nur sehr gering. Neue therapeutische
Strategien sind daher dringend erforderlich. Proteinkinasen stehen im Forschungsinteresse für die En-
twicklung neuartiger zielgerichteter Krebstherapien, da sie von zahlreichen genetischen Veränderungen
bei der Entstehung verschiedener Krebsarten betroffen sind. Das Hauptziel der vorliegenden Dissertation
lag in der Identifizierung neuer Protein- und Lipidkinasen, die für die Regulierung der Resistenzmecha-
nismen gegenüber Chemotherapeutika zuständig sind. Chemoresistenz stellt eine der Hauptursachen für
Therapieversagen in NB Patienten dar. Daher wurde ein RNA Interferenz (RNAi) Screen in Kombination
mit Cisplatin, eines der meistverwendeten Chemotherapeutika, durchgeführt. Somit war eine systematis-
che Untersuchung aller Kinasen des menschlichen Genoms möglich, die aufgrund der Herunterregulierung
ihrer Aktivität die Empfindlichkeit zu Cisplatin erhöht haben. Mehrere Kinasen wurden dadurch iden-
tifiziert, darunter der Rezeptor für Fibroblasten-Wachstumsfaktoren FGFR2. Um die klinische Relevanz
von FGFR2 zu validieren, wurde die Expression von FGFR2 und dessen Ligand FGF-2 in primären
NB Tumoren analysiert. Sowohl FGFR2 als auch FGF-2 wurden detektiert, was auf die Anwesenheit
einer autokrinen Schleife hinweist. Des Weiteren zeigten DNA Microarray Analysen mit Daten von über
250 Neuroblastom Patienten, dass die Expression von FGFR2 mit einer MYCN-Amplifikation korreliert,
einem Tumormarker schlechter Prognose. Schliesslich konnte gezeigt werden, dass die Hemmung von
FGFR2 mit einem niedermolekularen Inhibitor die Sensitivität gegenüber Cisplatin in NB Zellen erhöht,
was auf seine mögliche Verwendung als Angriffspunkt für eine medikamentöse Tumortherapie hindeutet.
Rezeptor-Tyrosin-Kinasen (RTK) und die von ihnen regulierten Signalkaskaden spielen eine entscheidende
Rolle bei der Krebsentstehung. Phosphoinositid-3-Kinasen (PI3K) werden dabei als wichtige Vermittler
von Wachstumssignalen, die aus verschiedenen Rezeptoren stammen, bezeichnet. In einem weiteren Pro-
jekt wurden verschiedene Ansätze verwendet, um das therapeutische Potenzial der IGF-1R/PI3K-Achse
in NB und MB zu analysieren. Daher wurde das antiproliferative Potenzial von R1507, ein monok-
lonaler Antikörper gegen IGF-1R, und PIK75, ein isoform-selektiver Inhibitor der Klasse IA PI3K in
verschiedene NB und MB Zelllinien getestet. Beide Wirkstoffe zeigten antiproliferative Effekte in einem
Teil der Zelllinien. Zusätzlich wurden diese Effekte in Anwesenheit von Chemotherapeutika verstärkt. In
ähnlicher Weise haben auch andere Studien nahe gelegt, dass die Effektivität einzelner Inhibitoren durch
Kombination mit anderen Inhibitoren oder Chemotherapeutika deutlich gesteigert werden kann. Eine
bessere Kenntnis über die Wirkmechanismen von PI3K wird daher zur Entwicklung geeigneter Kombina-
tionen beitragen. Ein weiteres Projekt dieser Dissertation war daher die Identifizierung MB- spezifischer
PI3K-regulierter Gene. Zu diesem Zweck wurden MB Zellen, in denen die verschiedenen PI3K Isoformen
PIK3CA und PIK3CD herunterreguliert waren, einer cDNA Microarray Analyse unterzogen, um ihre Ex-
pressionsprofile zu analysieren. Dieser Versuch ergab eine Liste von Genen, die spezifisch durch p110￿, die
vom PIK3CA kodiert wird oder p110￿, die vom PIK3CD kodiert wird, reguliert wurden. Mithilfe einer
bioinformatischen Analyse war die Identifizierung deregulierter, transkriptioneller Netzwerke möglich.
Daraus ergab sich c-Myc als der Transkriptionsfaktor, dessen Gene am signifikantesten differentiell de-
primiert wurden. Unter diesen befand sich auch der LIF Rezeptor (LIFR￿). Im Vergleich zu normalem
Kleinhirn zeigten MB Zellen eine erhöhte LIFR Expression. Um die funktionelle Relevanz von LIFR im
Medulloblastoma zu beurteilen, wurde seine Funktion mithilfe von siRNAs herunterreguliert oder durch
einen Antikörper gehemmt. Dies führte zu einer verringerten Zellproliferation. Da LIFR unter der Reg-
ulierung bekannter Onkogene (PIK3CA und MYC) liegt, stellt es einen interessanten Kandidaten für
weitere Studien dar. Zusammengefasst trägt die vorliegende Doktorarbeit zu einem besseren Verständnis
über die Rolle von Kinasen im Signalsystem von Neuroblastom und Medulloblastom bei. Weitere Va-
lidierungen sowie klinisch-orientierte Studien werden hoffentlich zu einer verbesserten Behandlung von
Patienten mit diesen Krebsarten beitragen.
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 SUMMARY 
 
Embryonal tumors represent an important group of childhood 
malignancies. Among them, medulloblastoma (MB) is a tumor of the 
central nervous system that arises in the cerebellum, while 
neuroblastoma (NB) is an extra cranial solid tumor that originates from 
the sympathetic nervous system. Despite intense multimodality 
therapy, the survival rates for high-risk patients remain very little. 
Therefore, novel therapeutic strategies are urgently required.  
Kinases have drawn much of the attention for the design of new 
targeted therapies due to their role in oncogenic transformation. In the 
present thesis, we used a loss-of-function kinome-wide RNA 
interference (RNAi) screen aimed at identifying new kinases which are 
critical for promoting drug resistance, a major cause of treatment 
failure in neuroblastoma. Several kinases have been identified amongst 
which the fibroblast growth factor receptor 2 (FGFR2) represented the 
most attractive candidate for further validation studies. RNAi mediated 
silencing of FGFR2, as well as pharmacological inhibition of the 
kinase activity of FGFR2, sensitized NB cells to cisplatin, a commonly 
used chemotherapy for the treatment of neuroblastoma. Analysis of the 
expression of FGFR2 in primary NB revealed that FGFR2, as well as 
its ligand FGF-2 are consistently expressed, indicating the presence of 
SUMMARY 
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an autocrine loop. Moreover, a cDNA microarray analysis comprising 
data of over 250 NB samples revealed that FGFR2 over-expression 
correlates with MYCN amplification and advanced stage disease, 
demonstrating for the first time the clinical relevance of FGFR2 in 
neuroblastoma. 
Receptor tyrosine kinases (RTK) and their downstream signalling 
cascades have been shown to play a crucial role in cancer development. 
In neuroblastoma and medulloblastoma, the phosphoinositide 3-kinase 
(PI3K) has been found to have an important role in mediating pro-
survival signals from different growth factor receptors such as IGF-1R 
or ERBB2. In a further project, we have analyzed the therapeutic 
potential of targeting the IGF-1R/PI3K axis in MB and NB with 
R1507a humanized monoclonal antibody against the IGF-1R, and 
PIK75 class IA PI3K inhibitor. Our findings demonstrate that a subset 
of NB and MB cell lines were responsive to these agents, particularly 
when combined with conventional chemotherapies. However, other 
agents targeting different RTKs or PI3K have previously demonstrated 
to have anti-proliferative effects in preclinical models, but translating 
the results into a clinical setting has been rather challenging. A better 
knowledge of the mechanisms of action of the signalling components 
downstream of RTKs may contribute to the identification of novel and 
suitable therapeutic strategies. 
In order to gain further insights into the mechanisms underlying the 
role of the different PI3K isoforms in MB in cell survival, we analyzed 
the impact of RNAi-mediated down-regulation of p110α and p110δ on 
the global gene expression of MB cells by means of DNA microarrays. 
By using bioinformatic tools, a comparative analysis of the sets of 
genes, which were differentially expressed, revealed c-Myc as the 
transcription factor, whose network of genes was mostly deregulated. 
This transcriptional network included the α-subunit of the receptor for 
the leukemia inhibitory factor (LIFRα) as target gene, which was one 
of the most significantly deregulated genes upon the downregulation of 
PIK3CA, encoding for the isoform p110α. LIFRα expression was found 
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elevated in primary MB, in comparison to normal cerebellum. 
Targeting the LIFRα by RNAi or by a neutralizing antibody 
significantly impaired MB cell proliferation. Being a downstream 
effector of the well characterized oncogenes PIK3CA and MYC in MB, 
LIFR represents an interesting target gene for further analysis. 
All together, the results obtained in this thesis provide insights into the 
role of kinase signalling in neuroblastoma and medulloblastoma. 
Further validations and clinical-oriented studies will hopefully 
contribute to the improvement of the therapeutic strategies for the 
treatment of these young patients. 
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 ZUSAMMENFASSUNG 
 
Embryonale Tumoren entstehen durch Entartung unreifer Zellen 
während der embryonalen Organ- und Gewebeentwicklung. Zu diesen 
zählen Medulloblastome (MB), bösartige Tumore des zentralen 
Nervensystems, die im Kleinhirn entstehen, und Neuroblastome (NB), 
extrakranielle solide Tumore des unreifen sympathischen 
Nervensystems. Die Behandlung solcher Tumore besteht aus der 
operativen Tumorentfernung und einer Kombination aus intensiver 
Chemo- und Strahlentherapie. Trotz dieser aggressiven therapeutischen 
Ansätze sind die Überlebensraten für Hochrisiko-Patienten nur sehr 
gering. Neue therapeutische Strategien sind daher dringend 
erforderlich. 
Proteinkinasen stehen im Forschungsinteresse für die Entwicklung 
neuartiger zielgerichteter Krebstherapien, da sie von zahlreichen 
genetischen Veränderungen bei der Entstehung verschiedener 
Krebsarten betroffen sind. Das Hauptziel der vorliegenden Dissertation 
lag in der Identifizierung neuer Protein- und Lipidkinasen, die für die 
Regulierung der Resistenzmechanismen gegenüber Chemotherapeutika 
zuständig sind. Chemoresistenz stellt eine der Hauptursachen für 
Therapieversagen in NB Patienten dar. Daher wurde ein RNA 
Interferenz (RNAi) Screen in Kombination mit Cisplatin, eines der 
ZUSAMMENFASSUNG 
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meistverwendeten Chemotherapeutika, durchgeführt. Somit war eine 
systematische Untersuchung aller Kinasen des menschlichen Genoms 
möglich, die aufgrund der Herunterregulierung ihrer Aktivität die 
Empfindlichkeit zu Cisplatin erhöht haben. Mehrere Kinasen wurden 
dadurch identifiziert, darunter der Rezeptor für Fibroblasten-
Wachstumsfaktoren FGFR2. Um die klinische Relevanz von FGFR2 
zu validieren, wurde die Expression von FGFR2 und dessen Ligand 
FGF-2 in primären NB Tumoren analysiert. Sowohl FGFR2 als auch 
FGF-2 wurden detektiert, was auf die Anwesenheit einer autokrinen 
Schleife hinweist. Des Weiteren zeigten DNA Microarray Analysen 
mit Daten von über 250 Neuroblastom Patienten, dass die Expression 
von FGFR2  mit einer MYCN-Amplifikation korreliert, einem 
Tumormarker schlechter Prognose. Schliesslich konnte gezeigt werden, 
dass die Hemmung von FGFR2 mit einem niedermolekularen Inhibitor 
die Sensitivität gegenüber Cisplatin in NB Zellen erhöht, was auf seine 
mögliche Verwendung als Angriffspunkt für eine medikamentöse 
Tumortherapie hindeutet. 
Rezeptor-Tyrosin-Kinasen (RTK) und die von ihnen regulierten 
Signalkaskaden spielen eine entscheidende Rolle bei der 
Krebsentstehung. Phosphoinositid-3-Kinasen (PI3K) werden dabei als 
wichtige Vermittler von Wachstumssignalen, die aus verschiedenen 
Rezeptoren stammen, bezeichnet. In einem weiteren Projekt wurden 
verschiedene Ansätze verwendet, um das therapeutische Potenzial der 
IGF-1R/PI3K-Achse in NB und MB zu analysieren. Daher wurde das 
antiproliferative Potenzial von R1507, ein monoklonaler Antikörper 
gegen IGF-1R, und PIK75, ein isoform-selektiver Inhibitor der Klasse 
IA PI3K in verschiedene NB und MB Zelllinien getestet. Beide 
Wirkstoffe zeigten antiproliferative Effekte in einem Teil der 
Zelllinien. Zusätzlich wurden diese Effekte in Anwesenheit von 
Chemotherapeutika verstärkt. In ähnlicher Weise haben auch andere 
Studien nahe gelegt, dass die Effektivität einzelner Inhibitoren durch 
Kombination mit anderen Inhibitoren oder Chemotherapeutika deutlich 
gesteigert werden kann. Eine bessere Kenntnis über die 
  ZUSAMMENFASSUNG 
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Wirkmechanismen von PI3K wird daher zur Entwicklung geeigneter 
Kombinationen beitragen. 
Ein weiteres Projekt dieser Dissertation war daher die Identifizierung 
MB-spezifischer PI3K-regulierter Gene. Zu diesem Zweck wurden MB 
Zellen, in denen die verschiedenen PI3K Isoformen PIK3CA und 
PIK3CD herunterreguliert waren, einer cDNA Microarray Analyse 
unterzogen, um ihre Expressionsprofile zu analysieren. Dieser Versuch 
ergab eine Liste von Genen, die spezifisch durch p110α, die vom  
PIK3CA kodiert wird oder p110δ, die vom PIK3CD kodiert wird, 
reguliert wurden. Mithilfe einer bioinformatischen Analyse war die 
Identifizierung deregulierter, transkriptioneller Netzwerke möglich. 
Daraus ergab sich c-Myc als der Transkriptionsfaktor, dessen Gene am 
signifikantesten differentiell deprimiert wurden. Unter diesen befand 
sich auch der LIF Rezeptor (LIFRα). Im Vergleich zu normalem 
Kleinhirn zeigten MB Zellen eine erhöhte LIFR Expression. Um die 
funktionelle Relevanz von LIFR im Medulloblastoma zu beurteilen, 
wurde seine Funktion mithilfe von siRNAs herunterreguliert oder 
durch einen Antikörper gehemmt. Dies führte zu einer verringerten 
Zellproliferation. Da LIFR unter der Regulierung bekannter Onkogene 
(PIK3CA und MYC) liegt, stellt es einen interessanten Kandidaten für 
weitere Studien dar. 
Zusammengefasst trägt die vorliegende Doktorarbeit zu einem besseren 
Verständnis über die Rolle von Kinasen im Signalsystem von 
Neuroblastom und Medulloblastom bei. Weitere Validierungen sowie 
klinisch-orientierte Studien werden hoffentlich zu einer verbesserten 
Behandlung von Patienten mit diesen Krebsarten beitragen. 
  9 
 
 
 
CHAPTER 1 
1 INTRODUCTION 
 
1.1 Neuroblastoma 
Neuroblastoma is an embryonal tumor that arises from the developing 
neural crest tissue [1]. Tumors can therefore develop anywhere in the 
sympathetic system, most of them arising in the adrenal medulla. Other 
common sites of the disease are neck, chest, abdomen and pelvis [2]. 
Neuroblastoma is the most frequently diagnosed cancer during the first 
year of life, the median age at the time of the diagnosis being 17 months 
[3, 4]. It accounts for 7-10 % of all cancers in children younger than 15 
years and around 15% of all childhood cancer related mortality [5]. 
Neuroblastomas exhibit very heterogeneous clinical behaviors. On the one 
hand, a subset of tumors undergo spontaneous and complete regression of 
the tumor with little or no therapy, while other tumors show rapid 
progression and are resistant to intensive multimodality therapies [2]. 
Approximately half of all cases are classified as high-risk for disease 
relapse at the time of diagnosis. Although the outcomes for patients with 
neuroblastoma have substantially improved in the past few decades, this 
improvement has mainly benefited patients with the more benign form of 
the disease. The overall survival rate for high-risk neuroblastoma patients 
is still less than 40% [6, 7]. Many efforts have been done in the past years, 
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and are still ongoing, to understand the biology of neuroblastoma and to 
better stratify patients into risk groups. This will definitely help to develop 
more specific therapies for patient subgroups and hopefully improve the 
outcomes for neuroblastoma patients.  
1.1.1 Genetic alterations 
Neuroblastoma predisposition 
Recent studies utilizing single nucleotide polymorphism (SNP) arrays of a 
large number of neuroblastoma patients have made genome-wide 
association studies (GWAS) possible, which has led to the identification 
of multiple common genetic variations that predispose to familial or 
sporadic neuroblastoma.  
Familial neuroblastoma is extremely rare, it accounts for only 1-2% of 
neuroblastoma cases [8-10]. The first identified predisposition gene in 
familial neuroblastoma was the paired-like homebox 2B gene (PHOX2B), 
which encodes for a transcription factor that is essential in the regulation 
of neurogenesis [11, 12]. Loss-of-function mutations in PHOX2B were, in 
most of the cases, associated with abnormalities of neural crest derived 
tissues [11, 12]. Germline mutations in the anaplastic lymphoma kinase 
(ALK) gene were subsequently identified in most of the hereditary 
neuroblastoma [13]. These mutations are found within the coding exons of 
its tyrosine kinase domain and result in constitutive activation of the ALK 
oncogene. ALK mutations are also found in 5 to 15% of somatically 
acquired neuroblastomas, underlying its importance for the development 
of neuroblastoma. Mutations in ALK and PHOX2B account for the 
majority of hereditary cases, but additional genes may still be discovered. 
In sporadic neuroblastoma cases, three common alleles with risk 
polymorphism have been identified, which are associated with high-risk 
neuroblastomas. These common SNP variations are found within the 
genes FLJ22536 at chromosome band 6p22.3, BARD1 at 2q35 and LMO1 
at 11p15 [14-17]. The identification of these SNP predisposition loci 
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marks areas of the genome in which somatically acquired variations 
contribute to disease progression. 
Somatically acquired genetic variations 
Chromosomal aberrations in neuroblastoma include loss or gain of 
genetical material. One of the first genetic aberrations found in 
neuroblastoma that could be consistently used as a biomarker for clinical 
phenotyping is genomic amplification of MYCN at chromosome band 
2p24 [18-20]. Approximately 20% of primary tumors display 
amplification of MYCN, which correlates with advanced stage disease and 
with adverse patient outcome [21]. Other DNA copy number aberrations 
have a prognostic value as well. Loss of heterozygosity (LOH) at 
chromosome 1p is identified in about one third of neuroblastomas and is 
highly associated with MYCN amplification and advanced disease stage 
[22-24]. There is evidence that allelic loss of 1p36 predicts an increased 
risk of relapse in patients with localized tumors [25, 26]. Despite intensive 
investigation, there is little known about tumor suppressor genes at 1p36 
that are important for neuroblastoma pathogenesis. Allelic loss at 
chromosome 11q, most frequently found at 11q23, is present in 35-45% of 
primary tumors [27]. It is rarely seen in tumors with MYCN amplification, 
but correlates with other high-risk features, such as advanced stage, 
unfavorable histology and older age [27, 28]. The most frequent allelic 
gain is at chromosome 17q, which is identified in over 50% of primary 
tumors [29, 30]. It results from unbalanced translocations and is associated 
with decreased survival [30, 31]. Breakpoints vary significantly, but the 
most commonly affected region is at 17q22. Candidate genes 
overexpressed as a consequence of 17q gain include BIRC5 (survivin), 
NME1 and PPMID [32-34]. The exact role of these genes in 
neuroblastoma oncogenesis remains yet to be studied. 
The total DNA content (ploidy) is considered to be a valuable prognostic 
factor as well and is frequently used for patient risk stratification. DNA 
copy-number aberrations are classified into two categories: whole-
chromosome gains or segmental chromosomal aberrations [2, 35]. Tumors 
with whole chromosome gains or losses display hyperdiploidy are 
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associated with lower risk disease and favorable outcomes. Segmental 
chromosomal aberrations are associated with high-risk disease and worse 
outcomes. A whole genome copy number analysis that included about 500 
neuroblastoma samples demonstrated that the strongest predictor of 
relapse was the presence of segmental chromosomal alterations, 
independently of other prognostic factors including age, stage, and MYCN 
status [35].  
1.1.2 Patient subgroups and therapeutical approaches 
Due to the biological heterogeneity of the tumors in newly diagnosed 
neuroblastomas, it has been difficult to develop a risk-stratification system 
that classifies patient subgroups. In an effort to improve the classification 
scheme, a large international consortium analyzed data of 8800 patients 
between 1990 and 2002 and proposed the new International 
Neuroblastoma Risk Group (INRG) classification system [36]. This 
system classifies patient groups based on the assessment of 13 prognostic 
factors, including age at diagnosis, INRG tumor stage histologic category, 
grade of tumor differentiation, DNA ploidy and copy number status at the 
MYCN oncogene locus and at chromosome 11q. Four clinical risk groups 
with different survival rates have been proposed: high-risk-, intermediate-
risk-, low-risk patients and patients with tumor stage 4S. An overview of 
the different risk categories is presented in Table 1-1. 
The advances made by the INRG committee have facilitated the selection 
of treatment regimens for neuroblastoma patients. Despite the improved 
risk-based therapies, there is still an ongoing interest in discovering new 
tumor markers with prognostic value to more precisely assign patients to 
appropriate therapy. Especially in the case of high-risk patients, for which, 
as described below, the survival rate remains dismal. 
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Variable 
 
 
Prognostic Category 
 
 
Low Risk Intermediate Risk High Risk Tumor Stage 4S 
 
Pattern of 
disease 
 
Localized 
tumor 
 
Localized tumor 
with locoregional 
lymph-node 
extension; 
metastases to bone 
marrow and bone 
in infants 
 
Metastases to bone marrow 
and bone (except in infants) 
 
Metastases to 
liver and skin 
(with minimal 
bone marrow 
involvement) in 
infants 
 
Tumor 
genomics 
Whole-
chromosome 
gains 
 
Whole-
chromosome gains 
Segmental chromosomal 
aberrations 
Whole-
chromosome 
gains 
Treatment Surgery Moderate-intensity 
chemotherapy; 
surgery 
Dose-intensive 
chemotherapy, surgery, and 
external beam radiotherapy 
to primary tumor and 
resistant metastatic sites; 
myeloablative 
chemotherapy with 
autologous hematopoietic 
stem-cell rescue; 
isotretinoin with anti-GD2 
immunotherapy 
 
Supportive care 
Survival 
rate  
> 98 % 90-95 % 40 to 50 % > 90 % 
Table 1-1. Patient stratification and risk adapted treatments (adapted from 
[21]). 
Low-risk patients 
Low-risk patients are those younger than one year at the time of diagnosis. 
They present with localized tumors, with whole chromosome gains and 
lack MYCN amplification [36]. The treatment of these patients usually 
consists of surgical tumor resection and, only in some cases, is followed 
by low dose chemotherapy (carboplatin, doxorubicin or etoposide) [21, 
37]. This patient group has an excellent outcome with a disease-free 
survival rate > 98% [21]. Stage 4S disease is considered a low-risk group, 
because of its unique favorable biological feature and its high incidence of 
tumor regression. The treatment is highly dependent on the clinical 
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presentation. In most of the cases, only supportive care is required. The 
disease free survival rate for patients with 4S tumors is > 90% [38, 39].  
Intermediate-risk patients 
Intermediate-risk patients are those generally older than one year at the 
time of diagnosis and present with tumors spreading to locoregional lymph 
nodes or bone marrow. Genetic alterations in these tumors are often whole 
chromosomal gains, which are associated with a more favorable outcome. 
For this patient group, treatment includes surgery followed by subsequent 
moderate chemotherapy. The outcome for intermediate risk-patients 
ranges between 90 to 95% [21]. 
High risk patients 
Patients older than one year and presenting with tumors that harbor 
segmental chromosomal aberrations have an unfavorable outcome are, 
therefore, considered high-risk patients. Current treatments for high-risk 
neuroblastomas include intensive chemotherapy cycles prior to surgery. It 
has been shown that increasing doses of induction chemotherapy are 
associated with improved response rates [40]. The most commonly used 
regimen consists of dose-intensive cycles of cisplatin and etoposide 
alternating with vincristine, doxorubicin, and cyclophosphamide [41].  
Myeloablative chemotherapy administered after the induction therapy and 
followed by autologous stem cell transplantation has been shown to 
improve disease-free survival rates [7, 42] and is considered by many 
groups to be part of the standard treatment of high-risk neuroblastoma 
[21]. Following myeloablation, patients are frequently treated with 13-cis-
retinoic acid in order to induce terminal differentiation of neuroblastoma 
and to eliminate residual cancer cells. Although most high-risk tumors 
initially respond to the therapy, there is a high incidence of relapse (50 - 
60%) and for this patient group there is no treatment known to be curative. 
The presence of residual cancer cells after chemotherapy that display 
acquired drug resistance, represent the major obstacle for successful 
treatment in this context. 
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1.2 Medulloblastoma 
Medulloblastoma is an embryonal tumor which arises from immature 
neuronal precursors in the cerebellum [43]. It is the most common brain 
tumor in children with an incidence peak at 8 years of age. It is considered 
as a grade IV tumor by the WHO (World Health Organization) due to its 
malignant phenotype. [44]. Medulloblastoma patients can be characterized 
as high-risk and standard-risk patients based on the clinical criteria and 
tumor histology, as described below and summarized in Table 1-2. 
Survival for children with medulloblastoma varies according to these 
parameters. However, brain tumors generally show worse prognosis 
compared to other pediatric malignancies, and, therefore, account for over 
25% of all cancer-related deaths in childhood [45].  
1.2.1 Histopathological classification 
Medulloblastomas are classified based on their histological features and 
four variants are recognized: classical medulloblastoma, desmoplastic 
medulloblastoma (D/N), medulloblastoma with extensive nodularity 
(MBEN) and large-cell anaplastic medulloblastoma (LC/A). Two further 
subtypes, melanotic medulloblastoma and medullomyoblastoma, are rarely 
seen and because of their similar clinical and genetic features to the other 
medulloblastoma classes, they are often classified as those [44].  Classical 
medulloblastoma accounts for 73% of all medulloblastomas, while large-
cell anaplastic medulloblastoma makes up about 17% and the 
desmoplastic subtype about 10%, respectively [46]. MBEN and D/N in 
general have a better outcome than classical medulloblastoma, while 
large-cell anaplastic medulloblastoma is associated with poor prognosis 
and short survival. Despite the fact that many medulloblastomas show 
identical histologic features, they have different responses to the assigned 
therapies and thus different outcomes. Recent advances in the molecular 
biology of medulloblastoma have shown the importance of a more 
accurate classification of patient groups, which includes the genetic 
profiles of the tumors [47].  
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1.2.2 Genetic alterations and aberrant signalling pathways in 
medulloblastoma 
The most frequently altered signalling pathways in medulloblastoma are 
the Sonic hedgehog (Shh) and the Wingless (Wnt) pathway (Figure 1-1). 
They were first identified from associations with the Gorlin’s and the 
Turcot’s syndrome. A recent genome-wide sequencing study in 
medulloblastoma identified a significant number of somatic mutations in 
both pathways, confirming their importance for medulloblastoma 
development [48]. 
 
 
 
Figure 1-1 Shh and Wnt pathways, from Ellison et al. 2011 [46]. 
Sonic Hedgehog (SHH) signalling pathway 
The Gorlin’s syndrome is a rare autosomal dominant disorder associated 
with skeletal deformities, which shows a high incidence of sporadic 
medulloblastoma [49]. The disease is characterized by germ-line 
mutations in the PTCH1 gene which encodes for a transmembrane 
receptor that binds to the Hedgehog (HH) family proteins. During the 
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normal cerebellum development, the receptor Ptch is responsible for 
binding and repressing the activity of the smoothened protein (SMO) [50]. 
Once SMO binds to SHH, Ptch-mediated repression is alleviated and the 
sonic hedgehog (SHH) signalling pathway is activated, which finally 
triggers the proliferation of granule cells. Loss of function mutations in the 
PTCH1 gene may result in aberrant activation of the pathway and 
deregulated proliferation of granule cells, which might promote malignant 
transformation [51]. In medulloblastoma, 17% of tumors show mutations 
in the PTCH1 gene [48]. In addition to the PTCH1 mutations, further 
mutations in the SHH pathway were found in SUFU and SMOH [46]. 
About 25% of all medulloblastomas contain mutations in the SHH 
pathway, most of them have a desmoplastic phenotype (D/N or MBEN), 
but some large cell anaplastic tumors (LC/A) may also have an SHH 
profile.  
Wingless (Wnt) signalling pathway 
A similar study involving the Turcot syndrome identified molecular 
determinants in the Wingless pathway that are associated with the disease. 
The Turcot syndrome is a rare heritable disorder, which is characterized 
by the development of CNS tumors, in particular medulloblastoma and 
glioblastoma [52]. The Wingless signalling pathway coordinates several 
developmental processes including the proliferation and fate of neural 
progenitor cells [53]. The Wnt cascade is activated through the activation 
of the Frizzled receptor by Wnt ligands. The activation of Frizzled induces 
the inactivation of the protein complex between APC, GSK3 and Axin, 
which is responsible for the phosphorylation and degradation of β-catenin. 
Thus, Wnt pathway activation promotes the translocation of β-catenin to 
the nucleus and the initiation of the transcription of genes important for 
the cell cycle, proliferation and differentiation, such as MYC, CCND1 and 
NRSF/REST. Germ-line mutations in the APC gene have been first 
identified and associated with an inherited predisposition to 
medulloblastoma [52]. Nevertheless, 13-15% of sporadic 
medulloblastomas have mutations in the Wnt pathway [48, 54]. Most of 
the mutations reported target the serine 33 and 37 residues of β-catenin 
CHAPTER 1 
18 
and prevent its phosphorylation and degradation by GSK-3. As a 
consequence, β-catenin acquires a constitutively active state, which may 
lead to the development of a malignant phenotype [55]. Wnt tumors have 
a classical pathology nearly in all cases. They are rarely found in the LC/A 
subgroup and they have never been reported in the D/N subgroup. 
Chromosomal abnormalities 
The most frequent chromosomal aberration found in 70% of 
medulloblastomas is the presence of isochrome i (17q), in 40%-60% of the 
cases accompanied by loss of 17p [56]. Other chromosomal abnormalities 
that have been identified are loss of chromosome 10q, 7q and 16q. Gene 
amplification in MYC or NMYC has been reported in 4% - 8% of 
medulloblastomas [57] and is associated with the more aggressive LC/A 
phenotype and poor outcomes [46, 58]. Interestingly, SHH and Wnt 
tumors rarely display abnormalities in chromosome 17 or amplification in 
MYC or NMYC.    
1.2.3 Current treatments 
Current treatments for medulloblastoma are based on risk group-adapted 
therapies (Table 1-1). Normally, they include surgical tumor resection 
followed by radiotherapy or chemotherapy, with adapted regimens for 
high-risk or standard-risk patients. Radiotherapy has shown to be one of 
the most powerful tools for the treatment of medulloblastoma, but its 
utility is limited, because of the deleterious side effects caused on the 
developing brain of young patients that appear at higher doses of 
irradiation. A subset of medulloblastomas responds to chemotherapy, the 
most commonly chemotherapeutic agents used being methotrexate, 
etoposide, cyclophosphamide and platimum derivatives. The combination 
of chemotherapy and radiotherapy has improved the 5-year overall 
survival rate to 55% to 76% in high-risk patients and to 70% to 80% in 
standard-risk patients. Unfortunately, attempts to further reduce disease 
related mortality have been restricted by the toxicity of the conventional 
treatments [47]. 
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Variable 
 
 
Prognostic Category 
 
 
Low Risk Standard Risk High Risk  
 
Age 
 
 
> 3 
 
> 3 
 
> 3 
 
< 3 
 
Pattern of 
disease 
 
< 1.5cm3 residual 
disease 
No Metastasis 
 
Classic or 
desmoplastic 
 
< 1.5cm3 residual 
disease 
No Metastasis 
 
Classic or 
desmoplastic 
 
> 1.5cm3 residual 
disease 
Metastasis 
 
LC/A 
 
 
Tumor 
genomics 
No MYC 
amplification 
Wnt MB 
No MYC 
amplification 
Shh or 
Non Shh/Wnt MB 
 MYC amplification 
Wnt, Shh or 
Non Shh/Wnt MB 
 
Treatment Chemotherapy Reduced dose CSI 
Chemotherapy 
 
Full dose CSI 
Chemotherapy 
 
Chemotherapy 
Survival 
rate  
> 80 % 80 % 40 to 60 % 20- 40 % 
Table 1-2 Patient stratification and risk adapted treatment. Data in this table have been 
derived from [46] and [59].  
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1.3 Receptor tyrosine kinase signalling and its 
implication in cancer 
1.3.1 Receptor tyrosine kinases 
Receptor Tyrosine Kinases (RTK) play a central role in the regulation of 
normal cellular processes, such as cell survival and proliferation, cell 
growth, metabolism, differentiation, cell adhesion and migration [60]. 
Defects in RTK signalling have been shown to be critical for the 
development and progression of many types of cancer. The elucidation of 
the involvement of RTKs in tumorgenesis has led to the design of new 
drugs that specifically inhibit RTK activity, contributing to the 
development of the first target-specific cancer therapeutics.  
Cells express a variety of RTK, which are divided into 20 subclasses 
according to their primary structure, ligand affinity and induction of 
biological response. All RTKs share a common molecular structure with a 
ligand-binding domain in the extracellular region, a single transmembrane 
helix, and a cytoplasmic region that contains the protein tyrosine kinase 
(TK) domain plus additional carboxy (C-) terminal and juxtamembrane 
regulatory regions [60]. Activation of the receptor occurs upon ligand 
binding, which induces conformational changes that allow for receptor 
dimerization. Upon dimerization, autophosphorylation of tyrosine residues 
within the receptor cytoplasmic domains takes place, generating docking 
sites for important signal transducers. These molecules contain Src 
homology 2 (SH2) domains or phosphotyrosine binding (PTB) domains, 
which either directly bind to phosphotyrosine sites on the receptor or are 
recruited indirectly by binding to other docking proteins, such as FRS2, 
IRS1 or Gab-1 [61], which may recruit additional adaptor or signalling 
proteins.  Due to the large number of existing docking, adaptor and 
signalling proteins, RTKs can clearly recruit multiple protein complexes to 
the membrane and influence a large number of different signalling 
molecules. The signalling pathway that is in turn activated depends 
exclusively on the protein complex which is recruited to the membrane 
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upon receptor activation. For the content of this thesis, the roles of the 
fibroblast growth factor receptor (FGFR) and insulin like growth factor 
(IGF-1R) are of importance and will be discussed below. 
FGFR 
The mammalian FGF family comprises 18 ligands, which bind to 4 highly 
conserved transmembrane RTKs (FGFR 1, FGFR2, FGFR3 and FGFR4) 
[62]. Activated FGFRs provide binding sites for FRS2, a key adaptor 
protein that is largely specific to FGFRs [63]. Binding of FRS2 allows for 
the recruitment of the adaptor protein growth factor receptor bound 2 
(Grb2), which in turn binds to the guanine nucleotide exchange factor 
SOS, which activates the RAS GTPases and starts downstream the 
RAF/MAPK signalling pathway. A separate complex that also involves 
Grb2 recruits Gab-1 (Grb2 associated binding protein 1) to the membrane 
and activates the PI3K/AKT signalling pathway. Another main substrate 
of FGFRs is the phospholipase Cγ (PLCγ), which directly binds to the 
phospho-tyrosine residues of FGFRs through its SH2 domains. Once 
PLCγ is recruited to the membrane, it hydrolyzes phosphatidylinositol-4,5-
biphosphate (PIP2) to phosphatidylinositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). IP3 induces the opening of Ca
2+
-channels and the 
accumulation of Ca
2+
 in the cytosol. Ca
2+
 and DAG promote the activation 
of protein kinase C family members (PKC), which partly reinforces the 
activation of the MAPK pathway by phosphorylating RAF [64]. Several 
other pathways are also activated by FGFRs, depending on the cellular 
context, including the p38 MAPK and Jun kinase pathways, signal 
transducer and activator of transcription (STAT) signalling and ribosomal 
protein S6 kinase 2 (RSK2) [62].  
FGFR regulates fundamental developmental processes during 
embryogenesis. Deregulation in FGFR signalling results in developmental 
syndromes, such as skeletal dysplasias. In adult tissue, FGFRs are known 
to regulate wound repair, angiogenesis, cell proliferation and 
differentiation, processes that are often deregulated in cancer cells. The 
importance of FGF signalling was highlighted by a screen for somatic 
mutations in the human kinome from 210 different human cancers which 
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identified the components of FGF signalling pathways as the most 
commonly mutated coding regions [65]. Genetic alterations of FGFR have 
been extensively described in solid tumors and hematologic malignancies, 
being the most prominent mutations in FGFR3 and gene amplifications in 
FGFR1 and FGFR2. Activating mutations in FGFR3 and FGFR2 are most 
frequently found in bladder cancer (in 50% of bladder cancers, which are 
associated with a non-muscle invasive disease and in 10-15% of the 
invasive type) (42). Mutations in FGFR3 are also found at lower rates in 
cervical cancer, myeloma and prostate cancer. Mutations in FGFR2 are 
found in 12% of endometrial cancers and amplification in 10% of gastric 
cancers, the last one being associated with poor prognosis. Amplifications 
in FGFR1 are frequently found in 10-15% of breast cancers and it are 
often accompanied by increased or altered expression of FGF ligands [66]. 
IGF-1R 
The Insulin-like Growth Factor 1 (IGF-1) Receptor is a transmembrane 
hetero-tetramer receptor with two extracellular α-subunits and two β-
subunits with intrinsic tyrosine kinase activity [67]. The IGF-1R has 
affinity for IGF-1 and IGF-2, which are polypeptide protein hormones 
similar to insulin [67]. As other RTKs, ligand mediated activation of IGF-
1R results in the autophosphorylation of its tyrosine residues, leading to 
the recruitment of the adaptor proteins IRS1 and Shc to the receptor β-
subunits intracellular domains [68, 69]. This process activates the 
PI3K/AKT and the RAS/RAF/MEK/ERK pathways resulting in the 
stimulation of cell growth, cell cycle progression, increased proliferation 
and inhibition of apoptosis.  
The importance of IGF-1R in normal mammalian development is clear 
from studies in mice lacking functional receptors. IGF-1R null mice are 
45% of the size of wild-type mice at the time of birth and die shortly after 
because of severe organ hypoplasia [70]. Due to its important role in 
growth and development, it is not surprising that deregulations in IGF-1R 
signalling lead to malignant transformation. Elevated levels of IGF-1 and 
IGF-2 have been associated with increased cancer risk (eg. colon, breast, 
and prostate) [71, 72]. Several studies have demonstrated that an intact 
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IGF-IR is necessary for cell transformation by many oncogenes [73]. In 
vivo models have demonstrated that IGF-IR expression induces tumor 
growth and metastasis, whereas decreasing IGF-IR expression leads to 
decreased tumor growth in the majority of tumors [74]. Indeed, the IGF1R 
has been frequently found over-expressed in a broad range of adult 
tumours, including colon, pancreas, prostate, kidney and breast cancer 
[75-77] and also childhood tumors [78, 79]. To date, there are about 30 
drug candidates targeting the IGF-1R, which are being investigated in 
clinical trials for the treatment for many cancer types [80]. 
Activation of the PI3K/AKT signalling pathway 
The phosphatidylinositol-3-kinase (PI3K) pathway regulates several 
cellular processes downstream of different RTKs, such as IGF-1R, FGF-R, 
vascular endothelial growth factor receptor (VEGFR), epidermal growth 
factor receptor (EGFR) or platelet-derived growth factor receptor 
(PDGFR) in response to growth factor stimulation [81]. PI3Ks represent a 
family of protein and lipid kinases, which are divided into three classes (I-
III) according to their sequence homology and in vitro lipid substrate 
specificity [82]. Among all isoforms, there is much more evidence for a 
role of class I PI3K in tumorgenesis and, therefore, it became the focus of 
attention in cancer research over the past decade.  
Class IA PI3Ks are heterodimers consisting of a p110 catalytic and a p85 
regulatory subunit. The p110 catalytic subunits p110α, p110β, and p110δ 
are highly homologous isoforms. The regulatory isoform p85 includes two 
Src homology 2 (SH2) domains and a p110 binding domain [83]. When 
activated, class IA PI3Ks catalyze the phosphorylation of 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-
3,4,5-trisphosphate (PIP3), which acts as a second messenger supporting 
the recruitment of the serine/threonine kinase AKT to the plasma 
membrane by binding to its pleckstrin homology domain [84, 85]. AKT 
represents a central node in the intracellular signalling networks. Once 
activated, AKT phosphorylates numerous targets starting a series of 
signalling cascades involved in diverse cellular functions. AKT inhibits 
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apoptosis by direct phosphorylation of BAD [86], caspase-9 [87] and 
FKHR [88]. Additionally, AKT inhibits p53-dependent cell death by 
phosphorylation of MDM2 [89]. Besides the regulation of the anti-
apoptotic pathway, AKT promotes cell cycle progression by the inhibition 
of glycogen synthase kinase-3β (GSK-3β), leading to the accumulation of 
cyclin D1 via myc [90]. AKT also promotes cell growth by activation of 
the rapamycin-sensitive complex mTORC1 [91], which is responsible for 
the activations of two important regulators of protein translation and 
ribosomal biogenesis: p70 ribosomal S6 kinase (S6K) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4E-BP1) [92, 93].  
The PI3K/AKT pathway is antagonized by the lipid phosphatase PTEN, a 
3-position phosphatase that converts PIP3 back to PIP2 [94, 95], thus 
controlling the levels of second messenger generated. PTEN is crucial for 
the regulation of the PI3K/AKT pathway, since there is no other related 
protein that compensates its loss of function. PTEN dysfunctions have 
been implicated in a wide range of cancer types, highlighting its 
importance for the proper regulation of cell growth and proliferation [96]. 
Activation of the Raf-MEK-ERK pathway 
Another key signalling pathway that can be regulated by RTKs is the 
mitogen-activated protein kinase (MAPK) pathway. All eukaryotic cells 
use multiple MAPK cascades for signal transduction. Each cascade 
consists of at least three evolutionary conserved enzymes that are activated 
sequentially: MAPKK kinase (MAPKKK), a MAPK kinase (MAPKK) 
and a MAP kinase (MAPK) [97]. MAPK pathways integrate signals from 
several receptor stimuli and induce a variety of cellular responses, 
including cell proliferation, differentiation, development, inflammatory 
responses and apoptosis [98]. Six distinct groups of MAPKs have been 
characterized in mammals; extracellular signal-regulated kinase ERK1/2, 
ERK3/4, ERK5, ERK7/8, Jun N-terminal kinase (JNK) 1/2/3 and the p38 
isoforms (ERK6) [99]. The best characterized MAPK signalling pathway 
represents the Raf-MEK-ERK pathway, which is deregulated in 
approximately one third of all human cancers [99]. This pathway is 
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activated by the GTPase Ras, a critical link between RTKs and ERK. 
Upon ligand binding, Grb2 and the guanine nucleotide exchange factor 
SOS are recruited to the plasma membrane. SOS promotes the exchange 
of GDP to GTP and the activation of Ras, which can directly 
phosphorylate Raf (Raf-1, B-Raf and A-Raf) to initiate the cascade. 
Activated Raf activates MEK1 and MEK2, which subsequently activate 
ERK1 and ERK2. The ultimate targets of ERK are a variety of subtrates 
including membrane proteins, cytoskeletal proteins and transcription 
factors [100]. The type of process that is regulated as a consequence of the 
RAF/MEK/ERK axis depends exclusively on the targets that ERK binds 
to. These properties might be linked to temporal differences in the strength 
and localization of ERK within the cell [100]. 
Most of the alterations leading to constitutive activation of ERK signalling 
occur at early steps of the pathway, either from aberrant signalling from 
RTK or from activating mutations in Ras and B-Raf. Ras and B-Raf 
mutations are in most of the tumors mutually exclusive, and mainly found 
in Ras, which was one of the first oncogenes identified. Activating Ras 
mutations are reported in pancreas- (90%), thyroid- (55-60%) non-small 
cell lung- (35%) and liver (30%) cancer, among others [101]. The high 
incidence of activating mutations in the Ras–Raf axis points for its role as 
regulatory hotspot [99]. 
Protein kinase C 
Protein kinase C (PKC) is a family of serine/threonine kinases consisting 
of nine isozymes: classical (PKCα, PKCβI, PKCβII, and PKCγ), novel 
(PKCδ, PKCε, PKCη, and PKCθ), and atypical (PKCζ and PKCι) [102]. 
They are divided into three subfamilies based on their second messenger 
requirements: classical PKC requires calcium, phorbol esters or 
diacylglycerol (DAG) for its activation, novel PKCs are activated by 
phorbol esters or DAG and atypical PKCs are unresponsive to calcium, 
phorbol esters or DAG.  Thus, classical and novel PKCs are activated 
through the same signal transduction pathway as PLC. The structure of all 
PKCs consists of a regulatory domain and a highly conserved catalytic 
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domain [103]. The second messenger requirement differences in the 
isoforms are a result of the regulatory region, which are similar within the 
classes, but differ among them.  
PKCs were originally thought to be pro-mitogenic kinases, but later it was 
shown that this effect is isoform- and cell-type dependent [102]. Upon 
PKC activation, which normally occurs at the plasma membrane, the 
different PKC isoforms redistribute to the nuclear membrane or to 
different organelles. The differential redistribution is the key for dictating 
substrate specificity and thus functional selectivity [104]. 
The role of PKC in tumorigenesis was first described because of the 
observation that phorbol esters promoted tumor formation on a mouse-
skin model. For many decades, PKCs have been linked to cancer, but the 
role of the specific isoforms is still very controversial [104].  
PKCs have shown to have opposing roles in the regulation proliferation, 
survival and apoptosis, which is particularly interesting for the widely 
expressed PKCε and PKCδ isoforms. PKCε promotes cell survival in 
many cell types through increased activation of the Akt pathway and up-
regulation of pro-survival factors. Over-expression of PKCε was also 
associated with resistance to chemotherapy and invasiveness [105]. PKCδ 
has been shown to have a dual role as both, positive or negative growth 
regulator. It was shown to induce cell cycle arrest and promote apoptotic 
signals in various cell types [106]. In another cellular context, PKCδ was 
shown to positively regulate proliferation, for example by stimulating the 
ERK pathway in breast cancer cells [107]. Also, PKCδ has been shown to 
be required for the proliferative effect of insulin-like growth factor 1 
(IGF1) [108].  
There is a limited number of mutations identified in PKCs in human’s 
cancer [88]. However, altered levels of PKC isoforms have been shown to 
correlate with several cancer-associated phenotypes, such as cell survival 
and proliferation or cell migration and invasion.  
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Figure 1-2. Schematic representation of receptor tyrosine signalling networks. FGFR and 
IGF-1R are activated by autophosphorylation in response to growth factor binding and 
recruit different docking or adaptor proteins to initiate the PI3K/AKT and the 
RAF/MEK/ERK signalling cascades, which are involved in the regulation of cell growth, 
cell proliferation and apoptosis. 
 
1.3.2  Genetic alterations in the RTK signalling networks in 
cancer 
Due to the central role of the RTK network in the control of cell 
proliferation, cell survival and cell death, it is not surprising that 
alterations in its components, which lead to increased pathway activation, 
result in an uncontrolled cell proliferation and malignant transformation. 
Extensive studies performed during the past years have identified 
numerous mutations or gene amplifications that target RTKs or 
components of downstream signalling pathways, such as the PI3K/AKT 
and MAPK pathway, in a number of human cancers [81, 109, 110]. The 
focus of this section is on the main genetic alterations in RTKs and its 
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downstream signalling components in neuroblastoma and 
medulloblastoma. 
 Neuroblastoma 
Receptor tyrosine kinases 
Among RTKs, ALK is probably the most frequently altered in 
neuroblastoma, accounting for 5 to 15% of neuroblastomas. Gain-of 
function mutations in ALK have been identified in conserved positions of 
the tyrosine kinase domain [13]. From the 12 residues identified, the most 
common mutational hotspots are R1275Q and F1174L. The R1275Q 
mutation is found in familial and sporadic neuroblastomas, whereas 
F1174L is restricted to sporadic tumors and is associated with 
amplification of the MYCN oncogene [111]. Gene amplifications in ALK 
have been also reported, but at lower frequencies than point mutations (2% 
of all neuroblastomas) [111]. Interestingly, it was shown that ALK 
amplifications occur almost exclusively with MYCN amplification [112]. 
The Trk receptor family has been shown to be differentially expressed in 
neuroblastomas and is frequently used as a prognostic marker in 
neuroblastoma. Overexpression of TrkA is characteristic for tumors with 
favorable biology, while TrkB expression correlates with MYCN amplified 
tumors and aggressive disease [113]. Several polypeptide growth factors 
have been shown to promote neuroblastoma proliferation and 
chemoresistance. Early studies identified IGF-I and IGF-II signalling 
loops to play a role in neuroblastoma cell survival [114-116]. IGF-IR 
expression has been shown to correlate with neuroblastoma tumorigenicity 
[117]. FGFR expression was only investigated in NB cell lines, in which 
FGFR1 expression and activation by FGF-2 was associated with MYCN 
expression [118]. 
Raf/Mek/Erk 
Although the Ras-Raf axis represents a hotspot for activating mutations in 
a high percentage of human cancers, they occur very infrequently in 
neuroblastoma [119-121]. Among other Ras effector genes that may also 
contribute to tumorigenesis, the RAS-association domain family 1 isoform 
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A (RASSF1A) has been identified to be epigenetically silenced in a 
significant proportion of high-risk neuroblastomas [122]. Although genetic 
alterations in the ERK pathway are rare, its involvement in mediating 
aberrant RTK signals has demonstrated to have a crucial role in 
neuroblastoma progression [123]. 
PI3K 
Also mutations in the PIK3CA gene have been extensively detected in a 
number of human cancers, but, in neuroblastoma, this event seems to be 
rare (2-3% of the cases) [124, 125]. In two independent studies, PIK3CA 
mutations were found in the catalytically protein domain indicating a 
possible increase in the p110α activity [124, 125]. However, expression of 
p110α was detected on a protein level in 92% of paraffin-embedded tissue 
sections [124]. As in the case of PIK3CA, genetic alterations in PIK3CD 
have been shown to be rare [126]. The expression of PIK3CD was later 
shown to correlate with patient age. Elevated mRNA expression of 
PIK3CD was found in patients younger than one year [127].  Currently, no 
genetic alterations have been reported in PIK3CB encoding the class IA 
PI3K isoform p110β.  
PTEN 
In neuroblastoma, alterations involving the PTEN gene has been rarely 
reported [124, 128, 129]. Reduced expression of PTEN seems to be an 
infrequent event in neuroblastoma. In addition, no associations with 
aggressive tumor biology could be demonstrated [129].  
Medulloblastoma 
Receptor tyrosine kinases 
Several studies have shown that growth factor signalling plays a key role 
in medulloblastoma biology. In fact, human medulloblastoma cells express 
a variety of growth factor receptors, amongst them ErbB-2, ErbB-4, IGF-
IR, platelet-derived growth factor (PDGFR), epidermal growth factor 
receptor (EGFR) and neurothrophin-3 receptor Trk were associated with 
medulloblastoma carcinogenesis [130-132]. Over-expression of ErbB-2, 
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ErbB-4 was reported in medulloblastoma tumor samples, and it was 
associated with reduced patient survival [130]. The expression of TrkC 
was as well correlated with patient survival, although in this study, 
increased expression of TrkC represented a marker of good prognosis. 
This might be explained because of its role in the regulation of apoptosis 
[131]. Further studies showed that IGF-1R is overexpressed and activated 
in medulloblastoma. Interestingly the expression of IGF-1R had a strong 
inverse correlation with TrkC expression [132]. 
Raf/MEK/ERK 
As in the case of neuroblastoma, there are only few studies that address a 
mutational analysis of the ERK pathway in medulloblastoma. While an 
early study identified a mutation in NRAS in a single MB cell line [133], a 
bigger study comprising 28 primary tumors detected no oncogenic 
mutations affecting NRAS, KRAS, HRAS, BRAF in any case [134], 
which suggested that alternative mechanisms are responsible for 
RAS/MAPK pathway activation in this disease. However, as in 
neuroblastoma, promoter hypermethylation was identified in the 
RASSF1A gene [135], suggesting a role in the development of embryonal 
tumors. 
PI3K isoforms 
Although the PI3K/AKT pathway has been extensively studied in many 
cancer types, relatively few data are available in medulloblastoma. A 
large-scale mutational analysis identified mutations in the PIK3CA gene in 
only 5% of medulloblastomas [136] and PIK3CA gene amplification was 
not detected [136, 137]. The different class IA PI3K isoforms were shown 
to have differentially expression patterns in medulloblastoma patient 
samples. Significant over-expression of PIK3CA gene in medulloblastoma 
tumor samples was found compared with normal cerebellum [137]. 
Additionally, protein over-expression of the PI3K catalytic isoform p110α 
was observed in human medulloblastoma samples (74%). On the contrary, 
significant increases in the expression levels of the remaining class IA 
PI3K isoforms (p110β, p110δ and p85) were not detected [137].  
 INTRODUCTION 
 
31 
The activation of the PI3K/AKT signalling pathway has emerged as an 
important element of medulloblastoma cell proliferation [137-139] and a 
key role in this pathway has been attributed to class IA PI3K p110α. The 
importance of p110α was proven, as its inhibition led to a decrease in cell 
proliferation and augmented the effects of chemotherapy in a cell line 
model [137]. 
PTEN 
Different studies reported that PTEN expression is reduced in 
medulloblastoma [138, 140]. In primary medulloblastoma samples, PTEN 
mRNA and protein expression were found significantly lower when 
compared to normal cerebellar tissue, independently of medulloblastoma 
histological subtype. In 50% of the tumor samples, reduction of PTEN 
expression was found to be associated with PTEN promoter 
hypermethylation [138]. PTEN homozygous loss at chromosome 10q was 
detected in 32% of medulloblastomas [140]. The fact that only a subset of 
samples lack of PTEN expression indicates that loss of PTEN does not 
seem to be a common mechanism in medulloblastoma development. In 
agreement with this, a different study found that the PTEN protein was 
expressed at higher levels in medulloblastoma samples and cell lines as 
compared to control samples [137]. 
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1.4 Targeting the human kinome in cancer 
1.4.1 Rationale for targeting kinases in cancer 
Tumorigenesis is a multistep process that involves dynamic changes in the 
genome of normal human cells, driving their progressive transformation 
into highly malignant derivatives [141]. Cancer cells can accumulate an 
immense variety of defects in the regulatory circuits that govern 
normal cell proliferation and homeostasis, that ultimately lead to 
malignant growth. Understanding these dynamic variations is crucial to 
develop novel targeted therapies to inhibit malignant tumor growth. 
Most of cellular processes are controlled by the reversible phosphorylation 
of distinct signalling proteins by protein kinases or phosphatases [142]. Up 
to 30% of all human proteins may be modified by phosphorylation [143]. 
The enzymatic activity of kinases is therefore under tight control, non 
proliferating cells having very low levels of phosphorylated proteins 
[142]. At least 518 distinct kinase-encoding genes in the human genome 
have been identified, from which 164 map to amplicons in cancer [144]. 
Given the large number of existing kinases and their different levels of 
regulation, it is not surprising that they are frequently deregulated in 
cancer.  
Alterations in kinase signalling can occur at many levels (Figure 1-3) 
[142]. Increased kinase activity can result from a gain-of-function 
mutation that disrupts auto regulation of the kinase and renders it 
constitutively active, independent of upstream signalling. For example, 
mutations in the tyrosine kinase domain of epidermal growth factor 
receptor (EGFR), that alter receptor signalling, have been identified in a 
subset of non–small-cell lung cancers [145]. Not only activating 
mutations, but also over-expression of receptor tyrosine kinases or 
downstream protein kinases can lead to aberrant signalling. Such is the 
case for the receptor tyrosine kinase ERBB2 (HER-2/neu) in breast cancer 
[146]. Lastly, increased kinase activity can result from loss-of-function 
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alterations in factors that antagonize kinase activity, such as phosphatases 
or inhibitory proteins. The most renowned example is probably the tumor 
suppressor PTEN. Loss-of-function mutations in PTEN are frequently 
found in many human cancers [147], which underlines the importance of a 
proper control mechanism for the maintenance of cell homeostasis. 
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 Figure 1-3. Alterations in RTK signalling. Over-expression of receptor tyrosine kinases 
or its ligands (right), activating mutations on the receptor (middle) or in downstream 
signalling factors (left) lead to aberrant RTK signalling. The possibilities to inhibit the 
signalling pathway are shown. 
 
Knowing the possible molecular mechanisms of grown deregulation in 
cancer cells and which key factors are involved in them, opened the 
possibility for researchers to design new treatment strategies based on 
targeting specific proteins which are responsible for an oncogenic 
phenotype. Tyrosine kinases emerged very soon as druggable targets, 
since their activity can be inhibited pharmacologically in several ways 
[142]. Small molecule inhibitors for example can bind at the catalytic site 
of the kinase, preventing the binding of ATP or substrates. Other kinase 
inhibitors function by blocking the dimerization of protein subunits to 
inhibit their activation. In addition to small molecule inhibitors, it is also 
possible to block signal transduction with antibodies against receptors or 
their ligands. They function through neutralization of ligand, inhibition of 
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ligand binding and/or receptor internalization. The large number of 
kinases known to be altered in cancer and all the possibilities to inhibit 
their function led to the development of an arsenal of pharmacological 
inhibitors and antibodies, which have been and are being tested in both 
preclinical and clinical settings.   
1.4.2 Targeting RTK signalling in neuroblastoma and 
medulloblastoma 
ALK 
Due to the high incidence of mutations in the ALK gene that have been 
identified in neuroblastoma, ALK has emerged as a novel promising 
therapeutic target [111]. Indeed, crizotinib an ALK inhibitor has recently 
entered the phase I clinical trial for the treatment of neuroblastoma and 
other solid tumors (clinical trial ID: NCT00939770, [46]). Preclinical 
studies have shown that neuroblastoma cell lines with ALK amplification 
or the R1275Q mutation are sensitive to crizotinib, but not those cell lines 
expressing the F1174L mutation [111]. On the contrary, neuroblastoma 
cell lines bearing the F1174L mutation were sensitive to another inhibitor 
named TAE684 [148]. Due to the different responses to ALK inhibitors 
and also the possible emergence of drug resistance, there is currently a big 
interest in searching for new ALK inhibitors [111], some of them are 
being identified form high-throughput screening against multiple RTK 
targets [149].  
IGF-1R 
The observation that NB cell lines secrete and respond to several IGFs to 
promote cell proliferation, has led to the design of anti-tumor strategies 
based on inhibiting the activity of IGF-1R. Several pharmacological 
inhibitors and neutralizing antibodies that inhibit IGF-1R signalling have 
been tested in vitro and in vivo and demonstrated anti-proliferative effects: 
the monoclonal antibodies SCH717454 [150, 151] and EM164 [152], 
AMG479 [153], and the tyrosine kinase inhibitors NVP-AEW541 [154, 
155], CP-751,871 [156] and BMS-554417 [157]. Due to the promising 
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results obtained in preclinical models, the anti-IGF-1R antibodies 
SCH717454 and Cixutumumab are currently being tested in Phase I and 
Phase II clinical trials (NCT00831844, NCT00960063 [46]). 
The therapeutic potential of inhibiting IGF1R signalling in 
medulloblastoma has been also studied [158-160]. For example, inhibitors 
NVP-ADW742 and NVP-AEW541 attenuated growth in medulloblastoma 
cell lines [160]. Interestingly, MB cell lines which showed resistance to 
NVP-AEW541, were associated with phosphorylation of GSK3 and could 
become much more sensitive following SNP-mediated GSK3 
dephosphorylation [160]. 
EGFR 
Given that medulloblastoma cells express ERBB2, ERBB4 and EGFR, the 
therapeutic potential of the inhibitors erlotinib and genitinib was assessed 
in vitro and in vivo [161-163]. Because of the anti-tumors effects observed 
in preclinical models, erlotinib entered Phase I and II clinical trials [46, 
161, 164]. Although erlotinib was well tolerated by children, only few 
showed a modest response to the treatment [164]. Recently, a dual 
inhibitor of HER1/2 and VEGFR1/2 named AEE788 showed anti-tumor 
activity in medulloblastoma xenografts [162]. Importantly, the subset of 
HER2-overexpressing medulloblastomas was shown to benefit most likely 
from AEE788 treatment, highlighting the importance of the identification 
of tumour markers to predict drug response.  
PI3K/AKT/mTOR 
Because of the fact that tumors express more than one RTK to activate 
downstream signalling pathways, targeting individual receptors may not 
always yield optimal results in inhibiting cell proliferation. A possible 
approach to overcome resistance to RTK inhibitors is targeting protein 
kinases that lie downstream of the several different growth factor receptors 
and are required for transmitting proliferative signals from the receptors. 
PI3K represents an attractive target for pharmacological inhibition, 
therefore many inhibitors have been developed and widely studied in 
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many cancer types [109]. One of the most prominent PI3K-inhibitors is 
PI-103, which has dual specificity against the isoform p110α and mTOR. 
PI-103 inhibited neuroblastoma growth in vitro and in vivo [165, 166]. In 
medulloblastoma, inhibition of the PI3K isoform p110α with the isoform 
specific inhibitors PIK75 and YM-024 were reported to have anti-
proliferative effects in medulloblastoma cell lines [137]. Inhibition of 
PDK1 with OSU03012 showed also cell growth inhibition in NB and MB 
in vitro and in vivo models [167]. Finally, the AKT inhibitor perifosine has 
as well shown anti-tumor effects, although so far only in vitro in MB and 
NB cell lines [168, 169]. 
1.4.3 Resistance to kinase inhibitors 
Although many TKIs showed to be able to inhibit cell survival and 
proliferation in preclinical settings, their use for patient treatment showed 
to be challenging [170]. One of the reasons may be that in vitro and in vivo 
models rarely represent the vast genetic heterogeneity of tumors occurring 
in patients. In addition, tumor cells can develop a number of mechanisms 
to circumvent drug activity. The identification of tumor subgroups that 
share genetic features will certainly help to choose appropriate treatments 
for each patient subgroup. Important lessons could be learned from studies 
performed with the EGFR inhibitors erlotinib and gefitinib for the 
treatment of glioblastoma (reviewed in the appendix). EGFR mutation and 
amplification represent the most prominent genetic alterations in 
malignant brain tumors [171]. Responsiveness of glioblastoma patients to 
EGFR inhibition correlated with expression of EGFRvIII, a constitutively 
active mutant of EGFR [172]. This study is of great importance, because it 
exemplifies how activating mutations might render cancer cells 
oncogenically addicted to a specific pathway and thus, sensitive to small 
molecule inhibitors targeting the specific oncogenic factor. Interestingly, 
the same study identified a subgroup of glioblastomas that did not respond 
to EGFR inhibition and their common genetic feature was loss of PTEN 
expression [172]. Another study in glioblastoma showed that response to 
erlotinib was also associated EGFR over-expression, but only in the 
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subgroup of glioblastomas with basal AKT phosphorylation [173]. None 
of the patients with tumors expressing high levels of activated AKT 
responded to erlotinib. Together, these studies exemplify some of the 
multiple mechanisms that cancer cells may use to overcome target 
inhibition.  
To date, numerous mechanisms of therapy resistance have been described 
in the literature. The majority of cancers are genetically complex: they 
normally use more than one signalling pathway to drive malignant growth. 
Therefore, their survival not solely depends on the activation of a single 
molecule or a receptor and it is unlikely that single agent treatment will 
induce complete inhibition of cell growth [174]. It has been observed that 
multi-targeting therapies show more potent effects in this context, and 
may represent a more promising option for patient treatment [174].  
1.4.4 Design of drug combination approaches 
Despite all the advances achieved in cancer biology, conventional 
chemotherapy targeting the DNA of proliferating cells is still most 
efficacious for cancer treatment. Although often limited by toxicity, 
chemotherapy has shown good responses for many cancer types [175]. For 
most of advanced tumors single drug treatment still represents a problem. 
Even though advanced tumors may initially respond, their genetic 
instability allows for the emergence of secondary mutations and 
alterations in their genome that leads to a more malignant phenotype with 
acquired resistance to the initial treatment [176]. To address this problem, 
several drug combinations have been tested and shown to be more 
effective in curing cancers. Therefore, many combinatorial regimens have 
been integrated in the clinic for the half past century, and in some cases 
they have yielded complete disease remission [176]. Since most of the 
conventional chemotherapies have, in principle, the same mode of action, 
it is likely that when cancer cells develop a mechanism of resistance to 
any agent, they will simultaneously acquire multi-resistance to other 
agents without being treated with them at first place [177]. The 
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identification of kinases that modulate the response to drug treatment 
provides a rational to design new therapeutic approaches, based on the 
combination of conventional chemotherapies with small molecule 
inhibitors. Indeed, some studies have prescuted some valuable 
combinations that are currently being tested in clinical trials [46]. 
Although this strategy is very promising, it remains challenging to identify 
the optimal combination for a certain type of tumor. The search for the 
adequate combination might be very time consuming and expensive. The 
use of genome-wide high-throughput screens has greatly facilitated the 
identification of molecular signatures that modulate the response of cancer 
cells to anticancer drugs. RNA interference (RNAi) screens have shown to 
have great potential in this context and are described in more detail in the 
next section. 
1.4.5 RNA Interference to enhance cancer drug target discovery 
RNA interference (RNAi) is a natural gene silencing mechanism that all 
organisms use as a post-transcriptional regulation of their gene expression. 
RNAi is considered to be an evolutionary ancient mechanism for 
protecting organisms from viruses [178]. Since many viruses use RNA, 
instead of DNA, as their genetic material, eukaryotic cells have evolved to 
recognize this double stranded RNA and to induce its degradation as an 
antiviral response. Since its discovery, the molecular mechanisms of 
RNAi have been extensively studied [179]. The RNAi response starts 
when an enzyme called dicer recognizes dsRNA and degrades it into small 
segments around 20 nucleotide pairs in length. A protein complex called 
RISC (RNA induced silencing complex) binds to the small RNA segments 
and uses one of its strands as a template to seek out mRNA transcripts 
with the complementary sequence and prevent its expression. The fact that 
RNAi works in a sequence-specific manner to degrade the target mRNA 
has enormously facilitated the design and development of synthetic small 
interfering RNA molecules (siRNA) to specifically ablate the function of 
any gene in the genome [180].  
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RNA interference is now commonly used to study the effects of blocking 
the expression of a gene of interest [181]. With the completion of the 
human genome sequencing and DNA microarray technologies, huge 
databases have been generated that led to the identification of several 
groups of genes which are deregulated in various diseases, but no 
information about the function of these genes was provided. The ability of 
RNA interference to induce gene down-regulation in a relative easy 
manner, has opened up the possibility to systematically target every gene 
of interest and to simultaneously probe gene function on a large scale 
[181]. This led to the development of several RNAi libraries, which are 
composed of collections of small interfering RNAs that can be genome-
wide or can be designed on a smaller scale to target a subgroup of genes 
(eg kinome-wide). RNAi libraries are nowadays produced by several 
commercial and academic laboratories. They are reliable and robust, 
contain several unique validated sequences per gene and are usually 
pooled in a 96- or 384- well plate format to perform high throughput 
screens. Commonly used readouts for arrayed libraries are luminescent 
cell viability or apoptosis assays, but also methods involving more 
sophisticated microscopic image analysis have been reported [182]. 
Several loss-of-function RNAi screens have been conducted in human 
cancer models in the past few years, and have reported novel key 
regulators of various cancer-related phenotypes [183-186]. 
RNAi are well suited for the identification of target genes that promote 
cell growth and are required for survival, as their specific silencing will 
potentially result in a selective decrease in survival of the cells, which 
were transfected with the respective siRNA. RNAi screens of this type 
identified survivin as a target in a colon carcinoma cell line harboring the 
activated KRAS oncogene [187], or PLK1 as a potential target in a 
medulloblastoma cell line [188]. RNAi screens can be well performed in 
combination with standard chemotherapeutic drugs. The so called RNAi 
chemosensitization screens have the ability to identify targets which are 
responsible for mediating drug resistance and help the design of drug-
combination strategies. Several recent studies have reported on RNAi 
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chemosensitization screens [184, 189, 190]. A genome-wide RNAi screen 
identified genes that modify the response to paclitaxel in non-small-cell 
lung cancer. The hit candidate genes included proteasome subunits, which 
when being inhibited by bortezomib had a synergistic effect with 
paclitaxel in patients [182]. This study highlights the use of RNAi screens 
to identify effective combination therapy targets. Similarly, other RNAi 
screens identified FER (fps/fes related tyrosine kinase) to sensitize HeLa 
cells to cisplatin, paclitaxel and etoposide [184], or MAPKAP1 to 
sensitize pancreatic cancer cells to gemcitabine [189].  
There is a growing number of RNAi chemosensitization screens reported, 
and a number of novel combination approaches proposed, which proves 
the potential of RNAi screening technologies, but also points out the 
importance for proper target validation in order to find druggable targets 
that can be used in a clinical setting. 
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1.5 Aims of the thesis 
Receptor tyrosine kinases and their downstream signalling cascades have 
been shown to play a crucial role in human cancers. Promising new cancer 
therapies are emerging from targeting signalling molecules with selective 
pharmacological inhibitors, in order to attenuate the survival or 
proliferative message in the cell. Therefore, it is important to identify 
which signalling pathways, and especially which components on those 
pathways are responsible for rendering cancer cells the oncogenic 
phenotype. The overall goal of the present thesis was to contribute to the 
knowledge of the molecular mechanism underlying cell survival and 
chemoresistance in two embryonal tumors: neuroblastoma and 
medulloblastoma. 
In the main project, a large-scale approach was designed that aimed for the 
screening of the human kinome in neuroblastoma to uncover kinases 
which are critical for promoting cell survival. Knowing that drug 
resistance is a major cause of treatment failure in high risk neuroblastoma 
patients, we performed a chemo-sensitizing kinome-wide RNAi screen to 
systematically identify new determinants of resistance to cisplatin, a 
commonly used therapeutic agent for the treatment of neuroblastoma. The 
screen was performed in two neuroblastoma cell lines with different 
MYCN status, in order to assess the differences in the sensitivity to 
cisplatin and to find target genes for each subgroup. After identification 
and validation of the candidate kinases, specific small molecule inhibitors 
against the candidate kinases were used to investigate whether the RNAi-
mediated effects observed on cell survival and response to cisplatin could 
be reproduced by means of pharmacological targeting of the kinases. An 
identical loss-of-function RNAi screen has previously been performed by 
our group for medulloblastoma. This study validated a novel role for 
PI3K-p110γ in medulloblastoma chemoresistance and suggested a rational 
to combine pharmacological inhibitors against p110γ with 
chemotherapeutic agents.  
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The second project is based on observations of previous work from our 
group. In previous studies, distinct roles of the PI3K isoforms in 
neuroblastoma and medulloblastoma have been investigated. In 
neuroblastoma, a novel function for the isoform p110δ in cell growth and 
survival was demonstrated. Down-regulation of either p110α or p110δ led 
to impaired cell growth, although the sensitivity of the isoform down-
regulation was cell type dependent. In medulloblastoma, p110α was 
shown to play the main role among all PI3K isoforms. Over-expression of 
isoform p110α was detected in a panel of medulloblastoma cell lines and 
tumour samples. Inhibition of p110α resulted in a decrease in cell growth 
and cell proliferation. Interestingly, a stronger decrease was observed by 
simultaneous down-regulation of p110α and p110δ. A better 
understanding of the mechanisms of action of p110α and the downstream 
effectors that contribute to oncogenic p110α signalling may lead to the 
identification of new therapeutic targets. Aiming at discovering new PI3K 
target genes, we performed a cDNA microarray analysis to compare the 
changes in the gene expression profiles of medulloblastoma cells caused 
by RNAi-mediated down-regulation of p110α, p110δ and their 
combination. With the use of bioinformatic tools, we analyzed 
transcriptional networks of genes that may be affected by the down-
regulation of the PI3K isoforms. Having identified these networks, we 
sought to analyze their contribution to medulloblastoma survival and 
proliferation. The expression of the validated target genes was assessed 
and, finally, the anti-proliferative effects of its inhibition in 
medulloblastoma cells were analyzed. With such studies we explored the 
pharmacological potential of the newly identified genes. 
In a third project, the goal was to further analyze the therapeutic potential 
of targeting the axis of the insulin-like growth factor-1 receptor (IGF-1R) 
and PI3K signalling in medulloblastoma and neuroblastoma. For this 
purpose, we used R1507, an IGF-1R specific humanized monoclonal 
antibody, and PIK75, a specific PI3K p110α inhibitor. Following 
inhibition of IGF-1R or p110α in NB and MB cell lines, the effects on cell 
proliferation and apoptosis were analyzed. In addition, we analyzed the 
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sensitization potential of PIK75 or R1507 to commonly used 
chemotherapeutic agents. 
Taken together, the objective of this thesis was to investigate the 
mechanisms of action of already known oncogenes, such as PI3K-p110α, 
and to further test the therapeutic potential of targeting them with 
pharmacological inhibitors. A second goal was the discovery of new target 
genes that are essential for promoting oncogenesis in medulloblastoma 
and neuroblastoma by using high throughput approaches. 
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2.1 Abstract 
Chemotherapeutic drug resistance is one of the major causes for 
treatment failure in high risk neuroblastoma (NB), the most common 
extra cranial solid tumor in children. Poor prognosis is typically 
associated with MYCN amplification. Here, we utilized a loss of 
function kinome-wide RNA interference screen to identify genes that 
cause cisplatin sensitization. We identified FGFR2 as an important 
determinant of cisplatin resistance. Pharmacological inhibition of 
FGFR2 confirmed the importance of this kinase in NB 
chemoresistance. Silencing of FGFR2 sensitized neuroblastoma cells to 
cisplatin induced apoptosis, which was regulated by the 
downregulation of the anti-apoptotic protein BCL2. Mechanistically, 
FGFR2 was shown to activate PKC-δ to induce BCL2 expression. 
FGFR2, as well as the ligand FGF-2, were consistently expressed in 
primary NB and NB cell lines, indicating the presence of an autocrine 
loop. Expression analysis revealed that FGFR2 expression correlates 
with MYCN amplification and advanced stage disease, demonstrating 
the clinical relevance of FGFR2 in neuroblastoma. These findings 
suggest a novel role for FGFR2 in chemoresistance and provide a 
rational to combine pharmacological inhibitors against FGFR2 with 
chemotherapeutic agents for the treatment of neuroblastoma. 
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2.2 Introduction 
The development of drug resistance is a major cause of treatment 
failure in many cancer types. Tumors can exhibit intrinsic drug 
resistance before initial therapy or acquire drug resistance through 
chronic drug exposure [1]. The multiple mechanisms leading to 
chemoresistance are subject of intensive study, but are not yet fully 
understood. Cisplatin is a platinum-based DNA-damaging cytotoxic 
agent [2]. It is one of the most potent antitumor agents and is widely 
used for the treatment of solid tumors including testicular, ovarian, 
colorectal, lung and head and neck cancers [3, 4]. Cisplatin induces 
apoptotic cell death, which results from DNA damage-mediated 
responses. However, several mechanisms to circumvent cisplatin 
mediated cell-death have been described, which limit its clinical 
efficacy as an anticancer drug. These mechanisms can occur before 
cisplatin binds to the DNA like reduced drug uptake to the cell, drug 
efflux or drug inactivation through GSH or metallothioneins [2, 5-7]. 
Resistance to cisplatin can also occur by mechanisms that affect the 
recognition of the DNA damage signal, like inactivation of TP53 [8], 
attenuation of the apoptotic response mediated by caspase inactivation 
[9] or overexpression of antiapoptotic BCL2 family members [10, 11]. 
Alterations in survival pathways are as well associated with drug 
resistance, for instance overexpression of HER-2/neu and over 
activation of PI3K/Akt pathway. Although not directly induced by 
cisplatin, these alterations compensate for cisplatin-induced cell death 
signals and contribute to a chemoresistant phenotype [12, 13]. 
Neuroblastoma is an embryonal tumor that originates from developing 
neural crest tissues [14].  It is the most common extracanial solid 
tumour and is responsible for 15% of all cancer-related deaths in 
childhood. Neuroblastomas show very diverse clinical behavior, 
ranging from a widely disseminated and highly aggressive disease to 
tumors that differentiate or spontaneously regress with little or no 
therapy. Amplification of the MYCN oncogene is found in 
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approximately 20% of neuroblastoma and correlates with poor disease 
outcome [15]. Current treatments for high-risk neuroblastoma patients 
include intense multimodality chemotherapies, including cisplatin, 
doxorubicin and vincristine [16, 17]. Although most high-risk 
neuroblastomas initially respond to therapy, 50 to 60% have a relapse 
with the appearance of more drug-resistant tumors. The identification 
of molecular mechanisms that lead to drug resistance may open a new 
window for the design of potential combination therapies to treat this 
patient group. 
Kinases control the phosphorylation of proteins and lipids, which are 
important to mediate cell survival signals in the cells. They are often 
deregulated in cancer cells, thus targeting kinases offers a rational 
strategy to inhibit cell survival and to overcome drug resistance. RNA 
interference (RNAi) libraries allow high through-put screens, which are 
based on systematically silencing gene expression in order to identify 
which genes are essential for a specific function in the cell [18]. Such 
screens have already proven to be a highly effective research tool for 
the identification of key determinants of drug sensitivity [19-21]. Here, 
we performed a kinome-wide RNAi screen to identify kinases that, 
when being downregulated, sensitize neuroblastoma cells to cisplatin 
induced cell death. We report that RNAi targeting of FGFR2 caused 
the strongest impact in cisplatin sensitization. Moreover, our data show 
that FGFR2 induces BCL2 expression through activation of PKC-δ, 
which suggests that overexpression of BCL2 contributes to cisplatin 
resistance in neuroblastoma and thus, provides evidence of the 
importance of FGFR2 signalling in neuroblastoma chemoresistance. 
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2.3 Material and methods 
Cell culture and reagents 
Neuroblastoma cells were cultured in RPMI 1640 supplemented with 
10% fetal calf serum, 2 mM L-glutamine and 1% 
Penicillin/Streptomycin (Sigma, Buchs Switzerland). All human 
neuroblastoma cell lines were kindly provided by Dr Brodeur, 
Children’s Hospital of Philadelphia, except LAN-1R which was 
provided by Dr. N. Gross (CHUV, Lausanne). The compounds SU-
5402, Rottlerin, PKCβ1 inhibitor, PKCζ inhibitor, LY-29402, PD-
98059, FGF-2 were purchased from Calbiochem (Darmstadt, 
Germany), Enzastaurin was purchased from Selleck Chemicals 
(Houston, TX, USA) and ABT-737 from Chemietek (Indianapolis, IN, 
USA).  
HTS Method 
Neuroblastoma cell lines (10
4
 cells per well for LAN-1 and 7.5 x 10
3
 
cells for SH-SY5Y) were plated in 96-well plates and transfected 24h 
later with siRNA (Silencer Kinase siRNA Library Ambion, Applied 
Biosystems, Foster City, CA, USA) at a final concentration of 30 nM, 
using Lipofectamine 2000 following the manufacturer’s instructions 
(Invitrogen, Carlsbad, CA, USA). The siRNA library used contained 
2157 unique small interfering RNAs (siRNAs) targeting each of the 
719 human kinase genes with 3 individual siRNAs per gene. 
Additional controls were added to each plate of the library. Negative 
controls: siRNA for GAPDH (Ambion), siCONTROL non-targeting 
siRNA Pool (Dharmacon, Waltham, MA, USA), ONTarget Plus non 
targeting siRNA (Dharmacon), and positive controls: siRNA for PLK1, 
EG5 and siCONTROL TOX (Dharmacon). Twenty-four hours 
following transfection, one replica plate was treated with cisplatin (2.5 
µM for LAN-1 and 0.75 µM for SH-SY5Y, Bristol-Myers Squibb, 
New York, NY, USA) and one replica plate with 0.01% NaCl vehicle 
in media. Cell viability was assessed after further 48h using Cell Titer 
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96 Aqueous One Solution Cell proliferation Assay (Promega, Madison, 
WI, USA) as per manufacturer’s instructions. The screen was 
performed in triplicate. To determine the sensitivity to cisplatin, log2 
ratios for each siRNA were computed from the mean of three replica 
siRNA in the presence of cisplatin vs. the mean of three replica siRNA 
in the absence of cisplatin, and expressed as surviving fractions, as 
previously described [50]. Median centered Z-scores were calculated 
from the surviving fractions, in order to allow comparisons. 
Validation of HTS screen 
Two distinct siRNA sequences targeting each candidate hit kinase were 
used to revalidate results from the screen (against FGFR2: siRNA IDs 
118292 and 1215; against PRKCD siRNA IDs 773 and 775; against 
PRKCB1 siRNA IDs 103309 and 261007 against PRKCZ siRNAs ID 
103575 and 103679, Ambion). A significance threshold of p<0.05 
(One-way ANOVA) was expected for each siRNA. Validation of 
RNAi gene silencing was evaluated 48 h after transfection by Western 
blotting for protein expression and by quantitative RT-PCR (Taqman) 
for mRNA expression. 
Antibodies and Western blotting 
Protein expression was analyzed by immunoblotting as described in 
[51]. The following antibodies were used: anti-Bek-1, anti-PKCδ, anti-
PKCβ1, anti-PKCζ, anti-Caspase-3 (Santa Cruz Biotechnology, Santa 
Cruz, CA USA), anti-phosphoThr-PKCδ, anti-Puma, anti-Bcl-XL, anti-
Bad (Cell Signalling Technology, Danvers, MA, USA), anti-Mcl-1, 
anti-BCL2, anti-Bim, anti-Bid, anti-Bak, anti-Bax (Epitomics, 
Burlingame, CA, USA) and anti-β-actin (Sigma). 
Quantitative RT-PCR  
Total RNA was extracted using the RNAeasy kit (Qiagen, Basel 
Switzerland) and converted into cDNA using the SuperScript First-
Strand Synthesis System (Invitrogen) for RT-PCR according to 
manufacturer’s instructions. Real time qPCR was performed using 
 RNAI SCREENING IDENTIFIES A NOVEL ROLE FOR THE AUTOCRINE FIBROBLAST GROWTH 
FACTOR SIGNALLING IN NEUROBLASTOMA CHEMORESISTANCE 
 
65 
Assays-on-Demand Gene Expression products (Applied Biosystems) 
FGFR2 (Hs01552926_m1), PRKCD (Hs00178914), and PRKCZ 
(Hs00177051_m1), PRKCB1 (Hs01034075), BCL2 (Hs00153350_m1) 
and GAPDH (Hs99999905_m1). Relative mRNA expression levels 
were calculated using the comparative threshold cycle (CT) method 
[52]. 
Cell viability assay 
Neuroblastoma cell lines (3 x 10
3
 cells/well) were seeded in 96-well 
plates and grown for 72h in 10% FCS-containing medium in the 
presence of inhibitors, growth factors or vehicle. Cell proliferation was 
assessed by MTS assay using the CellTiter 961 Aqueous One Solution 
Cell proliferation Assay (Promega, Madison, WI, USA) according to 
the manufacturer’s instructions. 
Fluorescence-Activated Cell Sorting Analysis 
For the assessment of apoptosis, cells were analyzed by quantitative 
analysis of phosphatidylserine exposure as previously described [53]. 
Cells were stained with Annexin V-FITC/PI following manufacturer’s 
instructions (Biotium, Hayward, CA, USA). Apoptosis was expressed 
as a percentage of Annexin-V and PI positive cells.  
Plasmid transfection 
Stable transfections were performed with Lipofectamine Plus 
(Invitrogen) following the manufacturer’s instructions. Cells were 
transfected with PRKCD constructs cloned into pWZL Neo Myr Flag 
retroviral plasmid (Plasmid 220603, Addgene, Cambridge, MA, USA) 
and empty vector as control. 48h after transfection, cells were diluted 
1:10 in culture medium containing G418 (0.8 mg/ml, Calbiochem). A 
mixed population of resistant cells was expanded and analyzed after 
selection. 
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Immunohistochemistry 
Paraffin-embedded tissue arrays mounted with 91 biopsies of 
neuroblastoma patients were obtained from the University Medical 
Center Hamburg-Eppendorf, Germany. For immunohistochemistry, the 
sections were prepared and stained as described in ref. [54], except the 
epitope retrieval was done by Proteinase K digestion for 5 min at 37°C. 
The antibodies anti-FGF-2 rabbit polyclonal antibody (ab16828) and 
anti-FGFR2 rabbit polyclonal antibody (ab10648) were purchased from 
Abcam (MA, USA).  
DNA microarray analysis 
Generation of tumor gene expression profiles was previously described 
in ref. [55] and the clinical characteristics of the neuroblastoma patients 
(n = 251) in ref. [56]. Raw and normalized microarray data are 
available at ArrayExpress (accession: E-TABM-38). 
Statistical analysis 
All statistical tests were performed with the software GraphPad Prism, 
except the CI values which were calculated with the software 
Calcusyn. The statistical significance of differences between groups 
was assessed with one way or two way ANOVA, using either Tukey or 
Bonferroni’s multiple comparison test; P < 0.05 was indicated with one 
asterisk, P < 0.01 with a double asterisk, P < 0.001 with a triple 
asterisk. 
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2.4  Results 
siRNA screen  to identify kinases mediating cisplatin resistance 
To identify genes conferring cisplatin resistance in neuroblastoma, we 
designed a robust RNAi-based loss-of function screen using a library of 
short interference RNA duplexes (siRNA) targeting each of the 719 
known protein and lipid kinases in the human genome. The screen was 
performed in two well-characterized neuroblastoma cell lines (LAN-1, 
SH-SY5Y). The cells were systematically transfected with the siRNAs 
and subsequently treated with low dose cisplatin and or vehicle. The 
dose of cisplatin used in the screen was optimized for each cell line to 
achieve a sensitizing effect of 20% decrease in cell survival (EC20) 
(data not shown). The results of the screen are represented as Z-scores 
approximating a normal distribution and are displayed in (Figure 
2-1a,b). In large scale screening approaches off target effects represent 
a significant source of false positive hits. Redundancy in the system 
most likely confirms RNAi target specificity [22]. To rule out off 
targets effects, we only considered a gene as a candidate drug 
resistance gene if at least two independent siRNAs, out of the three 
sequences which were included in the library, caused sensitization to 
cisplatin scaled by an average Z-score bellow – 3. Within the 
candidates in LAN-1 and in SH-SY5Y (supplementary Table 1) that 
fulfilled these criteria, FGFR2 (Z-score -4) resulted the top candidate 
in LAN-1 and PRKCD (Z-score -3) in SH-SY5Y. To validate the 
results obtained in the screen, two different individual siRNA 
sequences targeting FGFR2 and PRKCD were reassayed in both cell 
lines. As expected, resistance to cisplatin was conferred by PRKCD 
and FGFR2 downregulation in SH-SY5Y and LAN-1, respectively. 
Although not as strong as in LAN-1, the downregulation of FGFR2 
also sensitized SH-SY5Y cells to cisplatin (Figure 2-1c).  
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Figure 2-1 Human kinase siRNA high-throughput screen for cisplatin sensitizer 
kinases (a,b) Scattered plot of average Z-Scores from cisplatin sensitivity screen. (c) 
Cisplatin sensitivity assay repeated in triplicate for the hit candidate kinases FGFR2 
with two siRNA sequences in SH-SY5Y and LAN-1 cells. Survival fractions are 
shown, * P < 0.05 compared with scrambled siRNA control, error bars represent the 
SD of the mean of two independent experiments. 
The differences in the sensitivity to FGFR2 downregulation might be 
due to the lower expression levels of FGFR2 in SH-SY5Y compared to 
LAN-1 (Supplementary Figure 2). Thus, the role of FGFR2 as a drug 
resistance candidate gene was further investigated. 
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Validation of siRNA screen hit candidates 
To confirm the specificity of the observed effects, the two different 
siRNA sequences targeting FGFR2 were analyzed for target 
downregulation. Both siRNAs efficiently suppressed FGFR2 
expression at mRNA and protein level (Figure 2-2a), indicating that the 
HTS results were likely to be “on-target”. In order to establish the 
sensitivity to cisplatin treatment, dose-reponse curves were performed 
(Figure 2-2b). FGFR2 silencing significantly shifted EC50 values to 
lower cisplatin doses (siControl EC50 = 4.17, siFGFR2 EC50= 1.32 in 
LAN-1, siControl EC50= 5.02, siFGFR2 EC50= 1.59 in SH-SY5Y).  
 
 
Figure 2-2 Validation of cisplatin sensitizing candidate kinases (a) Validation of the 
siRNA transfection efficiency. Taqman PCR and Western blot showing FGFR2 gene 
downregulation after 48h of transfection with two different siRNA sequences in 
LAN-1 cells. (b) Cisplatin titration in LAN-1 cells transfected with siFGFR2 (white 
squares) or control siRNA (black circles), EC50 (siFGFR2) = 1.32, EC50 (siControl) 
= 4.17. (c) Cell viability assay in LAN-1 cells treated with increasing concentrations 
of cisplatin (circles), increasing concentrations of cisplatin in presence of SU-5402 at 
a constant ratio of 1.25 (triangles) and increasing concentrations of SU-5402 (white 
squares). The combination index according to the Chou-Taladay method is CI = 
0.818. Error bars represent the SD of three independent experiments. 
 
Further confirmation that FGFR2 signalling modulates resistance to 
cisplatin was obtained using SU-5402, a pharmacological inhibitor 
against FGFR2 (Figure 2-2c). To quantify drug synergism, the 
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combinational index CI was calculated by the Chou-Talalay method 
(CI= 0.818) indicating synergism between cisplatin and SU-5402 [23]. 
These results provide strong evidence of the potential role of FGFR2 – 
signalling in neuroblastoma chemoresistance. 
RNAi targeting of FGFR2 induces apoptosis in combination with 
cisplatin 
Cisplatin induces apoptosis associated with DNA damage [24]. We 
initially investigated whether FGFR2 gene silencing sensitized cells to 
cisplatin by triggering apoptosis. Following FGFR2 downregulation, 
the percentage of apoptotic cells was increased from 23.6 to 37.9 % as 
observed from the percentages of Annexin V-positive/PI-negative cells 
(Figure 2-3a). This event was accompanied by caspase-3 activation at a 
low cisplatin dose, at which no sign of apoptosis manifested by 
caspase-3 cleavage was observed in the control cells (Figure 2-3b).  
In order to investigate how FGFR2 initiates the cell death machinery, 
we analyzed the expression levels of the proapoptotic, as well as the 
antiapoptotic members of the BCL2 family of proteins (Figure 2-3c). 
Within the proapoptotic BH3-only proteins, only Bad was upregulated 
in response to cisplatin treatment, and this was only observed in cells 
which had FGFR2 downregulation. Bim, Bid and Puma levels either 
decreased or stayed unchanged. Mcl-1 has been previously shown to 
modulate cisplatin induced apoptosis [25]. In neuroblastoma cells, Mcl-
1 expression was not affected by cisplatin treatment. In contrast, the 
expression of the anti-apoptotic proteins BCL2 and BCL-XL increased 
in response to cisplatin treatment. In addition, BCL2 expression 
correlated with the expression of FGFR2, suggesting that BCL2 
expression is regulated by FGFR2 signalling. To confirm whether 
FGFR2 regulates BCL2 expression, the receptor was stimulated by its 
main ligand fibroblast growth factor-2 (FGF-2) and probed for BCL2 
expression. BCL2 levels dramatically increased after 24h of growth 
factor stimulation in a dose dependent manner (Figure 2-3d). This 
effect was evident for protein expression as well as for mRNA 
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expression, pointing out that the regulation of BCL2 by FGFR2 occurs 
at least in part at the transcriptional level. 
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Figure 2-3 FGFR2 Silencing sensitizes neuroblastoma cells to cisplatin induced 
apoptosis (a) FACS plots showing annexin V and propidium iodide (PI) staining after 
transfection of siFGFR2 or scrambled siRNA in presence or absence of cisplatin (1.5 
μM) in SH-SY5Y cells. Annexin V-positive/PI-negative cells were considered as 
apoptotic cells. Percentages of apoptotic cells were as follows: siControl cells, 26.6 % 
(- cisplatin) and 23.6 % (+ cisplatin); siFGFR2 cells 37.9 % (- cisplatin) and   33.8 % 
(+ cisplatin). (b) Cell lysates of siFGFR2 or siCONTROL transfected cells treated 
with 5μM cisplatin were analyzed by SDS Page and Western blot for apoptosis 
induced by caspase-3 activation. The bands corresponding to procaspase-3 (inactive), 
cleaved caspase-3 (active) and β-actin (loading control) are shown. (c) Western blot 
analysis of the indicated BCL2 family members in lysates of LAN-1 cells treated as 
described in (b). (d) BCL2 protein and mRNA levels quantified by taqman PCR of 
LAN-1 cells stimulated for 24h with increasing concentrations of FGF-2. 
Protein kinase C regulates cell survival in neuroblastoma downstream 
of FGFR2 
We next aimed at analyzing the mechanistic insights of the regulation 
of BCL2 expression by FGFR2. Given that FGFR2 is known to 
activate PKC family members through recruitment and activation of 
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PLCγ [26], we analyzed the possible implications of PKC in FGFR2 
signalling in neuroblastoma. In the initial RNAi screen, we assessed 
changes in cell survival induced by the inhibition of protein and lipid 
kinases in presence or absence of cisplatin.  Not only RNAi targeting 
of the protein kinase C family member PKCδ, but its isoforms PKCβ1 
and PKCζ showed a role in neuroblastoma survival (Supplementary 
Figure 1), and were as well validated. The RNAi-mediated 
downregulation of all three isoforms significantly decreased cell 
proliferation in both cell lines, suggesting that PKC signalling may 
have an important role in neuroblastoma survival (Figure 2-4a). In 
LAN-1 cells the downregulation of PRKCD alone strongly inhibited 
cell proliferation, thus, its combination with cisplatin had rather modest 
effects (Figure 2-4a). Among the PKC isoforms, the inhibition of 
PKCδ had the strongest impact on cell proliferation in both cell lines, 
which was further confirmed with isoform-selective pharmacological 
inhibitors (Figure 2-4b). Previous studies show that PKC regulates 
important cell survival pathways [27]. Western blot analysis revealed 
that the downregulation of PKCδ attenuated important cell survival 
pathways such as the ERK1/2- and mTOR/S6-signalling pathway 
(Figure 2-4d, e). Moreover, the downregulation of PRKCD, but not 
PRKCB1 or PRKCZ, induced apoptosis (Figure 2-4c) and 
downregulation of BCL2, suggesting its involvement in the control of 
apoptosis regulated by BCL2 expression (Figure 2-4d, e) and raising 
the hypothesis that PKCδ may act downstream of FGFR2 to regulate 
BCL2 expression. 
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Figure 2-4 Roles of PKC family isoforms in neuroblastoma cell survival and 
chemoresistance (a) Cisplatin sensitivity assay repeated for PKC family members 
PKC-β1, PKC-δ and PKC-ζ with isoform-specific siRNA sequences in SH-SY5Y and 
LAN-1 cells. The effects on cell viability of the siRNA-mediated target 
downregulation in presence (striped bars) or absence of cisplatin (black bars) was 
normalized to the non-targeting siControl and expressed as percentages. (b) Cell 
viability assay of LAN-1 cells treated for 72h with isoform-selective PKC inhibitors; 
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Rottlerin (circles), PKCβ1 inhibitor (squares), PKCζ inhibitor (triangles), pan-PKC 
inhibitor (rhombus). (c) Apoptosis was assessed by quantification of annexin 
V/propidium iodide (PI) staining after transfection of siPRKCD (26.6 %) or siControl 
in SH-SY5Y (32.3%) cells. (d) Protein expression analysis by Western blot of LAN-1 
cells transfected with siPRKCB1, siPRKCD and siPRKCZ.(e) Cell lysates of LAN-1 
cells incubated with Rottlerin (PKCδ inhibitor) for 24h were analysed for protein 
expression and phosphorylation of the indicated proteins.  
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Figure 2-5 FGFR2 activates PKCδ to modulate cisplatin resistance (a) LAN-1 cells 
were incubated with FGF-2 for 24h. Cell lysates were analysed for PKC-activity by 
Western blot. (b) LAN-1 cells incubated for 24h with the inhibitors (Enzastaurin 
10μM, Rottlerin 5 μM, PD-98059 25μM, LY-29402 10μM, Rapamycin 100μg/ml, 
SU-5402 10μM and DMSO as negative control) and 0.1μg/ml of FGF-2. BCL2 
mRNA levels quantified by taqman PCR and protein levels analyzed by Western blot 
are shown. (c) Protein extracts of Myr-PKCδ expressing LAN-1 cells were analyzed 
by Western blot for activated PKCδ (pPKCδ) and p-PKC Substrates and the indicated 
BCL2 family members. (d) Cell viability assay of stably expressing Myr-PKCδ cells 
incubated for 72h in presence of FGFR2 inhibitor (SU-5402 5 µM), PKCδ inhibitor 
(Rottlerin 5 µM) or DMSO. (e) Cisplatin titration of stably expressing Myr-PKCδ 
(EC50 = 12.11) and vector transfected cells (EC50 = 8.83). 
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To investigate this model, we first analyzed PKCδ activation in 
response to FGF-2 stimulation. Activation by phosphorylation of PKCδ 
occurred in a dose-dependent manner in response to FGF-2 and this 
correlated with the phosphorylation of PKC substrates (Figure 2-5a).  
FGF-2-induced BCL2 expression is mediated by PKC signalling but 
not MEK/ERK or PI3K/AKT/mTOR/S6K signalling 
In view of our previous results, we investigated the possibility that 
FGF-2-mediated activation of PKCδ could account for BCL2 
regulation. Inhibition of different signalling pathways downstream of 
FGFR2 will reveal which of them is important to regulate BCL2, if 
FGF-2 fails to induce BCL2 expression upon pathway inactivation. To 
prove this hypothesis we treated LAN-1 cells with FGF-2 and a panel 
of inhibitors including rottlerin and enzastaurin which target PKCδ and 
PKCβ1, PD-98059 a MEK inhibitor, LY-29402 a pan-PI3K inhibitor, 
rapamycin an mTOR inhibitor and SU-5402 which targets FGFR, and 
analyzed their effects on BCL2 expression. The concentrations of the 
inhibitors used were optimized to achieve optimal pathway inactivation 
(data not shown). The comparative western blot analysis reveals that 
only rottlerin and enzastaurin strongly inhibited FGF-2 mediated 
upregulation of BCL2 (Figure 2-5b). In contrast, the inhibition of the 
PI3K pathway or MEK/ERK pathway had no effect on BCL2 
expression. SU-5402 reduced the levels of BCL2, but only modestly 
compared to the observed effects by rottlerin or enzastaurin. 
Activation of PKCδ increases drug resistance in neuroblastoma cells 
Our results had demonstrated that FGFR2 signalling uses PKCδ to 
activate a prosurvival mechanism involving BCL2 regulation. To 
further support this model, we stably transfected LAN-1 cells with a 
myristoylated catalytically active PRKCD mutant. The expression of 
the constitutively active PKCδ mutant was confirmed as the cells 
showed higher levels of PKC substrate phosphorylation compared to 
cells transfected with the empty expression vector (Figure 2-5c). 
Western blot analysis of the anti-apoptotic BCL2 family members 
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showed that activation of PKCδ correlated with increased Bcl-XL and 
BCL2 levels, although the increases in BCL2 expression were rather 
modest (Figure 2-5c). We investigated whether activation of PKCδ 
could reverse the sensitivity of cells to FGFR2 inhibition. Therefore, 
we treated the stably transfected cells with the inhibitor SU-5402 and 
assessed cell proliferation. The PRKCD-Myr expressing cells were less 
sensitive to FGFR2 inhibition than cells transfected with the empty 
vector (Figure 2-5d). Inhibition of PKCδ by rottlerin lead to a 
significant decrease of cell survival in both transfected cell lines, but 
the difference in the sensitivity to PKCδ inhibition was less marked 
than in the case of SU-5402. Finally, cells transfected with activated 
PKCδ displayed enhanced survival under normal culture conditions 
(data not shown) and were more resistant against cisplatin treatment 
(EC50 shift from 8.83 to 12.11, Figure 2-5e). Together, these results 
show the ability of activated PKCδ to uncouple from FGFR2 signalling 
and to provide neuroblastoma cells a more chemoresistant phenotype. 
Importance of FGFR2 signalling in neuroblastoma chemoresistance 
To further confirm the potential role of FGFR2 in neuroblastoma 
chemoresistance, we used a cell line model derived from LAN-1 cells 
that were selected for doxorubicin resistance, and have proven as well 
resistance against other chemotherapeutic agents including cisplatin 
[28]. We analyzed the expression of FGFR2 and FGF-2 in LAN-1R 
cells (Figure 2-6a). FGFR2 was significantly overexpressed compared 
to its expression in LAN-1 cells. Moreover, LAN-1R cells expressed 
FGF-2 in protein and mRNA level, whereas in the other NB cell lines 
FGF-2 was only detected at mRNA level (Figure 2-6b). In LAN-1R the 
elevated levels of FGF-2 and FGFR2 were correlated BCL2 
expression, which is in agreement with the previous observations, that 
BCL2 was overexpressed in comparison to the parental cell line [28]. 
These results demonstrate the importance of FGFR2 signalling in 
neuroblastoma acquired chemoresistance.  
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Figure 2-6 Protein expression of LAN-1R cells (a) Protein extracts of LAN-1R cells 
were analyzed by Western blot for FGFR2, FGF-2 and BCL2.  (b) Semi quantitative 
PCR of FGF-2 in NB cell lines. 
Targeting BCL2 inhibits cell survival and enhances the effects of 
cisplatin in neuroblastoma cells  
ABT-737 is a potent BCL2 and Bcl-XL inhibitor that has shown great 
antitumor effects in preclinical models and has entered Phase I clinical 
trials for the treatment of adult cancers [29]. Given that neuroblastoma 
cells induced BCL2 as a pro survival mechanism to overcome cell 
death, targeting BCL2 with pharmacological inhibitors provides a 
rational to efficiently induce cell death in neuroblastoma. Here, we 
tested the effects of ABT-737 in the neuroblastoma cell lines SH-
SY5Y, LAN-1. In both cell lines, increasing concentrations of ABT-
737 impaired cell survival and had a strong synergistic effect with 
cisplatin (CI=0.512 for SH-SY5Y and CI=0.411 for LAN-1, Figure 
2-7a, b). In addition, we investigated if neuroblastoma cell lines that 
display a chemoresistant phenotype were also sensitive to BCL2 
inhibition. We therefore investigated the sensitivity to ABT-737 in 
LAN-1R cells and the above described LAN-1 cells, which stably 
express activated PKCδ. Also in both cell lines, ABT-737 inhibited cell 
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survival and had synergy with cisplatin, although compared with the 
parental cell line LAN-1, the combinational effect with cisplatin in 
LAN-1R was less significant (LAN-1-PRKCD-myr CI=0.473, LAN-
1R CI = 0.633, Figure 2-7c,d).  
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Figure 2-7 Targeting ABT-737 in neuroblastoma cell lines (a,b,c,d) Cell viability 
assay of SH-SY5Y (a), LAN-1 (b), PRKCD-myr LAN-1 transfectant (c) and LAN-1R 
(d) treated for 72h with ABT-737 (circles), cisplatin (rhombus) and the combination 
of ABT-737 and cisplatin at a constant ratio (1:2.5). Combinational indexes were 
calculated (SHSY5Y CI = 0.512; LAN-1 CI = 0.411; (PRKCD-myr LAN-1 
transfectant CI = 0.473; LAN-1R CI = 0.633). Error bars represent the SD of the 
mean of three independent experiments. 
Expression of FGFR2 in NB tumor samples 
In order to investigate the clinical relevance of FGFR2 and FGF-2 in 
neuroblastoma tumor samples, a total of 91 samples of neuroblastomas 
available as a tissue microarray (TMA) were probed for protein 
expression by immunohistochemical staining (Figure 2-8a-d). FGFR2 
was detected in all neuroblastoma primary tumors, whereas 80% was 
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scored as positive (53 of 66), 3% as strong positive (2 of 66) and 17% 
as weak positive (11 of 66). Among the metastatic tumors 81% were 
positive (21 of 26) and 19% were weak positive (5 of 26). Expression 
of FGF-2 was quantified positive for 30% of primary tumors (20 of 
67), strong positive for 3% (2 of 67), weak positive for 61% (41 of 67), 
and negative for only 6% (4 of 67). Notably, metastatic tumors showed 
higher scores for FGF-2, only one tumor was negative  for FGF-2 
accounting for 4% of all samples of metastatic tumors (26), 42% were 
positive (11 of 26) and 56% were weak positive (14 of 26).  
 
Figure 2-8 Analysis of the expression of FGFR2 and FGF-2 in NB patients (a-d). 
Representative NB samples of TMA analysis showing the different 
immunoreactivities for FGFR2 in positive (a) and weakly positive samples (b) and for 
FGF-2 in positive (c) and negative samples (d). (e) DNA microarray analysis of 251 
NB patient samples showing the expression of FGFR2 in correlation to tumor stage 
(stages 1,2,3,4S vs. stage 4, left panel) or to MYCN amplification status (right panel). 
P values from the Wilcoxon-test are indicated. 
Consisting with these findings, a DNA microarray study of 251 patient 
samples revealed that FGFR2 is expressed in neuroblastoma tumors 
and it moreover correlates with higher disease stage and MYCN 
amplification (Figure 2-8e). 
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2.5 Discussion 
The poor outcome of high-risk neuroblastoma patients with current 
multimodal therapies justifies the development of novel targeted 
therapies for this common childhood cancer. The development of 
chemoresistance has been demonstrated to be a major cause for 
treatment failure in neuroblastoma, as well as in many other human 
cancers [1, 17]. Cisplatin is commonly used in current multimodal 
therapeutic regimens in high risk NB and multiple resistance 
mechanisms have been described against this drug in human cancer [2-
4]. It has been demonstrated that the deregulation of intracellular 
signalling pathways controlling apoptosis plays a major role in 
cisplatin resistance in human cancer [2]. By using high throughput 
RNAi screens in established NB cell lines, we have identified novel 
potential drug targets involved in NB survival and resistance to 
cisplatin. A previous report using RNAi screening identified novel 
protein kinases involved in NB cell proliferation [30]. Amongst these 
kinases, CHK1 was validated as a novel target [30]. In our screen, the 
downregulation of CHK1 did not show significant effects in cell 
survival, the different results might be explained due to the biological 
variability within the cell lines used. However, in agreement with this 
screen, we identified in our cell lines also BMPR1A and RPS6KB1 as 
hit candidate kinases. Moreover, our screen identified AURKB as an 
important regulator of cell survival in neuroblastoma cells harboring 
MYCN amplification, consistent with a previous study in which the 
related isoform AURKA was identified from a shRNA screen as a gene 
that is required for the growth of MYCN-amplified neuroblastoma cells 
[31]. 
The comparative analysis of the kinases identified as chemosensitizer 
kinases in the NB cell lines used in our study revealed that FGFR2 was 
the most promising candidate. LAN-1 cells have MYCN amplification, 
while SH-SY5Y are MYCN single copy. This may in part explain that 
there were significant differences in the identity of the chemosensitizer 
kinases identified in the two NB cell lines. Intriguingly, MYCN 
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expression also correlated with FGFR2 expression in primary NB, 
which may account for the stronger impact of FGFR2 silencing on 
cisplatin sensitivity in LAN-1, as compared to SH-SY5Y. In support of 
our findings, the FGFR2 has been recently implicated in modulating 
resistance to cisplatin kinase in ovarian cancer [32].  
Alterations in FGFR2 have been widely identified in human cancers. 
Gene amplification or mutations of FGFR2 were reported in breast 
cancer, gastric cancer, lung cancer, ovarian cancer, and endometrial 
cancer [33-36]. Genetic alterations may induce aberrant FGFR2 
signalling activation due to the release of FGFR2 from auto inhibition, 
or through creation of FGF signalling autocrine loops [26]. In 
neuroblastoma, FGF-2 was previously identified in advanced-stage 
tumors (stages 3 and 4) compared with low-stage tumors (stages 1, 2, 
and 4S) [37]. Consistent with this study, our data indicate that FGFR2 
is activated by an autocrine loop involving FGF2 in NB cells. This 
model is based on the following observations: (i) FGF-2 is consistently 
expressed in primary NB and NB cell lines; (ii) FGF-2 activates 
FGFR2 signalling in NB cell lines at nanomolar concentrations; (iii) 
pharmacological inhibition of FGFR2 tyrosine kinase activity blocks 
the effect of FGF-2 on BCL2 expression; (iv) the expression of FGF-2 
and FGFR2 is up-regulated in NB cell lines with acquired 
chemoresistance. The observation that the expression of FGF-2 and 
FGFR2 is up-regulated in NB cell lines with acquired chemoresistance 
points to a more general role of this signalling pathway in the 
resistance of NB cells to other chemotherapeutic agents, such as 
doxorubicin. Moreover, the fact that FGFR2 is over-expressed in 
higher stage tumors emphasizes the importance of FGFR2 signalling in 
the development of malignant transformation in neuroblastoma. 
Mechanistically, FGFR2 signalling altered the expression profile of 
anti-apoptotic BCL2 family proteins in NB cells, resulting in a 
decrease in the sensitivity of the cells to cisplatin-mediated apoptosis.  
PKC isoforms were shown to play a major role in FGFR2 signalling to 
BCL2, in contrast to other signalling pathways, such as PI3K/mTOR 
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and Erk. BCL2 family proteins have been extensively studied for their 
role in modulating cancer chemoresistance. A previous study has also 
documented the potential of targeting BCL2 family proteins with ABT-
737 in NB [38, 39], which is consistent with our findings. Previous 
reports have documented that FGF-2 signalling protects small cell lung 
cancer (SCLC) cells from chemotherapy-induced apoptosis by 
modulating the expression levels of BCL2 family proteins [40, 41]. 
Intriguingly, PKC isoforms were reported to be involved in transducing 
FGF-2/FGFR-1 signals to BCL2 family proteins in SCLC cells, but the 
mechanism involved post-transcriptional events [40]. In contrast, FGF-
2-mediated up-regulation of BCL2 occurred at the transcriptional level 
in NB cells, which may be accounted for by differences in FGFR 
isoform involvement. Several transcription factors may be involved in 
transducing the signal from FGFR2/PKC to BCL2, including NF-kB 
[42]. PKC is known to regulate the inhibitor of kappa B kinase (IKK) 
and induce NF-kB activation B- and T-cells, a process which is 
important for the adaptive immune response [43, 44], although the 
main role is attributed to the isoform PKC-β1, it has been as well 
reported that NF-kB is activated by PLC-γ and PKCδ [45]. 
Importantly, our data have a direct relevance to translational cancer 
research in NB, since there are several pharmacological inhibitors of 
FGFR in clinical trials, including ZD-4547, BGJ398 and FP-1039, 
which are entering Phase I or II for the treatment breast cancer or 
gastric cancers with FGFR2 amplification, endometrial cancers with 
FGFR2 mutations or advanced solid cancers with FGFR1,2,3 
amplifications [46]. In addition, Enzastaurin is also in clinical trials for 
other human cancers [46, 47], such as glioblastoma, multiple myeloma, 
non-hodgkin's lymphoma, breast cancer and non small cell lung cancer. 
Among them, enzastaurin has already proven antitumor effects in 
myeloma and NSCLC patients [48, 49]. The ability to detect FGF-2 in 
the urine of cancer patients may also be relevant for the future 
development of novel prognostic biomarkers in NB patients.  
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Together, our findings indicate that FGFR2 is a determinant for 
cisplatin response and suggest a therapeutic option to improve the 
efficacy of chemotherapeutic agents in the treatment of high risk 
neuroblastoma patients. 
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2.6 Supplementary information 
 
SH-SY5Y  LAN-1 
 
Gene Z Gene Z 
PRKCD -3 FGFR2 -4 
EPHA5 -3 RPS6KA2 -4 
EPHB1 -3 SPHK2 -4 
FLJ10842 -3 HCK -3 
GALK2 -3 WEE1 -3 
GRK6 -3 BMPR2 -2 
MAP3K7IP2 -3 FYN -2  
Suppl. Table 2-1 Human kinase siRNA high-throughput screen for cisplatin 
sensitizer kinases. The kinases, which being down-regulated led to a sensitization to 
cisplatin treatment, with at least two unique siRNA sequences are listed. Z-scores are 
averages of the two siRNA unique sequences, which caused the sensitization to 
cisplatin. 
 
Suppl. Figure 2-1 Human kinase siRNA high-throughput screen for kinases involved 
in proliferation. Kinases, which when being downregulated led to a > 25% decrease 
in cell proliferation compared with a negative control, with at least two unique siRNA 
sequences. 
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Suppl. Figure 2-2 Protein expression of NB cell lines. Whole cell lysates of NB cell 
lines were extracted and analysed by western blotting for the expression of the 
indicated proteins. 
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3.1 Abstract 
Medulloblastoma is the most common malignant brain tumour in 
children and is associated with a poor outcome. We were interested in 
gaining further insight into the mechanisms underlying the role of the 
phosphoinositide 3-kinase (PI3K) p110α isoform in medulloblastoma 
cell proliferation and survival. The impact of RNA interference 
(RNAi)-mediated silencing of p110α on global gene expression was 
investigated in medulloblastoma cell lines, in order to identify potential 
target genes. DNA microarray analysis revealed a subset of genes that 
were selectively altered in expression upon p110α silencing, in 
comparison to silencing of the closely related p110δ isoform. Amongst 
these genes, the leukemia inhibitory factor receptor α (LIFRα) was 
validated as a novel p110α target in medulloblastoma. A bioinformatics 
analysis revealed a gene network involving c-Myc, which controls 
LIFRα expression downstream of p110α. LIFRα expression was found 
elevated in primary medulloblastoma, in comparison to normal 
cerebellum. In addition, an autocrine signalling loop involving 
leukemia inhibitory factor and the LIFRα was uncovered in 
medulloblastoma cell lines. Targeting the LIFRα by RNAi or by using 
a neutralizing antibody impaired medulloblastoma cell proliferation 
and induced apoptosis. Together these data reveal a novel function of 
the LIFR as a downstream target of PI3K signalling in 
medulloblastoma cell proliferation and survival.  
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3.2 Introduction 
Medulloblastoma is the most common malignant brain tumour in 
children and accounts for approximately 20% to 25% of all pediatric 
central nervous system tumours [1]. Most medulloblastoma occur at 
between 5 and 10 years of age [1, 2]. The standard treatment of 
medulloblastoma involves surgery followed by chemotherapy and, in 
the case of children older than 3-5 years, radiotherapy [3, 4]. Although 
these therapeutic approaches are often effective at shrinking the 
primary tumour, recurrence and metastasis frequently occur, so that the 
5-year survival rate is below 50% for high-risk patients [3]. There is an 
urgent need to develop novel targeted therapeutic approaches for 
medulloblastoma, which will originate from a better understanding of 
the disease biology.  
Medulloblastoma has been recognized to be a heterogeneous disease, 
and no recurrent cancer gene mutations have been found [4], although 
many of the mutations described so far affect key intracellular 
signalling pathways, such as sonic hedgehog (SHH) and Wnt/β-catenin 
[4]. Genomic studies in large series of primary medulloblastoma have 
led to a novel classification of medulloblastoma into different 
molecular subtypes, characterized by the activation of sonic hedgehog 
(SHH), Wnt/ β-catenin or c-Myc pathways [5, 6]. c-Myc plays an 
important role in medulloblastoma biology and targeting the signalling 
networks controlled by c-Myc may be a promising approach to develop 
targeted therapies for the subsets of tumors in which c-Myc is activated 
[7-9]. 
Another signalling pathway which is being considered to develop 
targeted therapies for medulloblastoma, is the receptor tyrosine kinase 
(RTK) cascade, which links polypeptide growth factors to cellular 
responses via their downstream signalling intermediates, in particular 
phosphoinositide 3-kinase (PI3K), Akt, the mammalian target of 
rapamycin (mTOR) and mitogen-activated extracellular signal-
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regulated kinase activating kinase (MEK) [10-14]. Clinical trials have 
started to evaluate the safety and efficacy of agents targeting this 
pathway in medulloblastoma. 
The PI3K signalling pathway controls key cellular responses, such as 
cell growth and proliferation, survival, migration and metabolism [15, 
16]. Over the last decades, it has been recognized that this intracellular 
signalling pathway is frequently activated by genetic and epigenetic 
alterations in human cancer, including malignant brain tumors [6, 14]. 
The PI3K family of signalling enzymes comprises eight catalytic 
isoforms, which are subdivided into three classes. The class IA PI3K 
isoform p110α is considered to be a validated drug target in human 
cancer, in particular because activating mutations in the PIK3CA 
frequently occur in human cancer.  In medulloblastoma, the PIK3CA 
gene is targeted by mutations at a low frequency [17], but the p110α 
isoform is found over-expressed in primary tumors and cell lines [14]. 
Targeting p110α by RNAi or isoform-specific inhibitors impaired 
medulloblastoma cell proliferation, survival and chemoresistance [14].  
In this report we have analyzed the downstream targets of p110α in 
medulloblastoma and show for the first time that selective gene 
networks, comprising c-Myc and the leukemia inhibitory factor 
receptor α (LIFRα) contribute to oncogenic p110α signalling in 
medulloblastoma. 
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3.3 Materials and Methods 
Cell culture and treatments 
The MB cell lines were obtained and cultured as described in [14], the 
stable clones DAOY V11 (empty vector transfected) and DAOY M2 
(MYC vector transfected) were described in [18] and the c-Myc-
inducible clones UW228 were described in [19]. Tetracycline and 
tamoxifen (Sigma, Buchs, Switzerland) were used to induce c-Myc 
expression. 
The PI3K inhibitors PIK75 and YM024 were dissolved in DMSO at 10 
mM and diluted to the indicated concentrations in cell culture medium 
just before use. The Anti-human LIFRα Antibody was purchased from 
R&D Systems (Minneapolis, MN, USA) and was diluted directly into 
the medium immediately before use. For growth factor stimulations, 
cells were grown to confluence, starved overnight in culture medium 
containing 1% FCS. Cells were maintained in serum-free RPMI for 1 h 
and were then stimulated with Oncostatin M (OSM, Sigma, Buchs, 
Switzerland) for 10 min. 
RNA Interference 
MB cell lines were transfected with siRNA pools, each comprising four 
individual oligonucleotides (SMARTpool small interfering RNA 
reagents; Dharmacon, Waltham, MA, USA), directed against PIK3CA, 
PIK3CD, MYC, LIFR using Lipofectamine 2000 (Invitrogen) as 
directed by the manufacturer for adherent cell lines. siCONTROL Non-
targeting siRNA Pool (Dharmacon) composed of four siCONTROL 
Non-targeting siRNAs was used as negative control. All siRNAs were 
used at a final concentration of 20 nM. Cells were incubated for 24 to 
72 h to allow target down-regulation. After 24, 48, and 72 h, mRNA 
and protein were extracted to assess protein expression by Western 
blotting and mRNA expression by TaqMan assay. 
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DNA microarray expression profiling and data analysis 
The cDNA microarray analysis was performed in collaboration with 
the Functional Genomic Center of the University Zurich, Switzerland. 
Human Genome-U133 Plus 2.0 Affymetrix GeneChips arrays 
(Affymetrix, Santa Clara, CA, USA) were used to assess the gene 
expression data. Raw data generated by the GCOS Software 
(Affymetrix) were processed by using the RMA method and further 
statistically analyzed by using the software R and applying Student’s t-
test. 
Each experiment represented a group of three independent biological 
replicates. Results are expressed as fold change, and differences in 
expression were considered significant if the fold change was > 2.0 or 
<-2 and the P-value < 0.01. Comparative and cluster analysis of the 
data were performed using the softwares Venny, Cluster 3.0 and 
TreeView. The GeneGO MetaCore (GeneGO, St Joseph, MI, USA) 
was used to identify affected pathways and networks of genes, 
according to their ontological categories. 
Gene expression analysis 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Basel, 
Switzerland) and converted into cDNA using High-Capacity cDNA 
Reverse Transcription Kit according to manufacturer's instructions 
(Applied Biosystems, Foster City, CA, USA). Assays-on-Demand 
Gene Expression products (Applied Biosystems) were used to measure 
mRNA expression levels of PIK3CA (Hs00907965_m1), PIK3CD 
(Hs00192399_m1), MYC (Hs00153408_m1), LIFR (Hs00158730_m1) 
and GAPDH (Hs99999905_m1; internal control gene). Relative mRNA 
expression levels were calculated using the comparative threshold 
cycle (CT) method. 
For semi-quantitative analysis of the gene expression, the One-Step 
RT-PCR Kit (Qiagen) was employed. The following primers were 
used: sequences LIF, LIFR, GAPDH (Microsynth, Balgach 
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Switzerland). DNA was stained with GelRed (Biotium, Hayward, CA, 
USA), and separated in 2.5% agarose gels. 
Western blotting 
Cell lysates were prepared in RIPA buffer (50mM Tris-Cl, pH 6.8, 
100mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with 
Complete Mini Protease Inhibitor Cocktail (Roche Applied Sciences) 
and with the phosphatase inhibitors β-glycerophosphate (20mM) and 
Na3VO4 (200 mM). Proteins were separated by SDS–polyacrylamide 
gel electrophoresis and western blotting on polyvinylidene fluoride 
membranes PVDF (Amersham, GE Healthcare, UK). Antibodies 
specific for PI3K p110α, p110δ, c-Myc, LIFR, Akt1/2/3, ERK 1/2, 
STAT3, S6 protein (Santa Cruz Biotechnology, CA, USA), phospho- 
ERK1/2 (Thr202/Tyr204), phospho-Akt (Ser473; Thr308), phospho-S6 
(Ser235/Ser236; Ser240/Ser244), phospho-STAT3 (Tyr705) (Cell 
Signalling Technology, Inc., Danvers, MA, USA), β-actin (Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland). Chemiluminescence was 
detected using SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Fisher Scientific Inc., Rockford, IL, USA). 
Plasmid transfections 
DAOY cells were transfected with expression plasmids using the 
Lipofectamine Plus reagent (Invitrogen) according to the 
manufacturer's recommended protocol. The plasmids pcDNA3-
PIK3CA Nr. 3 and 4 encoding wild type PI3K-p110α and pcDNA3 
(negative control) were described in [20]. 
Cell proliferation and apoptosis assays 
Cell proliferation was assessed using the Cell Titer 96 Aqueous Cell 
Proliferation Assay (Promega, Madison, WI, USA). Apoptosis was 
assessed measuring the activity of caspases 3 and 7 using Caspase-Glo 
3/7 Assay (Promega) as per manufacturer’s instructions. Data are 
expressed as average values from three independent experiments. 
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Statistical analysis 
All experiments were performed at least in triplicates. Data are 
represented as mean ± s.d. The statistical significance of differences 
between groups was assessed with ANOVA using Tukey’s post tests 
using the statistical software GraphPad PRISM 5; P <0.05 were 
considered significant and indicated with a single asterisk, a double 
asterisk if P <0.001 or a triple asterisk if P <0.001. 
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3.4 Results 
Gene expression analysis reveals selective gene subsets regulated by 
p110α 
In order to investigate whether the class IA PI3K isoform p110α 
controls the expression of specific gene subsets in medulloblastoma, 
we performed DNA microarray analysis in DAOY cells transiently 
transfected with either control siRNA, siRNA targeting p110α, siRNA 
targeting p110δ, or the combination of p110α and p110δ siRNAs. The 
efficacy of the down-regulation of the target proteins by the respective 
siRNAs was demonstrated by Western blot analysis, as well as 
quantitative RT-PCR (Figure 3-1a). Silencing p110α  
significantly affected the expression of over 350 genes, while silencing 
p110δ resulted in significant changes in about 250 genes, and both 
p110α and p110δ about 300. A comparative analysis revealed that 60 
genes were commonly found as downstream targets of p110α and 
p110δ. The resulting sets of differentially expressed genes were further 
analyzed by using different bioinformatics tools, in order to search for 
functional networks between genes based on the gene ontology and to 
narrow down the amount of data generated (Figure 3-1). 
Silencing of p110α perturbs multiple transcriptional networks in 
medulloblastoma 
To gain insight into the transcriptional networks affected by silencing 
of p110α and p110δ in medulloblastoma cells, we performed a 
biostatistics analysis of the gene expression data with GeneGO 
MetaCore. The transcriptional networks that were most significantly 
altered comprised c-Myc, the estrogen receptor (ER), p53 and STAT3 
(Table 1). The transcriptional network involving c-Myc included the 
LIFRα as a target gene (Figure 3-1c). LIFRα was found to be more 
significantly down-regulated in DAOY cells transfected with p110α 
siRNA, than in the case of p110δ siRNA (Figure 3-1b and Table 2), 
suggesting that it is selectively regulated by p110α. Interestingly, 
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STAT3, a downstream target of the LIFR (Figure 3-5) was identified as 
one of the most significantly altered networks (Table 1). Thus, down-
regulation of PIK3CA and PIK3CD perturbs multiple transcriptional 
networks in medulloblastoma cells, most notably c-Myc, which is 
involved in controlling LIFRα expression [21]. 
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Figure 3-1 Gene expression analysis.  (a) DAOY cells were transfected with siRNA 
against PIK3CA, PIK3CD or PIK3CA and PIK3CD and analyzed 48h post 
transfection for gene down-regulation at mRNA level by real-time PCR and at protein 
level by Western blot. (b) Heat map representing the expression of PIK3CA and 
PIK3CD commonly regulated genes. (c) GeneGo Metacore analysis of transcriptional 
networks, the network of c-Myc-regulated genes is shown. 
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Table 3-1 Genes involved in the 
transcriptional network of c-Myc. 
Foldchanges in the gene expression 
of DAOY cells with were transfected 
with the indicated siRNAs (targeting 
PIK3CA, PIK3CD or both) versus 
control siRNA are listed for the 
genes which are transcriptionally 
regulated by cMyc. 
 
 
 
 
 
PI3K-p110α dependent regulation of LIFRα expression 
In order to validate the LIFRα as a bona fide target of p110α in 
medulloblastoma cell lines, we first used quantitative RT-PCR 
(TaqMan) and Western blot analysis to confirm the results obtained 
from the DNA microarrays. Down-regulation of the expression of the 
LIFRα could indeed be demonstrated at the mRNA and protein level 
upon p110α silencing (Figure 3-2a). We next sought to investigate 
whether pharmacological inhibition of p110α also reduced LIFRα 
expression levels in medulloblastoma cell lines. YM024, a selective 
p110α inhibitor effectively reduced the expression levels of the LIFRα 
in a dose-dependent manner (Figure 3-2b). The levels of LIFRα down-
regulation achieved by treatment of DAOY with a low dose (1 μM) of 
 PIK3CA PIK3CD PIK3CA/D 
LIFR -6.5 -2.0 -1.3 
myotrophin -4.2 -2.6 -1.1 
p19 -3.1 -2.1 -3.0 
SOX2 -2.3 -4.0 -2.2 
SLC6A15 -2.3 -3.2 -3.8 
SEC61A2 -2.2 -3.0 -2.7 
ATF3 -1.2 -2.4 -3.2 
MCL1 -1.3 -2.9 -1.7 
CXCR4 -1.9 -2.9 -1.8 
Cyclin E2 -3.1 -1.3 1.3 
CD69 -2.7 -2.3 -3.1 
pCIP/SRC3 -2.7 -1.9 -2.0 
BFL1 -1.7 -1.7 -3.0 
POLR3G -4.9 1.4 1.3 
SLC16A6 -1.1 3.2 1.8 
NFIA 1.3 2.2 2.6 
MBNL1 2.0 3.2 3.7 
LAMP2 2.8 5.0 6.2 
CDK6 4.6 4.5 3.8 
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YM024 were comparable to the response observed upon p110α 
silencing by siRNA (Figure 3-2a,b). 
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Figure 3-2 PI3K-p110α dependent regulation of LIFRα expression. Expression of 
LIFRα was analyzed by quantitative real-time PCR and Western blot in DAOY cells 
transfected with siRNA against PIK3CA (a), or treated with YM024 at 1 µM or 5 µM 
(b). (c) The pcDNA3 vector containing a coding sequence for PIK3CA was 
transfected into DAOY cells, 48h post transfection cell lysates were analyzed for 
PIK3CA and LIFRα protein up-regulation by Western blot or LIFRα mRNA 
expression semi quantitative RT-PCR. 
 
To further confirm these observations, DAOY cells were transiently 
transfected with a plasmid encoding wild type p110α. Increased 
expression of p110α induced an up-regulation of the LIFR both at the 
mRNA and protein level (Figure 3-2c). Collectively, these results 
confirm that p110α controls the expression of the LIFRα in 
medulloblastoma cell lines.  
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Regulation of LIFR by c-Myc downstream of p110α 
We next aimed at analyzing the mechanism in which p110α may 
regulate LIFRα expression. According to the analysis of transcriptional 
networks performed with GeneGo, c-Myc is a transcription factor for 
LIFRα. To confirm this, possible binding sites of c-Myc on LIFR 
promoter sequence were investigated using the software Genomatix. 
More than 40 possibilities were found (data not shown), providing us a 
hint that also in medulloblastoma cells c-Myc may bind to the LIFRα 
promoter.   
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Figure 3-3  p110α regulates LIFR expression through c-Myc. The protein expression 
levels of c-Myc and LIFRα were evaluated by western blot in (a) DAOY-derived cell 
clones (empty-vector-transfected DAOY V11, MYC-transfected DAOY M14) and 
(b) in UW228 MycER cells induced for c-Myc expression by tamoxifen for 24h, 48h 
and 72h. (c) LIFRα protein level was analysed by western blot in inducible UW228 
MycER cells treated with 100nM of the p110α inhibitor PIK75 for 12h, 24h, and 30h. 
Phospho S6 Ser 235/236 and c-Myc expression were also analysed. (d) C-Myc was 
induced with tamoxifen in presence or absence of 100nM PIK75 and analysed for 
LIFR expression.  
First, we analyzed the expression of LIFRα in a DAOY-derived cell 
clone, which over-expresses c-Myc and we found a correlation between 
c-Myc and LIFR expression (Figure 3-3a). Secondly, we used the 
inducible MB cell line UW228-MycER which expresses a fusion 
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product of c-Myc and the estrogen receptor upon induction by 
tamoxifen. We observed that LIFR is expressed in a time dependent 
manner which is synchronized with the induction of c-Myc expression 
(Figure 3-3b). Moreover, inhibition of p110α by PIK75 abolished c-
Myc induced expression of LIFRα (Figure 3-3c). 
Expression of LIFRα and LIF in medulloblastoma 
Our previous work has documented an over-expression of p110α in 
primary medulloblastoma, as well as in medulloblastoma cell lines 
[14]. Therefore, we hypothesized that the LIFRα may also be over-
expressed in medulloblastoma. A panel of medulloblastoma cell lines 
was screened for LIFRα expression by semi quantitative RT-PCR and 
Western blot analysis (Figure 3 4a,b). MB cell lines displayed 
increased expression of the LIFRα, when compared to normal brain or 
cerebellum (Figure 3-4b). We next sought to investigate whether LIF 
was co-expressed with its receptor in medulloblastoma cell lines. This 
analysis showed that 5 out of 6 cell lines expressed detectable levels of 
LIF mRNA (Figure 3-4a). In addition, three cell lines (DAOY, UW228 
and PFSK) co-expressed LIF and high levels of the LIFRα (Figure 
3-4a,b), indicating the presence of an autocrine loop in a subset of 
medulloblastoma cell lines. 
The expression of the LIFRα was next determined in primary 
medulloblastoma, by re-analyzing DNA microarray data obtained in 
primary brain tumors (available from the public database Oncomine). 
The LIFRα was found to be over-expressed in medulloblastoma, when 
compared to normal cerebellum (Figure 3-4c). Together these data 
show that the LIFRα is over-expressed in primary medulloblastoma 
and medulloblastoma cell lines, and that an autocrine signalling loop 
involving LIF and its receptor is present in a subset of cell lines. 
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Figure 3-4 Expression of LIFRα and LIF in medulloblastoma cell lines and primary 
brain tumors. (a) LIF and LIFR mRNA expression in medulloblastoma cell lines was 
analysed by semi quantitative RT-PCR. (b) LIFRα protein levels in medulloblastoma 
cell lines vs. normal brain (NB) tissue were evaluated by Western blot and compared 
with β-actin as the loading control. (c) Box-plot illustrating the expression of LIFRα 
in medulloblastoma tumor samples (N = 60) versus normal cerebellum (N = 4), 
teratoid rhabdoid (N = 5), glioblastoma (N = 10), neuroectodermal tumor (N=6). 
LIFR activation stimulates multiple intracellular signalling pathways 
in medulloblastoma 
In order to investigate whether the LIFR is indeed functional in 
medulloblastoma cell lines, we analyzed the activation status of 
downstream signalling pathways in response to cell stimulation with 
oncostatin M (OSM), a potent activator of LIFR signalling. Dose-
dependent activation of STAT3 could be detected, starting at a 
concentration of OSM of 5 ng/ml and with a maximal effect at 50 
ng/ml in DAOY cells (Figure 3-5). In addition, a significant activation 
of Akt and Erk1/2 was observed at a concentration of 10 ng/ml and 5 
ng/ml, respectively (Figure 3-5). In view of the activation of these 
classical downstream signalling pathways, it can be concluded that the 
LIFR is indeed functional in medulloblastoma cell lines.  
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Figure 3-5 LIFR stimulation activated intracellular signalling pathways in 
medulloblastoma cell lines. Cell lysates of DAOY cells stimulated with oncostatin M 
(OSM) for 10 min were analyzed for protein expression and phosphorylation of the 
indicated proteins. 
Impact of LIFRα down-regulation on cell proliferation and survival in 
medulloblastoma 
We have previously shown that p110α contributes to a variety of 
cellular responses in medulloblastoma cell lines, including cell 
proliferation and survival [14]. Therefore, we studied the impact of 
targeting the LIFRα by RNA interference or by using a neutralizing 
antibody on medulloblastoma cell responses. We first used siRNA to 
transiently down-regulate the expression of the LIFRα in 
medulloblastoma cell lines (Figure 3-6a). Down-regulation of the 
LIFRα induced apoptosis, as shown by increased caspase-3/7 activity 
and led to decreased cell proliferation in DAOY and UW228 cell lines 
(Figure 3-6c).  
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Figure 3-6 Effects of LIFRα down-regulation on medulloblastoma cell proliferation 
and survival. (a) Protein expression level of LIFR in DAOY cells transfected with 
siRNA against LIFRα compared to the control siRNA transfected cells. (b) Induction 
of apoptosis was evaluated in DAOY after 24h of transfection of LIFRα-siRNA or 
control siRNA. (c) The effects on cell viability of the siRNA-mediated target down-
regulation of LIFRα (white bars) compared to control siRNA (black bars) in DAOY 
and UW228 cells was assessed for the indicated time points and expressed as 
percentages (d) Cell viability was evaluated in DAOY cells treated for 48h with an 
anti-LIFRα neutralizing antibody at the indicated concentrations. 
 
These results were confirmed using a neutralizing antibody directed 
against the LIFRα. Antibody treatment induced a dose-dependent 
decrease in cell proliferation in DAOY cells (Figure 3-6d). Together 
these findings confirm that the LIFRα contributes to cell proliferation 
and protection from apoptosis in medulloblastoma cell lines. 
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3.5 Discussion 
The PI3K/Akt pathway has been demonstrated to play a key role in 
medulloblastoma cell proliferation, survival, chemoresistance and 
migration [6, 14, 22, 23]. Mutations in PIK3CA were reported in 
primary medulloblastoma [17], as well as increased expression of 
PIK3CA at the mRNA and protein level [14]. Isoform-specific or broad 
specificity PI3K inhibitors have shown anti-tumor activity in 
medulloblastoma models in vitro and in vivo [14, 22]. In general, these 
agents reduced the activation status of classical PI3K downstream 
targets, such as Akt, mTOR, S6K or GSK-3β [24]. 
Targeting p110α by RNAi or isoform-specific inhibitors had more 
pronounced effects on medulloblastoma cell responses than in the case 
of p110β or p110δ, indicating a selective role for p110α in 
medulloblastoma [14]. This hypothesis was also confirmed by the 
observation that PIK3CA was over-expressed in primary 
medulloblastoma, compared to normal cerebellum, which was not the 
case for PIK3CB or PIK3CD [14]. In view of these observations, we 
hypothesized that p110α may control the expression of a selective 
subset of genes implicated in medulloblastoma cell proliferation and/or 
survival. The comparative DNA microarray analysis of 
medulloblastoma cell lines in which either p110α or p110δ were down-
regulated by siRNA identified such a gene subset. The LIFRα was 
validated as a downstream target of p110α by a combination of 
approaches, including pharmacological inhibition or over-expression of 
the class IA PI3K isoform. The observation that LIFRα expression was 
elevated in primary medulloblastoma, in comparison to normal 
cerebellum further supports this model, in view of the over-expression 
of PIK3CA which we previously reported on [14].  
Importantly, the LIFR was shown to be functional in medulloblastoma 
cell lines, since its activation stimulated classical downstream 
signalling pathways, such as JAK/STAT, Erk1/2 and PI3K/Akt. 
Moreover, the observation that medulloblastoma cell lines generally 
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express LIF confirms the presence of an autocrine loop in this 
malignant brain tumor [25, 26]. LIF is a pleiotropic cytokine, which 
can sustain proliferation or differentiation depending on cell type or 
maturation [27]. Deregulated LIF secretion has also been previously 
described in human cancer, such as breast cancer, rhabdomyosarcoma 
and medulloblastoma [25, 28, 29]. In medulloblastoma, cell lines, LIF 
expression was reported to be regulated by p53 [30]. Targeting LIFR 
downstream signalling has been evaluated in medulloblastoma. 
Interfering with STAT3 by using a non-peptide small molecule STAT3 
inhibitor was reported to decrease cell viability and induce apoptosis in 
medulloblastoma [31]. A study using resveratrol also reported on the 
importance of STAT3 signalling in maintenance and survival of 
medulloblastoma cells [32]. 
Previous studies have reported on cross-talks between the PI3K/Akt 
pathway and myc family genes. GSK-3β, which is directly regulated by 
phosphorylation through Akt controls Myc phosphorylation and 
stability [33-35]. In embryonal tumors, including medulloblastoma, 
targeting the Akt and Erk pathways using a quassinoid analogue 
induced c-Myc and N-myc down-regulation [7, 8]. Inhibition of PI3K 
using a selective inhibitor was also reported to induce N-myc down-
regulation in neuroblastoma [36]. N-myc was shown to play an 
important role in the regulation of PI3K-mediated VEGF secretion in 
neuroblastoma cells [37, 38]. Recently, myc amplification has been 
reported to be implicated in the resistance of tumors with activated 
PIK3CA to pharmacological inhibitors of p110α [39, 40].  
Together our results delineate a novel signalling pathway from p110α 
to c-Myc and LIFR, which contributes to key medulloblastoma cell 
responses and may be further studied to develop novel targeted 
therapies for this common and devastating childhood malignancy. 
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3.6 Supplementary information 
No Network GO Processes 
Total 
nodes 
p-Value 
1 c-Myc 
positive regulation of biological process, regulation of cell 
proliferation, regulation of developmental process, negative 
regulation of osteoblast differentiation, detection of 
mechanical stimulus involved in sensory perception of sound 
25 < 0.001 
2 
ESR1 
(nuclear) 
positive regulation of estrogen receptor signalling pathway, 
regulation of estrogen receptor signalling pathway, positive 
regulation of steroid hormone receptor signalling pathway, 
steroid hormone receptor signalling pathway, response to 
unfolded protein 
16 < 0.001 
3 p53 
negative regulation of developmental process, regulation of 
developmental process, regulation of multicellular organismal 
process, negative regulation of apoptosis, negative regulation 
of programmed cell death  
14 < 0.001 
4 STAT3 
regulation of biological quality, growth hormone receptor 
signalling pathway, response to growth hormone stimulus, 
negative regulation of cellular process, response to estradiol 
stimulus  
13 < 0.001 
5 C/EBPalpha 
regulation of cell proliferation, negative regulation of cell 
proliferation, positive regulation of cell proliferation, response 
to vitamin, regulation of developmental process 
12 < 0.001 
6 STAT1 
positive regulation of developmental process , intracellular 
signalling cascade, regulation of cell death, regulation of 
programmed cell death, regulation of developmental process 
11 < 0.001 
7 
RelA 
(p65 NF-kB 
subunit) 
positive regulation of biological process, inflammatory 
response, positive regulation of cellular process, positive 
regulation of cell proliferation, regulation of cell proliferation 
11 < 0.001 
8 E2F1 
response to extracellular stimulus, response to vitamin, 
negative regulation of biological process, negative regulation 
of cell proliferation, response to vitamin D 
10 < 0.001 
9 NF-kB 
germinal center formation, response to wounding, 
inflammatory response, regulation of response to stimulus, 
regulation of cell proliferation 
9 < 0.001 
10 c-Jun 
regulation of response to external stimulus, multicellular 
organismal process, negative regulation of cell proliferation, 
regulation of cell death, regulation of programmed cell death 
9 < 0.001 
Suppl. Table 3-1 Analysis of transcriptional networks by GeneGo Metacore. Hit list 
of the transcription factors whose networks of genes were mostly affected by the 
RNAi mediated downregulation of PIK3CA and PIK3CD in DAOY cells. 
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4.1 Abstract 
The receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K) 
pathway is fundamental for cancer cell proliferation and is known to be 
frequently altered and activated in neoplasia, including embryonal 
tumors. Based on the high frequency of alterations, targeting 
components of the PI3K signalling pathway is considered to be a 
promising therapeutic approach for cancer treatment. Here, we have 
investigated the potential of targeting the axis of the insulin-like growth 
factor-1 receptor (IGF-1R) and PI3K signalling in two common 
cancers of childhood: neuroblastoma, the most common extra cranial 
tumor in children and medulloblastoma, the most frequent childhood 
brain tumor. By treating neuroblastoma and medulloblastoma cells 
with R1507, a specific humanized monoclonal antibody against the 
IGF-1R, we could observe cell line-specific responses and in some 
cases a strong decrease in cell proliferation. In contrast, targeting the 
PI3K p110α with the specific inhibitor PIK75 resulted in broad anti-
proliferative effects in a panel of neuro- and medulloblastoma cell 
lines. Additionally, sensitization to commonly used chemotherapeutic 
agents occurred in neuroblastoma cells upon treatment with R1507 or 
PIK75. Furthermore, by studying the expression and phosphorylation 
state of IGF-1R/PI3K downstream signalling targets we found down-
regulated signalling pathway activation. Together, our studies 
demonstrate the potential of targeting the IGF-1R/PI3K signalling axis 
in embryonal tumors. Hopefully, this knowledge will contribute to the 
development of urgently required new targeted therapies for embryonal 
tumors.   
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4.2 Introduction 
Second to accidents, cancer is still the leading cause of death for 
children. Embryonal tumours represent approximately 30% of 
childhood malignancies and often display resistance to current 
therapeutic regimens. Therefore, embryonal tumors are associated with 
lower survival rates compared to other childhood cancers. Treatment 
failure for disseminated disease is frequent, and results in survival rates 
< 20%. Thus, novel therapeutic options are urgently needed for this 
group of tumours to improve survival rates and quality of life of 
patients. Embryonal tumors are dysontogenetic tumours whose 
pathological features resemble those of the developing organ or tissue 
of origin and include the entities medulloblastoma and neuroblastoma. 
Medulloblastoma is the most common malignant brain tumour in 
children and accounts for approximately 20% to 25% of all pediatric 
central nervous system tumours. Neuroblastoma is an embryonal tumor 
that originates from developing neural crest tissues.  It is the most 
common extracanial solid tumor and is responsible for 15% of all 
cancer-related deaths in childhood. The fact that these cancers occur in 
infants and young children suggests that only a limited number of 
genetic changes may lead to tumor development, making these cancers 
an attractive model to identify new molecular targets. The development 
of novel targeted therapies is of particular importance for embryonal 
tumors, as these malignancies are orphan diseases. Common 
intracellular signalling pathways and chromosomal deletions including 
1p36 and 11q loss have been previously identified in different 
embryonal tumors, including medulloblastoma and neuroblastoma [1-
10].  
Several intracellular signalling pathways have indeed been 
demonstrated to play a key role in embryonal tumor biology. Indeed, 
polypeptide growth factors such as insulin-like growth factor-1 (IGF-
1), epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), neuregulins and neurotrophins have been shown to control 
embryonal tumor proliferation, survival, differentiation and metastasis 
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[11-15] by binding to specific receptor tyrosine kinases (RTKs). 
Moreover, expression of the ErbB-2 and ErbB-4 RTKs in embryonal 
tumor samples was shown to correlate with reduced patient survival, 
while Trk receptor expression correlated with a less aggressive tumor 
phenotype [13]. Therefore a better understanding of the involvement of 
RTKs and their downstream targets in human embryonal tumor biology 
may yield important clues for the development of new drugs for the 
disease. Targeting receptor tyrosine kinases such as the IGF-1R is a 
promising approach to develop novel anti-cancer therapies in 
embryonal tumors, such as neuroblastoma and sarcoma [15-23]. Indeed 
the first results from clinical trials evaluating the safety and efficacy of 
IGF-1R neutralising antibodies in children and adolescents with 
embryonal tumor have been reported [24]. In this trial, the humanized 
IGF-1R neutralizing antibody R1507 displayed minimal toxicities and 
some responses in ESFT were observed [24].  Importantly, no dose-
limiting toxicities were identified and the maximum tolerated dose was 
not reached [24]. Human embryonal tumor cells have been reported to 
express a variety of growth factor receptors, some of which can be 
activated by mutations, over-expression and/or establishment of 
autocrine loops [13]. Amongst these polypeptide growth factor 
receptors are the RTKs IGF-1R, EGFR, ALK, ErbB-2, ErbB-4, c-Kit, 
PDGFR, Trk and fibroblast growth factor receptor (FGFR) [25-40]. 
Therefore, given that embryonal tumor cells express a variety of 
different growth factor receptors, targeting individual receptors may 
not provide a successful therapeutic strategy in all embryonal tumor 
entities. A potentially complementary approach would be to identify 
signalling molecules which lies downstream of several different growth 
factor receptors and which are essential for transmitting their 
proliferative and/or survival message. Combinatorial targeting of 
receptor tyrosine kinases (such as the IGF-1R) and their downstream 
signalling mediators is a very promising approach to develop more 
efficient anti-cancer therapies [16, 17, 22, 41-43].  
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Phosphoinositide 3-kinase (PI3K) is a good example of this, playing a 
crucial role in controlling cell proliferation, survival and 
motility/metastasis downstream of many different growth factor 
receptors and oncogenic Ras mutants [44-47]. PI3K signalling activates 
a crucial intracellular signalling pathway  involving phosphoinositide-
dependent protein kinase-1 (PDK1), Akt, the mammalian target of 
rapamycin (mTOR) and the ribosomal protein S6 kinase (S6K), which 
controls cell growth, proliferation and survival [44-46]. The importance 
of PI3K/Akt/mTOR signalling in cancer is highlighted by the fact that 
mutations in the tumor suppressor gene PTEN occur frequently in 
human tumors, including glioblastoma [44, 48-50]. PTEN is a 
phosphatase that antagonizes the action of PI3K by de-phosphorylating 
the D-3 position of polyphosphoinositides [44, 48, 49].  Reduced 
expression of PTEN resulting in activation of PI3K signalling was 
recently described in embryonal tumors such as medulloblastoma and 
neuroblastoma [51, 52]. Moreover, various reports have described 
activating mutations in the PIK3CA gene encoding the catalytic p110α 
isoform of PI3K in a variety of human cancers, including, breast, colon 
and ovarian cancer, as well as embryonal tumors [50, 53, 54]. In 
addition, PI3K/Akt/mTOR signalling has been demonstrated to mediate 
the proliferation of embryonal tumor cells [55, 56] and to contribute to 
signalling by ErbB-2 and IGF-1R [57-59]. Activation of Akt was also 
reported in embryonal tumors, correlating with poor outcome in some 
entities [60]. Thus, targeting the PI3K/Akt/mTOR signalling pathway 
may represent an attractive novel approach to develop novel therapies 
for embryonal tumors [61]. Indeed, there now exist multiple 
pharmacological inhibitors of the PI3K/Akt/mTOR pathway which 
have entered clinical trials for adult and pediatric cancer [43, 45, 47, 
62-64]. The PI3K/Akt/mTOR pathway is also an important contributor 
to the resistance of human tumors to drugs targeting receptor tyrosine 
kinases [65-67]. Inhibitors of the PI3K/Akt/mTOR signalling pathway 
have also been shown to be effective in combination with IGF-1R 
inhibitors [20, 42]. 
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In the present report, we have evaluated the anti-proliferative potential 
of the humanized anti-IGF-1R antibody R1507 and of PIK75, a class 
IA PI3K inhibitor, in medulloblastoma and neuroblastoma cell lines. 
We present evidence, that these agents are effective as monotherapies 
in subsets of embryonal tumor cell lines and can be effectively 
combined with standard chemotherapeutic drugs.  
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4.3  Materials and methods 
Cell Culture 
 Human neuroblastoma cell lines were kindly provided by Dr Brodeur, 
Children’s Hospital of Philadelphia. The cells were grown in RPMI 
(Life Technologies/Invitrogen) supplemented with 10% (v/v) fetal calf 
serum (FCS) and penicillin/streptomycin/L-glutamine and passaged 
every 3-5 days by trypsinization.  
The medulloblastoma cell lines’ provenience has been previously 
described [68]. DAOY, UW-228 and PFSK human cell lines were 
purchased from the American Type Culture Collection. D341 Med and 
D458 Med medulloblastoma cells were the kind gift of Dr. Henry 
Friedman (Duke University, Durham, NC). Cell lines that were not 
purchased from the American Type Culture Collection in 2009 were 
tested for their authentication by karyotypic analysis using molecular 
cytogenetic techniques, such as comparative genomic hybridization. 
DAOY medulloblastoma cell line was grown in Richter’s MEM Zinc 
option medium (Invitrogen) with 10% FCS (fetal bovine serum; 
Sigma) and penicillin/streptomycin (Invitrogen). PFSK primitive 
neuroectodermal tumor (PNET) cell line was grown in RPMI 1640 
(Invitrogen) with 10% FCS and penicillin/streptomycin/L-glutamine. 
The UW-228 medulloblastoma cell line was grown in DMEM 
(Dulbecco’s modified Eagle’s medium; Invitrogen) with 10% FCS and 
penicillin/streptomycin/L-glutamine. D341 Med and D458 Med 
medulloblastoma cell lines were grown like DAOY but with the 
addition of 100M non-essential amino acids (GIPCOTM MEM 
Invitrogen). All cells were grown in a humidified atmosphere at 37° 
and 5% CO2. 
Reagents 
The PI3K inhibitors PIK75 was dissolved in DMSO (Sigma, Buchs, 
Switzerland) at 10 mM and diluted into cell culture medium just before 
use. R1507, a fully human IgG1 monoclonal antibody to IGF-1R, was 
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obtained from La-Roche, and was diluted directly into the medium 
immediately before use. The chemotherapeutic agents cisplatin 
(Bristol-Myers Squibb), doxorubicin (Pfizer) and etoposide 
(Calbiochem) were used in combination with PIK75 or R1507 at the 
indicated concentrations. 
Cell Proliferation 
Neuroblastoma and medulloblastoma cells were seeded in 96-well 
plates at a density of 3’000-10´000 cells/well and grown for 48-118 hrs 
in cell culture containing high (10%) serum. Cell proliferation was 
analyzed by the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega) according to the manufacturer’s 
instructions.  
Western blotting 
Cell lysates were prepared in RIPA buffer (50mM Tris-Cl, pH 6.8, 
100mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with 
Complete Mini Protease Inhibitor Cocktail (Roche Applied Sciences) 
and with the phosphatase inhibitors β-glycerophosphate (20mM) and 
Na3VO4 (200 mM) and normalized using a bicinchoninic acid (BCA) 
protein assay (Pierce, Rockford, IL, USA). Cell lysates were separated 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to a hydrophobic polyvinylidene difluoride (PVDF) 
membrane (Hybond-P; Amersham Biosciences, GE Healthcare, UK) 
and immunoblotted with the indicated antibodies prior to 
chemiluminescent detection (SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Fisher Scientific Inc., Rockford, IL, 
USA). Antibodies specific for IGF1Rβ, PI3K p110α, Akt1/2/3, ERK 
1/2, S6 protein (Santa Cruz Biotechnology, CA, USA), phospho- 
ERK1/2 (Thr202/Tyr204), phospho-Akt (Ser473; Thr308), phospho-S6 
(Ser235/Ser236; Ser240/Ser244). 
  
NOVEL AGENTS TARGETING THE IGF-1R/PI3K PATHWAY IMPAIR CELL PRO-LIFERATION AND 
SURVIVAL IN SUBSETS OF MEDULLO- AND NEUROBLASTOMA 
 
123 
4.4 Results 
Anti-proliferative activity of R1507 and PIK75 in panels of 
neuroblastoma and medulloblastoma cell lines 
We have previously described panels of neuroblastoma and 
medulloblastoma cell lines, which were characterized for expression of 
components of the IGF-1R/PI3K signalling pathway [20, 69, 70]. In the 
present study, the impact of the humanized anti-IGF-1R antibody 
R1507 was evaluated on cell proliferation in vitro in the panels of 
neuroblastoma and medulloblastoma cell lines (Figure 4-1). The 
antibody displayed anti-proliferative activity in 2 out of 8 
neuroblastoma cell lines, namely SH-SY5Y and LAN1 (Figure 4-1a 
and Figure 4-6a).  In SH-SY5Y, R1507 induced a maximal decrease in 
cell proliferation of 70% at 12.5μg/ml (Figure 4-1a). In LAN1 a 
maximal activity of 30% reduction in cell proliferation was observed 
(Figure 4-6a). R1507 showed anti-proliferative activity in 2 out of 5 
medulloblastoma cell lines, namely PFSK and D458 (Figure 4-1b). In 
D458, a maximal decrease in cell proliferation (60%) was observed at 
15μg/ml, while in PFSK the maximal effect was 40% inhibition of the 
response (Figure 4-1b). In NB and MB cell lines, the activity of R1507 
was cell-line specific and the antibody had a profile similar to the IGF-
1R tyrosine kinase inhibitor NVP-AEW541 [20]. NVP-AEW541 was 
more active in SH-SY5Y and LAN-1 than in other neuroblastoma cell 
lines [20], and PFSK were more sensitive to NVP-AEW541 than 
DAOY and UW228 cells.  
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Figure 4-1 The effect of R1507 on (a) NB and (b) MB cell lines after 48 hours. Error 
bars represent ±S.D. of means from 3 experiments, each with 6-8 replicates. NB 
different scales. 
 
The impact of the class IA PI3K inhibitor PIK75 was evaluated on cell 
proliferation in vitro in the panels of neuroblastoma and 
medulloblastoma cell lines. The inhibitor displayed anti-proliferative 
activity in the neuroblastoma cell line panel, with IC50 values in the 
range of 50-100 nM (Figure 4-2a).  In medulloblastoma cell lines, 
PIK75 was more active in D341 and D458 cells (IC50= 20 nM) than in 
UW228 cells. The activity of PIK75 in DAOY and PFSK cells was 
previously described in [69]. 
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Figure 4-2 The effect of PIK75 on NB and MB cell lines. a) neuroblastoma cells 
after 48 hours. b) D341 and D458 Med cells after 118 hours, UW228 cells after 70 
hours. Error bars represent ±S.D. of means from 1 to 3 experiments, each with 4-8 
replicates. NB different scales. 
 
Impact of R1507 and PIK75 on intracellular signalling pathway 
activation 
The impact of R1507 and PIK75 on the activation status of the 
Akt/mTOR pathway in NB cell lines was investigated by Western blot 
analysis (Figure 4-3). R1507 strongly affected the activation status of 
Akt and the phosphorylation of the mTOR downstream target 
ribosomal S6 protein in both NB and MB cell lines.  (SH-SY5Y in 
Figure 4-3a, LAN1 cells Figure 4-3b as well as in medulloblastoma 
PFSK cells Figure 4-3c). Concentrations of 6.25-100 µg/ml R1507 all 
reduced Akt Ser 473 phosphorylation, whereas only concentrations of 
more than 6.25 or 12.5 were needed to reduce S6Ser235/236 
phosphorylation.  
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Also PIK75 was able to inhibit Akt/mTOR activation, as seen on the 
decreases in the phosphorylation of S6 protein in both NB cell lines 
treated, although only in LAN-1 cells the phosphorylation of 
AktSer473 was affected (Figure 4-3b). 
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Figure 4-3 Western blots showing change in phosphorylation in response to different 
treatments. The effect of treatment with PIK75 and R1507 on phosphorylation of  Akt 
and S6 downstream in the PI3K/Akt/mTOR signalling pathway in neuroblastoma (a) 
SH-SY5Y, (b) LAN1 and (c) PFSK cells. 
 
The inhibitory effects of PIK75 in Akt/mTOR signalling in MB cell 
lines cells were previously described in [69] and correlate with the 
effects observed in neuroblastoma cells. 
Combination of R1507 with standard chemotherapeutic agents in 
neuroblastoma and medulloblastoma cell lines 
We have previously shown that the IGF-1R tyrosine kinase inhibitor 
NVP-AEW541 enhances the effects of cisplatin on cell proliferation 
and apoptosis in neuroblastoma cell lines [20]. In support of this 
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finding, the concomitant treatment of the R1507-responsive SH-SY5Y 
neuroblastoma cell line with R1507 and cisplatin resulted in additive 
effects on cell proliferation (Figure 4-4a). For neuroblastoma WAC2 
cells that did not respond to R1507 in single treatment (Figure 4-1), 
there was no additional effect of R1507 in combination with cisplatin, 
doxorubicin or etoposide (Figure 4-1a). In medulloblastoma PFSK and 
UW228 cells, the combination of R1507 and cisplatin was more 
effective than the single agents (Figure 4-4b). This is not surprising for 
PFSK, that also showed sensitivity to R1507 alone, but in UW228, 
cisplatin seems to confer R1507 sensibility. In R1507-insensitive 
DAOY cells no such effect was observed (Supplementary Figure 4-1). 
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Figure 4-4 Combinational treatments of R1507 with chemotherapy in NB and MB 
cell lines after 48 hours. a) SH-SY5Y and b) WAC2 c) PFSK cells and d) UW228 
cells treated with R1507 (white squares 0 μg/ml, grey squares 25 μg/ml and black 
squares 50 μg/ml)  and cisplatin. Error bars represent ±S.D. of means from 1 to 3 
experiments, each with at least 4 replicates. For combination treatments of WAC2 
and DAOY cells which are irresponsive to R1507, see Supplementary Figure 4-1. 
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Combination of PIK75 with standard chemotherapeutic agents in 
neuroblastoma cells 
In the neuroblastoma cell lines LAN1 and WAC2, the concomitant 
treatment with PIK75 and doxorubicin or etoposide resulted in additive 
effects on cell proliferation (Figure 4-5). At selected, relatively low 
concentrations, where PIK75, doxorubicin or etoposide alone reduced 
cell proliferation to 60-80%, combination treatments of PIK75 and one 
of the chemotherapeutic agents brought reductions to 40-50%. Our 
previous work on medulloblastoma has shown that PIK75 sensitizes 
medulloblastoma cell lines to doxorubicin [69]. 
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Figure 4-5 Additive effects of treatment with PIK75 in combination with different 
chemotherapies in NB cell lines after 48 hours. a) Combinatory treatment of PIK75 
with doxorubicin in LAN-1 (right) or WAC-2 (left) cells. b) Combinatory treatment 
of PIK75 with etoposide in LAN-1 (right) or WAC-2 (left) cells. Error bars represent 
±S.D. of means from 3 experiments, each with at least 4 replicates. 
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Activity of R1507 and PIK75 in chemoresistant NB cell lines 
We next investigated whether R1507 or PIK75 had also 
antiproliferative effects in neuroblastoma cell lines with acquired 
resistance to standard chemotherapeutic agents. R1507 displayed no 
significant anti-proliferative activity in LAN-1 cells with acquired 
resistance to doxorubicin (Figure 4-6a). In contrast, PIK75 displayed 
almost comparable anti-proliferative activity in either parental LAN-1 
or their chemoresistant counterparts (Figure 4-6b). Western blot 
analysis of the protein expression of LAN1R cells showed that these 
cells express reduced levels of IGF-1R compared to the parental cell 
line LAN1. In addition, the phosphorylation levels of ERK1/2 and 
AKT at the positions Ser 473 and Thr308 were also lower in LAN1R 
than in LAN1 (Figure 4-6c). 
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Figure 4-6 Sensitivity to R1507 and PIK75, and presence of IGFR in neuroblastoma 
cell lines LAN1 and LAN1R, a LAN1 cell line resistant to doxorubicin. a) R1507 
treatment for 48 hours. b) PIK75 treatment for 48 hours. Error bars represent ±S.D. of 
means from 3 experiments, each with 3 replicates, except that there was only one 
experiment with 500nM PIK75 in b. c) Western blot analysis of the indicated proteins 
in LAN1 and LAN1R cell extracts. 
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4.5 Discussion 
In the present report we have evaluated the anti-proliferative activity of 
the humanized anti-IGF-1R antibody R1507 in the embryonal tumors 
neuroblastoma and medulloblastoma cell lines in vitro. As a single 
agent, R1507 was effective in a subset of neuro- and medulloblastoma 
cell lines, while a majority of cell lines did not respond. The profile of 
R1507 in neuro- and medulloblastoma was similar to NVP-AEW541 in 
terms of the identity of the cell lines which were sensitive to the single 
agent [20]. In neuroblastoma cell lines that were sensitive to R1507 as 
single agent, the effects of R1507 and chemotherapy (cisplatin, 
doxorubicin and etoposide) were additive, a result which was also 
observed with NVP-AEW541 [20]. However, neuroblastoma cells 
which were not sensitive to R1507, showed also no additive effects in 
cell growth inhibition to when combined with chemotherapies. By 
contrast, in medulloblastoma R1507 showed strong synergistic effects 
with cisplatin not only in MB cells which were initially sensitive to 
R1570 (PFSK), but also MB cells which were insensitive to R1507 as a 
single agent (UW228). Analysis of the mechanisms of action revealed 
that R1507 inhibits cell growth by attenuation of the AKT/mTOR 
signalling pathway in neuroblastoma and medulloblastoma cells. 
Similar observations were obtained by inhibition of IGF1R with NVP-
AEW541 [20]. 
Our previous work using RNAi targeting of class IA PI3K isoforms has 
revealed that targeting these enzymes in neuroblastoma and 
medulloblastoma cell lines can induce apoptosis and decrease cell 
proliferation [69,70]. These results are supported by the findings 
presented here, which show that PIK75 displays a broad anti-
proliferative activity in neuroblastoma cell lines. Also in 
medulloblastoma, we observed that PIK75 has anti-proliferative 
activity, but one cell line (UW228) was rather resistant to the drug. The 
exact mechanism(s) underlying this observation are at present unclear, 
but may be caused by an enhanced activation of Erk1/2. A decrease in 
activity of class IA PI3K inhibitors has been observed previously in 
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cell lines with mutant KRAS and attributed to the enhanced activation 
of the Erk pathway [71]. The combination of PIK75 with 
chemotherapy (doxorubicin and etoposide) showed enhanced cell 
growth inhibition as compared with single agent treatment in 
neuroblastoma cell lines. Consistent with these findings, a recent report 
demonstrated that PI103 a dual inhibitor against p110α and mTOR 
strongly synergizes with various chemotherapeutics including 
doxorubicin, etoposide and cisplatin [72]. In medulloblastoma, our 
previous work has also demonstrated improved the anti-proliferative 
effects for PIK75 in combination with different chemotherapeutic 
agents [69].  
Because neuroblastoma and medulloblastoma cells may express a 
variety of different growth factor receptors, we and others have 
postulated that targeting individual receptors may not always provide 
the best therapeutic option [20,70]. To overcome this problem, an 
alternative approach was proposed, which is based on targeting 
downstream signalling molecules that are regulated by different growth 
factor receptors to transmit the proliferative message. Our findings 
support this approach, since we observed that generally a bigger 
number of NB and MB cell lines most likely responded to PIK75 than 
to R1507. Importantly, PIK75 effectively inhibited proliferation in a 
chemoresistant neuroblastoma cell line in a comparable manner as in 
the parental cell line, demonstrating its broad anti-proliferative activity. 
By contrast, R1507 was ineffective in the chemoresistant 
neuroblastoma cells, which was most likely caused by loss of 
expression of the IGF-1R. The AKT/mTOR pathway was also found to 
be deregulated in the chemoresistant cells, pointing that this signalling 
pathway may not be essential for the acquired chemoresistant 
phenotype of the cells. However, our previous findings in 
medulloblastoma cells showed elevated levels of phosphorylated AKT 
as a consequence of short time exposure with doxorubicin [69]. The 
molecular mechanisms underlying these observations are at present 
unclear, but may be of importance, in view of the fact that some 
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clinical trials have been initiated with R1507 in patients previously 
treated with chemotherapy. 
The evaluation of the anti-proliferative potential of the humanized anti-
IGF-1R antibody R1507 and the class IA PI3K inhibitor PIK75 
presented here provides important insights that may be considered for 
the design of further clinical-oriented studies aimed at targeting IGF-
1R/PI3K in embryonal tumors.  
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4.6 Supplementary Information 
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Suppl. Figure 4-1 Effects of the treatment of R1507 in combination with 
chemotherapy in NB and MB cell lines after 48 hours. a) Combination with 
doxorubicin in WAC2 cells b) Combination with cisplatin in WAC2 and DAOY 
cells. Error bars represent ±S.D. of means from 1 to 3 experiments, each with at least 
4 replicates.  
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CHAPTER 5 
5 CONCLUSIONS AND OUTLOOK 
 
The aim of this thesis was the identification and characterization of 
novel genes, which are responsible for promoting cell survival and 
chemoresistance in NB and MB, and which could represent potential 
therapeutic targets for future patient treatments. The motivation for this 
study was the poor survival rates in patients with high risk features. 
Many efforts have been done in the past decades to better characterize 
the biology of these tumors. In particular, large-scale approaches, such 
as DNA microarrays, have been carried out aimed at identifying 
specific tumor finger prints [1-3]. An amount of data was promptly 
generated, indicating the differential expression or mutational status of 
several genes in cancer cells compared to normal cells. But in most of 
the cases it remained to be discovered, which was the particular 
function of the identified genes. It became more important to design 
new, or adapt the existing large-scale approaches to address the 
functionality of these deregulated genes in cancer cells. 
At the time this project was initiated, there were no functional high-
throughput screens that interrogated oncogenic phenotypes in 
neuroblastoma cells reported in the literature. Contemporary to this 
study, other functional RNAi screens have been performed [4, 5], using 
shRNA or siRNA libraries targeting different subsets of genes to study 
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loss-of-function responses. Recently, an RNAi screen seeking for 
kinases that are essential for neuroblastoma survival was reported [4]. 
However, a chemosensitizing RNAi screen like ours (described in 
chapter 2), designed to identify kinases that modulate response to 
chemotherapies commonly used in the clinics has not been reported so 
far in neuroblastoma. Since chemotherapy is still the first-line 
treatment in the clinics and chemoresistance is a major cause of 
treatment failure and poor outcomes [6], this study is of great 
importance for the development of novel targets for combinational 
approaches.  
The kinome-wide RNAi screen presented in this thesis identified novel 
potential drug targets involved in neuroblastoma survival and 
resistance to cisplatin. Among the survival kinases, the different 
isoforms of the Protein kinase C family PKC-β1, PKC-δ and PKC-ζ, 
were shown to play an important role in neuroblastoma survival. The 
previously reported survival RNAi screen in NB identified and 
validated CHK1 as a novel survival kinase [4]. In our cell lines, CHK1 
does not seem to play a main role in cell survival, which might be 
explained due to the biological variability within the cell lines used in 
both screens. Nevertheless, the kinases BMPR1A and RPS6KB1 were 
commonly identified as survival kinases in both studies, suggesting that 
they have a more general role in neuroblastoma biology, and indicating 
that further studies would be interesting. Among the chemosensitizer 
kinases, the fibroblast growth factor receptor 2 (FGFR2) has emerged 
as the most promising candidate and was further validated. 
Although RNAi screenings have shown to be valuable tools for the 
low-cost and -time consuming identification of genes associated with 
specific phenotypes, this technique is only feasible in in vitro models. 
The problematic of translating the results to a clinical setting remains 
challenging. To address this issue, we have accessed a data base of 
DNA microarrays comprising tumor samples of 251 NB patients. The 
expression of FGFR2 was shown to correlate with advanced tumor 
stage. In addition, IHC analysis of NB primary samples demonstrated 
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also the expression of FGFR-2, as well as the ligand FGF-2, at a 
protein level. These findings suggest that targeting FGFR-2 in 
neuroblastoma might have a clinical relevance. 
Consistent with our study, a previous study detected FGF-2 over-
expression in neuroblatoma tumors at advanced stages (3 and 4) 
compared with low-stage tumors (stages 1, 2, and 4S) [7], but the 
mechanistic insights or the therapeutic potential of targeting FGF-
2/FGFR signalling in neuroblastoma were not yet elucidated. In the 
present study, we hypothesize that FGFR2 is activated by an autocrine 
loop involving FGF-2 in NB cells. We demonstrated that primary NB 
and NB cell lines are able to synthesize FGF-2. Stimulation of NB cells 
with FGF-2 resulted in FGFR2 activation, which finally led to the up-
regulation of the anti-apoptotic factor BCL2. PKC isoforms were 
shown to play a major role in FGFR2 signalling to BCL2, in contrast to 
other signalling pathways, such as PI3K/mTOR and ERK. Our studies 
performed in NB cell lines with acquired chemoresistance 
demonstrated that FGF-2, FGFR2 and BCL2 are up-regulated, 
highlighting the importance of this factors for rendering the cells 
resistance against chemotherapies. 
Overexpression of BCL2 represents one of the mechanisms that 
contribute to cisplatin resistance [8]. It is therefore not surprising that 
the down-regulation of BCL2, mediated by FGFR2 inhibition, 
sensitizes cells to cisplatin induced cell death. The analysis of the 
mechanisms of action downstream of FGFR2 was also of importance, 
because it led to the identification of other possible targeting sites on 
the signalling pathway that might have a pharmacological potential, as 
well. Beside the inhibition of FGFR2 with SU-5402, also inhibiting the 
downstream effectors using the PKC inhibitors Rottlerin and 
Enzastaurin showed anti-proliferative effects in neuroblatoma. 
Furthermore, the BCL2 inhibitor ABT-737 has shown to have a great 
impact in growth inhibition in NB cells with acquired chemoresistance. 
This observation is in agreement of a previous study, in which has also 
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documented the potential of targeting BCL2 family proteins with ABT-
737 in NB [9-11]. 
As described in the introduction, genetic alterations in FGFR2 have 
been implicated in various cancer types, resulting in aberrant FGFR2 
signalling activation, due to the release of FGFR2 from auto inhibition, 
or through creation of FGF signalling autocrine loops [12]. Several 
pharmacological inhibitors against FGFR are currently being tested in 
clinical trials, including ZD-4547, BGJ398 and FP-1039, which are 
entering Phase I or II for the treatment breast, gastric or endometrial 
cancers, or advanced solid cancers [13]. Within this thesis, we have 
only analyzed the pharmacological potential of the FGFR2 inhibitor 
SU-5402 in neuroblastoma. This inhibitor has also affinity for FGFR1 
and FGFR3. Because of the homology among the isoforms, it is 
difficult to design isoform-specific small molecule inhibitors. Most of 
the available FGFR inhibitors target more than one isoform. Our 
studies with siRNAs point that the down-regulation of FGFR2 is 
sufficient to sensitize NB cells to cisplatin treatment. However, it 
remains to be studied, whether the inhibition of FGFR1 or FGFR3 by 
SU-5402 also contribute to neuroblastoma chemosensitization. In terms 
of future perspectives, other inhibitors against FGFR could be also 
tested in neuroblastoma. Of particular interest are those which are 
being tested in clinical trials for other cancer types. Further, it would be 
interesting to see whether the in vitro anti-proliferative effects of SU-
5402 or maybe other FGFR2 inhibitors can be reproduced in in vivo 
models. In this context, also the inhibitors enzastaurin and ABT-737 
represent attractive targets for further in vivo studies. 
As extensively described in the introduction and reviewed in the 
appendix, the PI3K signalling pathway plays a major role in 
neuroblastoma and medulloblastoma biology. Therefore, the goal of the 
next projects (described in chapter 3 and 4) was to investigate the 
potential of targeting IGF-1R and PI3K in neuroblastoma and 
medulloblastoma. By treating NB and MB cell lines with R1507, a 
specific humanized monoclonal antibody against the IGF-1R and 
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PIK75 a small molecule inhibitor against PI3K p110α, we could 
observe cell line-specific responses, for some cell lines a strong 
decrease in cell proliferation. Additionally, sensitization to commonly 
used chemotherapeutic agents occurred in neuroblastoma cells upon 
treatment with R1507 or PIK75. The findings of this study, together 
with a number of previous studies that investigated the potential of 
targeting the PI3K signalling pathway in other cancers in vitro and in 
vivo, lead us to the conclusion that PI3K inhibitors may have an effect 
in tumor growth inhibition, but used as single agents, the effects are too 
modest, particularly to be adopted as a standard regime for patient 
treatment [14]. However, their application in combination with other 
chemotherapies have yielded so far better results and might be 
beneficial when applied in patients [14]. 
The more we know about the mechanisms underlying PI3K signalling, 
the better we will be able to predict which the best combinations to 
optimize treatment response are. To gain a better knowledge of PI3K 
downstream effector genes, we analyzed the gene expression profiles 
of MB cells upon RNAi mediated down-regulation of PIK3CA or 
PIK3CD, encoding for the PI3K catalytic isoforms p110α and p110δ. 
By using bioinformatic tools, a comparative analysis of the sets of 
genes, which were differentially expressed, revealed a transcriptional 
network of genes involving c-Myc. C-Myc is a well characterized 
oncogene and a marker of poor prognosis in medulloblastoma [15]. 
There are some reports suggesting crosstalks between PI3K/AKT 
signalling and c-Myc [16-18]. In large-cell MB, PI3K/GSK3β were 
shown to be involved in HGF-induction of c-Myc. Recently, MYC 
amplification was associated with resistance to pharmacological 
inhibitors of p110α [19]. 
Being a transcription factor, direct pharmacological targeting of c-Myc 
has proven difficult [20]. Therefore, targeting c-Myc responsive genes 
represents an option. The transcriptional network of c-Myc included 
LIFR as target gene, which was one of the top deregulated genes upon 
PIK3CA down-regulation. Different lines of evidence validated LIFR 
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as a p110α downstream target. LIFR was on one hand down-regulated 
upon pharmacological inhibition or RNAi mediated down-regulation of 
p110α and on the other hand up-regulated upon p110α up-regulation. A 
c-Myc inducible cell line model confirmed that LIFR transcription is 
mediated by c-Myc. Although the analysis of the DNA sequence of 
LIFR showed promoter binding sites for c-Myc, this remains to be 
confirmed experimentally, for example by ChIP assay, whether c-Myc 
directly binds to LIFR. 
There are some reports about the role of LIFR in human cancers, 
including glioblastoma and medulloblastoma, although its role has not 
been extensively studied [21, 22]. A possible role for LIFR in 
medulloblastoma was suggested by the elevated expression of LIFR in 
primary MB and MB cell lines as compared with normal cerebellum. 
Activation of LIFR by LIF or OSM is known to activate classical 
signalling cascades such JAK/STAT, MAPK and PI3K/AKT which 
can influence cell survival, proliferation and differentiation. Consistent 
with our data, a previous study reported deregulated LIF expression in 
MB [22]. In terms of mechanisms, our study showed for the first time a 
functional role for LIFR in medulloblastoma. The therapeutic potential 
of targeting LIFR in medulloblastoma is underlined by the fact that its 
down-regulation by siRNA impaired cell growth in a similar magnitude 
as PIK3CA down-regulation. Confirming these observations, a 
monoclonal antibody against LIFR-α has demonstrated to have 
inhibitory effects on medulloblastoma survival and proliferation. 
Being a downstream effector of the famous oncogenes and outcome 
predictors p110α and c-Myc in medulloblastoma, LIFR definitely 
represents an interesting target for further analysis. In the first instance, 
more MB cell lines could be tested, in order to identify a subgroup of 
responding MB cells. Also the combination with chemotherapies or 
PI3K inhibitors could be analyzed for synergistic effects. If successful, 
these studies could initiate the development of novel strategies to target 
LIFR in vivo and hopefully later also applied in clinical settings. 
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The use of large-scale approaches in NB and MB allowed us to the 
identification of novel target genes. In neuroblastoma, the potential of 
combining FGFR2 inhibition with chemotherapy was presented. In 
medulloblastoma, LIFR was identified as an important regulator of cell 
survival downstream of p110α/c-Myc. Further studies focused on the 
therapeutic potential of FGFR2 and LIFR would be definitely of great 
interest. Nevertheless, only FGFR2 and LIFR have been validated from 
our screens. The high throughput techniques used in this work allowed 
the generation of an amount of data, from which other interesting 
candidate genes could be validated. Such studies would also contribute 
to our knowledge of the molecular mechanisms undergoing in MB and 
NB. Building a solid knowledge about the complexity of the signalling 
networks in cancer cells will hopefully one day provide us the 
appropriate tools to combat this devastating disease. 
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Abstract 
Brain tumors comprise a wide variety of neoplasia classified according 
to their cellular origin and their morphological and histological 
characteristics. The transformed phenotype of brain tumor cells has 
been extensively studied in the past years, achieving a significant 
progress in our understanding of the molecular pathways leading to 
tumorigenesis. It has been reported that the phosphoinositide 3-kinase 
(PI3K)/AKT signalling pathway is frequently altered in grade IV brain 
tumors resulting in uncontrolled cell growth, survival, proliferation, 
angiogenesis and migration. This aberrant activation can be explained 
by oncogenic mutations in key components of the pathway or through 
abnormalities in its regulation. These alterations include 
overexpression and mutations of receptor tyrosine kinases (RTKs), 
mutations and deletions of the phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) tumor suppressor gene, encoding a 
lipid kinase that directly antagonized PI3K activity, and alterations in 
Ras signalling. Due to promising results of preclinical studies 
investigating the PI3K/AKT pathway in grade IV brain tumors like 
glioblastoma and medulloblastoma, the components of this pathway 
have emerged as promising therapeutic targets to treat these malignant 
brain tumors. Although an arsenal of small molecule inhibitors that 
target specific components of this signalling pathway are being 
developed, its successful application in the clinics remains a challenge. 
In this article we will review the molecular basis of the PI3K/AKT 
signalling pathway in malignant brain tumors, mainly focusing on 
glioblastoma and medulloblastoma, and we will further discuss the 
current status and potential of molecular targeted therapies. 
 
Keywords: 
AKT, clinical trial, glioblastoma, medulloblastoma, mTOR, 
phosphoinositide 3-kinase, PTEN 
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INTRODUCTION 
Grade IV Brain Tumors – Glioblastoma and Medulloblastoma 
Malignant brain tumors represent a large diversity of neoplasms with 
an incidence of 7.2 cases per 100’000 persons per year in the United 
States (between the years 2004 and 2006) [1]. These tumors can be 
classified according to their cellular origin, histology and morphology. 
According to the 2007 World Health Organization classification, the 
main classes of tumors of the central nervous system are tumors of 
neuroepithelial tissue, tumors of cranial and paraspinal nerves, tumors 
of the meninges, lymphomas and haematopoietic neoplasms, tumors of 
the sellar region and metastatic tumors [2]. Among others, the group of 
neuroepithelial tissue tumors includes astrocytic tumors like 
glioblastoma, the most common malignant brain tumor in adults (age 
45-84 years), and embryonal tumors like medulloblastoma, the most 
common malignant brain tumor in early childhood (age 0-4 years) [1-
2]. 
The broad category of glioma includes astrocytoma, glioblastoma, 
oligodendroglioma and others, and accounts for 32% of all brain 
tumors [1]. These tumors arise from glial cells, which are non-neuronal 
cells that provide support and nutrients to the neurons. Grade I tumors 
(e.g. pilocytic astrocytoma) and grade II tumors (e.g. 
oligodendroglioma) are considered as low-grade brain tumors, whereas 
grade III tumors (e.g. anaplastic astrocytoma) and grade IV tumors 
(e.g. glioblastoma) are classified as high-grade malignant brain tumors. 
Even though low-grade brain tumors generally possess more favorable 
characteristics concerning treatment possibilities and patient survival, 
they can still be lethal by progressing to higher grades of malignancy 
(e.g. low-grade diffuse astrocytoma can transform to anaplastic 
astrocytoma and glioblastoma) [2]. Gliomas account for 80% of 
malignant brain tumors, with the highly heterogeneous and highly 
infiltrating glioblastoma representing the largest and most-malignant 
subgroup (54% of gliomas) [1]. Regarding younger patients, gliomas 
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represent 55%, 40% and 34% of all brain tumors and 71%, 74% and 
82% of malignant brain tumors in young children (age 0-14 years), 
adolescents (age 15-19 years) and young adults (age 20-34 years), 
respectively [1]. Glioblastoma can arise as de novo primary tumors, 
predominantly in older adults, or as secondary tumors that have 
developed over a period of several years from low-grade tumors, which 
occur predominantly in younger adults and are much less common than 
primary glioblastomas [3-4]. Both tumor types are morphologically and 
clinically indistinguishable [5], but show distinguishable gene 
alterations: primary glioblastoma are mainly characterized by 
overexpression or mutation of the epidermal growth factor receptor 
(EGFR), deletions and mutations in the phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN) and p16 deletions [6-8], 
whereas secondary glioblastoma usually carry p53 gene alterations and 
overexpression of platelet-derived growth factor receptor (PDGFR) [9]. 
Pediatric high-grade gliomas appear to be biologically and clinically 
distinct from adult high-grade gliomas, but show genetic alterations 
that are more similar to adult primary glioblastoma than adult 
secondary glioblastoma. Compared to high-grade gliomas in adults, 
EGFR amplification and mutation, PTEN mutations and p53 alterations 
is relatively rare in high-grade gliomas in children [10-12]. However, 
just as in adult high-grade gliomas, PDGFR amplification was 
observed to similar extends and appeared to be mutually exclusive with 
EGFR amplification [10-11]. Quite contrary to this observation, 
PDGFRA has been shown to be the predominant target of focal 
amplification in pediatric high-grade gliomas [13], representing a 
useful marker in the distinction between high-grade gliomas in children 
and adults, and a possible therapeutic target. The standard treatment of 
glioblastoma includes surgical resection, radiotherapy and 
chemotherapy. Surgical resection is difficult due to the highly 
infiltrative nature of glioblastoma, rendering complete resection 
impossible [4]. After resection, state-of-the-art glioblastoma treatment 
consists of radiotherapy in combination with temozolomide treatment, 
leading to a median increase in survival of 2.5 months compared to 
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radiotherapy alone, and a median time to progression after treatment of 
6.9 months [14]. An important marker in respect to temozolomide 
treatment is the O
6
-methylguanine-DNA methyltransferase (MGMT) 
protein, a DNA repair enzyme that can repair DNA damages caused by 
DNA alkylating agents like temozolomide [15]. Significant survival 
benefits have been observed for patients carrying methylation of the 
MGMT promoter, which results in gene silencing [16]. Despite 
aggressive treatment, almost all glioblastoma eventually recur – 90% at 
the original site [4]. The median survival of low-grade astrocytoma 
patients is 5 years, but most patients die due to progression to high-
grade astrocytoma, whereas the median survival for glioblastoma 
patients is one year [3]. 
Embryonal tumors, including medulloblastoma, are thought to arise 
from fetal or embryonal tissue due to alterations in normal 
developmental processes [17]. As mentioned above, medulloblastoma 
is the most common postnatal malignant brain tumor (children of 0-4 
years) [1] and is considered as a grade IV malignant brain tumor [2]. 
These tumors can be further subdivided into classes of classic 
medulloblastoma, desmoplastic medulloblastoma, medulloblastoma 
with extensive nodularity, anaplastic medulloblastoma and large cell 
medulloblastoma [2]. Medulloblstoma account for 13% of all brain 
tumors in children younger than 14 years old [1] and mostly arise in the 
cerebellum [18]. After birth, the cerebellum is the only region in the 
brain that shows high rates of cell division, especially high 
proliferation of granule cell precursors [18], which is regulated by 
sonic hedgehog (SHH) signalling [19-20]. Therefore, genetic 
alterations in medulloblastoma include deregulations of the SHH 
signalling pathway [21-26], such as heterozygous loss of SHH receptor 
patched 1 (PTCH1) gene, alterations in the wnt signalling pathway [27-
30], as well as c-Myc gene amplification and c-Myc mRNA 
overexpression [21]. Historically, medulloblastoma patients have been 
stratified into standard-risk and high-risk patients according to clinical 
factors. Patients older than three years of age with no evidence of 
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metastasis to other organs and none or small residual tumor post 
operation are considered as standard-risk patients, whereas patients 
who do not meet these criteria and show anaplastic histology are 
considered as high-risk patients [31]. Over the last decade, it became 
evident that stratification according to clinical parameters and histology 
alone is not sufficient to clearly decide on the most successful 
treatment. Further investigations led to the discovery of different 
molecular markers, which are better suitable for risk stratification and 
outcome prediction. These factors include for example TrkC 
expression and c-Myc mRNA expression [32], c-Myc amplification 
[33], overexpression of human epidermal growth factor receptor 2 [34], 
nuclear β-catenin and survivin expression [35], DNA copy-number 
aberrations of chromosomes 6q and 17q [36] and genes encoding for 
members of the histone deacetylase family (HDAC5 and HDAC9) [37]. 
Standard treatment of medulloblastoma includes surgical resection 
followed by chemotherapy and radiotherapy. Compared to earlier 
treatments, today’s treatments use lower doses of radiation by 
combination with different chemotherapeutic regimens [38-43], which 
is especially helpful for young patients since radiation therapy can 
cause deleterious side effects on the developing brain. This kind of 
combinational therapy as medulloblastoma treatment increases the 5-
year event-free survival to 75% [44], even though almost half of the 
high-risk medulloblastoma patients die from tumor recurrence [45]. 
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PI3K/AKT Signalling Pathway 
The phosphoinositide 3-kinase (PI3K) pathway regulates several 
cellular processes such as cell survival, proliferation, growth, apoptosis 
and cytoskeletal rearrangement (reviewed in [46]). PI3Ks represent a 
family of protein and lipid kinases, which are divided into three classes 
(I-III) according to their sequence homology and in vitro lipid substrate 
specificity [47]. Class I PI3Ks are able to catalyze the phosphorylation 
of phosphoinositol (PI) on the inner leafted of the cell membrane. The 
main substrate of class I PI3Ks in cells is phosphatidylinositol-4,5-
bisphosphate (PIP2). Thus, class I PI3K activation leads to PIP2 
phosphorylation and results in the accumulation of 
phosphatidylinositol-3,4,5-trisphosphate (PIP3). Class I PI3K isoforms 
are further subdivided into two subgroups, depending on the receptors 
by which they are regulated. While class IA binds to receptor tyrosine 
kinases (RTKs), class IB is exclusively activated by G protein-coupled 
receptors [47-49]. Class IA PI3Ks are heterodimers consisting of a p110 
catalytic and a p85 regulatory subunit. The p110 catalytic subunits 
p110α, p110β and p110δ, which are encoded by PIK3CA, PIK3CB and 
PIK3CD, respectively, are highly homologous isoforms. PIK3R1, 
PIK3R2 and PIK3R3 encode the p85 isoforms which share a core 
structure that includes two Src homology 2 (SH2) domains and a p110 
binding domain named inter-SH2 domain [50]. The adaptor subunit 
p85 is crucial for the activation of p110 by RTKs. Activation of the 
p85-p110 complex occurs either through direct interaction of the SH2 
domain of p85 with phosphotyrosine residues on the RTK or through 
the adaptor proteins insulin receptor substrate 1 and 2 (IRS1 and IRS2) 
that couple to activated RTKs [51-52]. Class IA PI3K can also be 
activated by the small GTPase Ras, through its Ras binding domain. 
This is of great importance, since oncogenic mutations in Ras lead to 
the constitutive activation of the PI3K signalling pathway. Similarly to 
class IA, class IB isoforms consist of a regulatory p101, p84 or 
p87PIKAP and a catalytic subunit p110γ.  
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There are three distinct class II PI3K isoforms: PI3KC2α, PI3KC2β 
and PI3KC2γ. In contrast to class I PI3K isoforms, they consist of only 
a single catalytic subunit and are able to catalyze the formation of 
phosphatidylinositol-3-monophosphate (PIP) and PIP2, but not PIP3. 
Although it is known that they are activated by RTKs, cytokine 
receptors and integrins, the consequences of this activation are not well 
understood [47]. Class III PI3Ks consist of a single member Vsp34, 
which can only phosphorylate the inositol ring of PI to PIP [47]. To 
date, there is much more published evidence about the role of class IA 
PI3K in tumorgenesis. Therefore, it appears to have the most relevant 
function in this aspect within the PI3K family. Especially the class IA 
PI3K p110α has become the focus of attention in the cancer research 
field over the past decade.  
Activation of class IA PI3Ks occurs upon ligand-mediated 
phosphorylation of different RTKs, such as insulin-like growth factor 
receptor 1 (IGF-1R), vascular endothelial growth factor receptor 
(VEGFR), EGFR or PDGFR in response to growth factor stimulation 
[53]. As a consequence, PIP3 is generated and acts as a second 
messenger supporting the recruitment of the serine/threonine kinase 
AKT to the plasma membrane by binding to its pleckstrin homology 
domain [54-55] and activating several pathways downstream of AKT, 
as described below. PIP3 levels in the cell are controlled by PI3K 
activity and by the lipid phosphatase PTEN, a 3-position phosphatase 
that converts PIP3 back to PIP2 [56-57]. These control mechanisms 
have antagonizing effects leading either to AKT activation or 
deactivation. PTEN is crucial for the regulation of the PI3K/AKT 
pathway, since there is no other related protein that compensates its 
loss of function. PTEN dysfunctions have been implicated in a wide 
range of cancer types, highlighting the importance of PTEN for the 
proper regulation of cell growth and proliferation [58]. 
Full activation of AKT is further achieved through phosphorylation of 
Thr308 by PDK1 and of Ser473 by the rapamycin-insensitive mTOR 
complex 2 (mTORC2) [59-62]. AKT represents a central node in the 
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intracellular signalling networks. Once activated, AKT phosphorylates 
numerous targets starting a series of signalling cascades involved in 
diverse cellular functions (see Fig. (1)).  
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Fig. (1). Schematic representation of the PI3K/AKT signalling pathway. RTKs, 
EGFR and IGF-1R, are activated by autophosphorylation in response to growth factor 
binding. Upon activation of RTK, the Grb2-SOS complex binds to the receptor 
initiating the ERK pathway. On the other hand PI3K’s regulatory subunit p85 
dimerizes with its catalytic subunit p110. PI3K, when activated, catalizes the 
phosphorylation of PIP3 on the cell membrane, which binds subsequently to the PH 
domain of AKT. AKT phosphorylation is negatively regulated by the tumor 
suppressor PTEN. The recruitment of AKT to the cell membrane enables its 
phosphorylation by PDK1 and mTORC2. Following AKT activation, it initiates the 
activation of a cascade of protein kinases, involved in the regulation of cell growth, 
cell proliferation and apoptosis. 
 
AKT inhibits apoptosis by direct phosphorylation of BAD [63], 
caspase-9 [64] and FKHR [65]. Inhibition of FKHR nuclear 
translocation prevents the activation of proapoptotic factors, such as 
Fas-Ligand and TRAIL. Additionally, AKT inhibits p53 dependent cell 
death by phosphorylation of MDM2 [66]. Besides the regulation of the 
anti-apoptotic pathway, AKT promotes cell cycle progression by the 
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inhibition of glycogen synthase kinase-3β (GSK-3β), leading to the 
accumulation of cyclin D1 via myc [67]. 
AKT also promotes cell growth by activation of the rapamycin-
sensitive complex mTORC1 [68]. AKT phosphorylates the tuberous 
sclerosis complex 2 (TSC2) protein tuberin, inhibiting the ability of the 
TSC1-TSC2 complex to prevent Rheb activation [69-70]. This allows 
the activation of the mTORC1 complex, which in turn phosphorylates 
two regulators of protein translation and ribosomal biogenesis: p70 
ribosomal S6 kinase (S6K) and eukaryotic translation initiation factor 
4E-binding protein 1 (4E-BP1) [71-72]. S6K phosphorylates the S6 
protein of the small 40-S ribosomal subunit, ultimately leading to 
ribosome formation and thus protein synthesis. Phosphorylation of 4E-
BP1 releases eIF4E, which subsequently forms complexes with several 
other initiation factors which control protein translation. mTOR is of 
special interest, since it is able to associate with two alternative 
partners, called raptor and rictor [62, 68, 72]. It operates in two places 
of the circuity, upstream of AKT as an mTOR-rictor complex 
(mTORC2) and downstream as an mTOR-raptor complex (mTORC1). 
This dual function gives mTOR powerful position in the cell. Hence, 
mTOR is able to regulate cell survival and proliferation by controlling 
AKT activity and cell growth by regulation of S6K and 4E-BP1 
phosphorylation. 
The importance of the PI3K/AKT signalling pathway in cancer is 
supported by the extensive evidence of deregulation of several 
components of the pathway in a wide spectrum of human cancers. 
Genetic analysis of human tumor samples performed over the past two 
decades have identified gain-of-function mutations and amplification in 
RTKs such as EGFR, PDGFR and IGF-1R [73-77], both leading to 
constitutively activated receptor signalling in cancer cells. Aberrant 
activation of the PI3K/AKT pathway can also occur through oncogenic 
mutations in the different PI3K isoforms. Mutations in the PI3K 
regulatory subunit p85 include deletions in the inter SH2 domain, 
which leads to PI3K activation independent of RTK signalling [78]. 
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Genetic amplification or mutation of PIK3CA was identified in breast, 
colon, glioma, ovarian, gastric and cervical tumors [79-85] which 
makes p110α one of the most frequently mutated kinases in all tumor 
types [86]. Oncogenic mutations in all three AKT isoforms are also 
often observed in human cancers. While somatic mutations are more 
frequent in AKT1, gene amplification is mostly found in AKT2 [87]. 
One of the most significant evidence of the involvement of PI3K 
signalling in cancer stems from studies of the PTEN gene. PTEN was 
first identified as a tumor suppressor gene in glioblastomas and breast 
cancer [58, 88] and was later widely implicated in various cancer types. 
PTEN inactivation occurs through several mechanisms such as loss of 
heterozygosity, loss of function mutations or through epigenetic 
silencing. PTEN is after p53, the second most commonly mutated 
tumor suppressor gene in cancer [89]. Further evidence of mutational 
studies indicates that PIP3 phosphatase activity is responsible for the 
tumor-suppressor function of PTEN [56, 90], suggesting a key role of 
PIP3 levels in carcinogenesis. 
In this review, we will describe the role of key players of the 
PI3K/AKT pathway in the development of malignant brain tumors. 
Recent studies investigating the expression and alterations in this pro-
survival signalling pathway will be summarized, while mainly focusing 
on the different PI3K isoforms and their antagonist PTEN. Further, we 
will discuss the progress made in the development of targeted therapies 
for the treatment of grade IV brain tumors. Emphasis will be put on 
pharmacological inhibitors against the pathway components EGFR, 
class IA PI3K isoforms and mTOR. The different strategies to inhibit 
the pathway and the design of combinational therapies will be 
evaluated. Finally, we will discuss the future potential of inhibitors of 
the PI3K/AKT signalling pathway, as well as their issues and 
limitations as a novel anticancer strategy. 
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ALTERATIONS AND FUNCTIONS OF PI3K/AKT 
SIGNALLING PATHWAY COMPONENTS IN GRADE IV 
BRAIN TUMORS 
Alterations in the pro-survival PI3K/AKT signalling pathway have 
been reported in a number of cancers, including cancers of the central 
nervous system. The most prominent genes altered include RTKs, 
mainly EGFR and its truncated version EGFRvIII, PTEN and PIK3CA, 
the gene encoding the catalytic subunit p110α of the class IA PI3Ks. 
The focus of the discussion in this chapter is on alterations of the 
different PI3K isoforms and their antagonist PTEN. Alterations in 
EGFR in malignant brain tumors have been extensively reviewed 
previously [91-97] and would be beyond the scope of this review. 
Most of the investigations concerning alterations in PI3K/AKT 
signalling in brain tumors have been performed with patient samples 
from glioblastoma, the most common and most malignant tumor of the 
central nervous system in adults. On the contrary, relatively few data 
are available in medulloblastoma, the most common malignant brain 
tumor in early childhood. An overview of the genetic alterations of 
major components of the PI3K/AKT pathway in these two tumor types 
is given in Fig. (2). This figure also indicates the percentage of 
glioblastoma and medulloblastoma tumor samples showing the 
corresponding gene alterations. The original studies reporting these 
data will be discussed below.  
An investigation using general expression profiling in glioblastoma 
samples by cDNA microarrays determined that most of the genes 
altered in this type of cancer are involved in cell adhesion, signal 
transduction, cell cycle, apoptosis and angiogenesis [98]. 
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Fig. (2). Alterations in the PI3K/AKT signalling pathway in the most common 
malignant brain tumors of adults and young children, glioblastoma (left) and 
medulloblastoma (right), respectively. Percent of alterations detected in tumor 
samples are indicated. (a): [99-101, 133, 139], (b): [79, 81, 99-101, 118, 133, 139], 
(c): [58, 79, 99-101, 118, 139], (d): [103-104], (e): [79, 81], (f): [104-106]. 
 
The first study, that specifically investigated the genetic alterations in 
components of the PI3K/AKT signalling pathway in glioblastoma 
tumor samples, revealed genetic alterations in PTEN (loss of 
expression or homozygous deletion) and EGFR (gene amplification) in 
about one third of the patients [99]. Additionally, differential mRNA 
overexpression of the catalytic PI3K isoforms was detected [99]. An 
integrated analysis of 22 human glioblastoma samples by Parsons et al. 
revealed that alterations of genes of the PI3K/AKT pathway occur in 
around 50% of glioblastomas, including alterations in EGFR (37%), 
PTEN (30%), PIK3CA (10%) and PIK3R1 (8%) [100]. 
The first comprehensive genomic characterization of 206 human 
glioblastoma samples was performed by The Cancer Genome Atlas 
(TCGA) Research Network and defined the pro-survival PI3K/AKT 
signalling pathway as one of the three core pathways in this cancer 
type, harboring at least one genetic event in 88% of glioblastoma tumor 
samples [101]. The other two core pathways defined by TCGA were 
the p53 signalling and the retinoblastoma (pRB) signalling pathways, 
which were found to be altered in 87% and 78% of glioblastoma 
samples, respectively [101]. Additionally, it has been observed that 
about three quarters of glioblastoma samples harbored alterations in all 
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three core pathways, suggesting that the deregulation of these pathways 
is a core requirement of glioblastoma pathogenesis [101]. 
An alternative way of investigating core pathways and driver genes in 
glioblastoma was performed by Cerami et al. using an automated 
network-based approach [102]. Taking into account that cellular 
networks contain functional modules and that tumors usually target 
specific modules that are critical for their growth, they used part of the 
original data created by TCGA as a starting point [102]. With this 
method they were able to identify many of the same driver gene 
candidates as the original TCGA approach (among these were EGFR, 
PTEN, CDK4 and MDM2), defining the PIK3R1 module as the largest 
and most densely interconnected network [102]. Additionally, their 
modules corresponded very closely to the three original TCGA core 
pathways and to the findings of the study by Parsons et al. 
As mentioned above, studies on gene alterations in the PI3K/AKT 
signalling pathway in medulloblastoma are rare. Similar to 
observations in glioblastoma, these studies show alterations in PTEN 
and EGFR [103-105]. A study focusing on medulloblastoma revealed 
that activation of the PI3K/AKT signalling pathway is an important 
element of medulloblastoma cell proliferation and suggested that this 
activation probably represents a common event in medulloblastoma 
pathogenesis [106]. The authors argued that AKT activation is due to 
significantly reduced expression of PTEN mRNA and PTEN protein, 
rather than to mutations or homozygous deletions in the PTEN gene 
[106]. Another report, taking a closer look at PI3K signalling and the 
different PI3K isoforms in medulloblastoma, revealed that especially 
the catalytic subunit p110α is significantly upregulated in 
medulloblastoma samples compared to normal cerebellum [107]. This 
gives further evidence for the importance of PI3K/AKT signalling in 
medulloblastoma pathogenesis. 
 
 REVIEW ARTICLE 
171 
PTEN 
Besides alterations in EGFR, mutation or loss of heterozygosity at 
chromosome 10q23 is a highly common phenomenon in cancers of the 
brain, especially in glioblastoma. The first description of the PTEN 
gene, which is located at this chromosome position, was performed by 
Li et al. [58]. The authors identified the PTEN protein as a protein 
tyrosine phosphatase and postulated that it acts as a tumor suppressor 
by antagonizing the action of PI3Ks. Further, PTEN mutations were 
commonly detected in primary glioblastomas (17-20% [58, 108]) but 
rarely in lower grade gliomas, postulating that mutations in this tumor 
suppressor arise rather late in tumorigenesis. 
Cell culture experiments revealed several important functions of 
PTEN’s lipid phosphatase activity in cell signalling, proliferation and 
survival. Next to the tumor suppressor function of PTEN, it was shown 
that loss of PTEN and expression of EGFRvIII act synergistically in the 
transformation of neural precursor cells, which induce tumors that 
resemble human glioblastomas [109]. Specifically, these cells were less 
dependent on epidermal growth factor (EGF) and insulin, showed 
increased migration and invasion, decreased susceptibility to apoptosis 
and enhanced formation of neurosperes and colonies in soft agar [109]. 
Not only has the lipid phosphatase activity of PTEN, which counteracts 
PI3K activity, been shown to play an important role in tumor cells, but 
also the protein phosphatase activity of PTEN has been linked to be 
involved in tumor cell functions. It has been shown that the protein and 
lipid phosphatase activities of PTEN are both required to suppress 
invasion, whereas either activity alone was sufficient to significantly 
inhibit proliferation [110]. Investigations on migrating glioma cells 
showed that integrin-dependent migration of these cells is regulated by 
the protein phosphatase activity of PTEN, but is independent of its lipid 
phosphatase function [111]. This integrin-dependent migration was 
independent of PI3K and AKT activity and the authors suggested that it 
is rather mediated by the action of the protein phosphatase of PTEN on 
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Src family kinase activity and downstream RAC1 GTPase activity 
[111]. Further, mutations in PTEN in glioblastoma cell lines have been 
shown to be associated with decreased radiosensitivity and sensitivity 
to temozolomide, which could be restored by introducing wild-type 
PTEN into these cells [112]. It was also suggested that PTEN has the 
capacity to induce the transcriptional activity of p53 in the tumor and 
stromal compartment, thereby suppressing the tumor-induced 
angiogenic response of glioblastoma cells in vivo [113]. It was 
proposed that the two tumor suppressor genes PTEN and p53 are 
located on the same signalling axis and coordinate the control of 
growth and angiogenesis in brain tumor cells [113]. 
Supporting results that were obtained from cell culture experiments, 
analysis of glioblastoma patient samples showed that loss of tumor 
suppressor protein PTEN is highly correlated with expression levels of 
phosphorylated AKT and AKT activity [114-115]. Additionally, it was 
found that activation of AKT is significantly correlated with levels of 
phosphorylated mTOR, activation of the family of Forkhead 
transcription factors and ribosomal protein S6 phosphorylation [114]. 
A significant inverse correlation was determined between PTEN 
protein expression and glioma grade, showing significantly decreased 
PTEN expression in grade IV glioblastomas compared to lower grade 
gliomas and non-tumor brain tissue [116]. Additionally, a significant 
correlation between PTEN protein expression and the survival time of 
glioblastoma patients was detected [115], favoring patients with PTEN 
expression. 
PTEN promoter methylation might serve as a marker to distinguish 
between different grades of gliomas. It was shown that methylation of 
the PTEN promoter was common in grade II and III astrocytomas, 
oligodendrogliomas, oligoastrocytomas and secondary glioblastomas, 
whereas it was rarely detected in primary glioblastomas and not 
detected at all in non-tumor brain samples [117]. This gives further 
evidence to the evolution of secondary glioblastoma from lower grade 
gliomas, indicating that secondary glioblastomas would share some 
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characteristics like their low-grade precursors. It was speculated that 
PI3K activation via PTEN alteration is different in primary than in 
secondary glioblastomas: promoter methylation and loss of 
heterozygosity of PTEN might be the mechanisms in secondary 
glioblastoma, whereas mutation plus methylation or loss of 
heterozygosity plus methylation might be the mechanisms in primary 
glioblastomas [117]. Further speculation about the PI3K/AKT 
signalling pathway activation in secondary glioblastoma includes the 
possibility of PIK3CA gain-of-function mutations rather than PTEN 
mutations [79]. PTEN mutations are commonly found in primary 
glioblastomas and are rather uncommon in secondary glioblastomas, 
whereas it appears to be the opposite for mutations in PIK3CA: no 
PTEN mutations were found in tumors with mutations in PIK3CA [79]. 
This might indicate that mutations in PTEN and PIK3CA are mutually 
exclusive in malignant glioma. 
In primary medulloblastoma samples, it was observed that PTEN 
mRNA expression was significantly lower when compared to normal 
cerebellar tissue, independently of medulloblastoma histological 
subtype. In addition, PTEN protein was not detectable by 
immunohistochemical staining in medulloblastoma samples when 
compared to control tissue [106]. PTEN mRNA was detected in all 
medulloblastoma cell lines investigated and indicates that homozygous 
deletion of PTEN does not seem to be a common mechanism in 
medulloblastoma [106]. Rather, the authors reported that 50% of the 
samples harbor PTEN promoter methylation, suggesting that alterations 
in transcription may be involved in PTEN regulation that leads to 
activation of the PI3K/AKT signalling pathway [106]. On the contrary, 
a different study found that the PTEN protein was expressed at higher 
levels in medulloblastoma samples and cell lines as compared to 
control samples [107]. 
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PIK3CA and Genes Encoding other PI3K Isoforms 
As mentioned above, differential mRNA expression levels of PI3K 
isoforms have been detected in one of the first investigations of 
alterations in the PI3K/AKT signalling pathway in glioblastoma. Gene 
amplification of PIK3C2B (6%) but not of PIK3CD and PIK3CA was 
detected, while over-expression of PIK3CD mRNA (6%) was present 
[99]. Differential levels of the different class IA PI3K isoforms have 
also been detected in medulloblastoma patient samples. Significant 
overexpression of PIK3CA gene in medulloblastoma tumor samples 
was found compared with normal cerebellum, whereas no significant 
differences in expression was observed for the remaining class IA PI3K 
isoforms (catalytic and regulatory subunits) [107]. Compared to normal 
brain tissue, protein overexpression of the PI3K catalytic isoform 
p110α was observed in human medulloblastoma samples (74%) as well 
as high basal expression of phosphorylated AKT and phosphorylated 
ribosomal protein S6 [107]. It was shown that PI3K p110α promotes 
medulloblastoma cell survival, activates signalling through AKT, is 
important in protecting medulloblastoma cells against chemotherapy-
induced cell death and supports the migratory capacity of these cells 
[107]. 
Mutations in the PIK3CA gene in brain tumor samples have been 
reported in different studies and to different extents. A first 
investigation by Samuels et al. in 2004 found high frequencies of 
PIK3CA mutations in human cancers, including glioblastoma (27%), 
but no mutations in medulloblastoma samples [81]. On the contrary, 
mutations in the PIK3CA gene were detected in only 5% of 
glioblastoma samples, as well as in 5% of medulloblastoma patient 
samples, using a large scale mutational analysis of different brain 
tumor types by Broderick et al. [79]. The differences in the percentage 
numbers between these two studies might be due to the fact that in the 
first study, the whole PIK3CA gene was investigated, whereas in the 
latter study only exons 9 and 20 – encoding for the helical and catalytic 
domain, respectively – of the gene were investigated. However, 
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Samuels et al. observed that most of the mutations in PIK3CA were 
clustered in the helical and catalytic domain [81]. Nevertheless, both 
studies reached the conclusion that PIK3CA mutations occur late in 
tumorigenesis, since PIK3CA mutations have been shown in late stage 
colon cancer [81] and more frequently in secondary glioblastoma than 
in primary glioblastoma [79]. Interestingly, it has been stated by 
Broderick et al. that no significant PIK3CA gene amplification or 
increase in gene expression was detected in glioblastoma and 
medulloblastoma samples [79]. This suggests that the higher activation 
of PI3K p110α in brain tumors is not due to gene amplification or 
overexpression but rather results from mutations in the PIK3CA gene. 
A third study, by Hartmann et al. [118], examined all coding exons of 
the PIK3CA gene and observed mutations in 7% of glioblastoma 
patient samples, rather giving support to the study by Broderick et al. 
The authors also showed that the detected mutations clustered together 
in specific regions of the gene. Apart from malignant brain tumors, this 
effect has also been observed in other human cancer types [80, 119-
124] and gives further support to the concept of somatic “hot spot” 
mutations. It was demonstrated, that the “hot spot” mutant PIK3CA 
H1047R (catalytic domain) conferred more lipid kinase activity in 
immunoprecipitated PI3K complexes than the wild-type protein [81], 
suggesting that the catalytic isoform p110α functions as an oncogene in 
human cancers. This observation was further supported by other 
research groups and in other cancer types, showing that the conserved 
“hot spot” mutations in PIK3CA are indeed able to increase kinase 
activity and that they possess oncogenic potential [81, 122, 125-130]. 
As already observed by Broderick et al., PIK3CA and PTEN mutations 
seem to be mutually exclusive, because tumors harboring mutations in 
PIK3CA show a lack of mutations in PTEN [79, 118]. Therefore, it can 
be speculated that mutations in PIK3CA provide an alternative 
mechanism to activate PI3K/AKT signalling. However, as mentioned 
before, PIK3CA mutations appear at relatively low rates and might 
thus, compared to PTEN, play only a minor role in glioblastoma 
pathogenesis. 
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The crystal structure of the adaptor-binding domain of the catalytic 
p110α isoform (bovine) in complex with the inter-Scr homology 2 
(iSH2) domain of the regulatory PI3K p85α isoform (human) was 
recently solved by Miled et al. [131] and led to a model of the 
mechanism of PI3K p110α activation by mutations in PIK3CA. The 
authors found three cancer-specific mutations that were located in the 
adaptor-binding domain, but none of these residues was located at the 
interface between the PI3K p110α adaptor-binding domain and the 
PI3K p85α iSH2 domain [131]. It was rather observed that there was a 
highly conserved adaptor-binding domain surface patch outside this 
conserved interface, where two of these mutations were located and 
represented a plausible docking site for other domains of the complex 
[131]. Mutations in this surface patch may reorient the adaptor subunit 
or even change the orientation of the enzyme on the membrane [131]. 
Increased PI3K p110α activity probably results from a destruction of 
charge-charge interactions between the PI3K p110α and PI3K p85α 
subunits, which is caused by mutations in the helical domain of PI3K 
p110α and results in the inability of a minimal PI3K p85α fragment to 
inhibit PI3K p110α’s catalytic activity [131]. 
A more recent determination of the crystal structure of PI3K p110α (all 
five domains) in complex with PI3K p85α (only N-terminal SH2 and 
iSH2 domains) by Huang et al. [132] made it possible to determine the 
effects of PIK3CA mutations in all PI3K p110α domains. The surface 
patch of the adaptor-binding domain mentioned above was shown to be 
in hydrogen-bonding distance with residues of the PI3K p110α kinase 
domain, suggesting that mutations in this patch might result in 
conformational changes of the kinase domain, which would probably 
alter enzymatic activity [132]. Another cancer-specific mutation 
location in the C2 domain of PI3K p110α was shown to be within 
hydrogen bonding distance of the PI3K p85α iSH2 domain residues, 
suggesting that this mutation may disrupt the interaction between these 
two domains and would presumably alter the regulatory effect of p85α 
on p110α [132]. “Hot spot” mutations in the helical domain cause a 
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charge reversal and, consistent with Miled et al., presumably abrogate 
the inhibitory effect of the p85α nSH2 domain by modifying the 
orientation of the p85α nSH2 domain to the helical and kinase domains 
of p110α [132]. Alterations in the kinase domain of PI3K p110α, like 
the “hot spot” mutant PIK3CA H1047R, most likely have a direct effect 
on the conformation of the activation loop and would therefore change 
the interaction with PI substrates [132].  
Somatic alterations in PIK3R1 have been much less frequently reported 
than alterations in PIK3CA, and consist of truncations and deletions or 
mutations in the iSH2 domain [101, 132]. The first report of an 
alteration in the regulatory PI3K p85α subunit gene has been reported 
by Mizoguchi et al., namely a 9-base pair deletion, along with frequent 
balanced copy number increases of both PIK3CA and PIK3CD [133]. 
The alterations in PIK3R1 result in the destabilization of the PI3K p85α 
iSH2 domain, which is important for the contact with the PI3K p110α 
C2 domain [132]. These mutations would therefore relieve the 
inhibitory effect of PI3K p85α on PI3K p110α and seem to have 
equivalent effects as mutations in the p110α C2 domain. PI3K p85α 
regulatory subunit mutants, with mutations in the iSH2 domain but 
intact p110-binding site, do not affect the stabilization of the p110 
subunits but impair the ability of p85α to negatively regulate p110 
isoform activity, leading to promotion of cell survival and anchorage-
independent growth, as well as to increased levels of phosphorylated 
AKT when compared to wild-type PI3K p85α cells (in a PI3K p110-
activity-dependent manner) [134]. It has also been shown that these 
mutant PI3K p85α/p110(α/β or δ) holoenzymes can be effectively 
inhibited by p110(α/β or δ) inhibitors, indicating that pan-p110 
inhibitors are likely to be efficacious in patients with PI3K p85α 
mutations [134]. 
As can be seen above, most of the studies on PI3K alterations in brain 
tumors have been focusing on class IA PI3K ioforms, especially PI3K 
p110α. Isoforms of class II PI3Ks have not been studied that 
intensively, but PI3KC2β has lately been detected to possibly play an 
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important role in glioblastoma resistance to erlotinib, an EGFR tyrosine 
kinase inhibitor. It has been demonstrated that the expression of 
PIK3C2B gene correlated significantly with glioblastoma cellular 
resistance towards erlotinib [135], and PI3KC2β might therefore as 
well represent a possible therapeutic target in glioblastoma. 
The PI3K/AKT signalling pathway has also been linked to other 
important features of gliomas, such as radioresistance, migration and 
clinical outcome. For example, glioblastoma cell lines with activated 
AKT due to loss of PTEN expression have been shown to be more 
resistant against radiation therapy after serum starvation [136]. PI3K 
activity has also been shown to be necessary for AKT activation in 
actively migrating glioblastoma cells, where phosphorylated AKT was 
mainly located at the leading edge of the migrating cells [137]. When 
migration was suppressed in glioma cells, the cells were more prone to 
apoptosis, suggesting that the suppression of apoptosis by PI3K 
activation is accompanied by the acquisition of migration [137]. 
Components of the PI3K/AKT signalling pathway have also been 
shown to correlate well with proliferating glioma cells and tumor grade 
of human gliomas (AKT2 [138]), and clinical outcome of patients with 
glioblastoma (PIK3CD [98]). Another gene related to the PI3K/AKT 
signalling pathway is PIKE and it was shown to be amplified in 12%-
19% of glioblastoma samples [102, 139]. PIKE is a PI3K enhancer, 
which binds to and enhances AKT kinase activity in a GTP-dependent 
manner [140]. This gene was shown to be co-amplified with the 
adjacent CDK4 gene in primary glioblastoma samples [139] and has 
additionally been identified to be part of the PIK3R1 module in the 
automated network analysis by Cerami et al. [102]. This indicates that 
PIKE represents a putative oncogene and an activator of the PI3K/AKT 
signalling pathway. 
Overall, genetic alterations in PI3K subunit genes seem to occur in 
human glioblastoma at a lower rate than originally suspected and they 
are much less common than alterations in the PTEN gene. 
Nevertheless, they represent a PTEN deregulation-independent 
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alternative mechanism for the activation of the PI3K/AKT signalling 
pathway and render the different PI3K isoforms as potential clinical 
targets. 
 
TARGETING THE PI3K/AKT SIGNALLING PATHWAY IN 
GRADE IV BRAIN TUMORS 
Due to the relatively high incidence of alterations in PI3K/AKT 
signalling in cancer, this pathway represents an attractive target for the 
treatment of malignant brain tumors. As has been discussed above, 
PI3K/AKT pathway activation occurs through different mechanisms, 
involving EGFR overactivation by amplification or mutation, gain-of-
function mutations in PIK3CA, as well as loss-of-function of PTEN 
tumor suppressor gene. Consequently, activation of the PI3K signalling 
network appears to be an obligatory event in glioblastoma progression. 
It seems feasible that counteracting the effects of PTEN loss and/or 
EGFR overactivation in brain tumors can have therapeutic advantages. 
Indeed, a few studies have shown that re-expression of PTEN inhibits 
the growth and transforming ability of glioma cells, and sensitizes them 
to chemotherapeutic agents such as etoposide [141-142]. Restoration of 
PTEN expression in PTEN null cells is not a clinically applicable 
approach at present. Instead, small molecule inhibitors targeting the 
components of the PI3K/AKT signalling pathway represent a more 
promising strategy. Importantly, it has been shown in a recent study 
that patients with heavily-pretreated, diverse, advanced cancers and 
PIK3CA mutations display significantly higher response rates to 
treatment with inhibitors targeting the PI3K/AKT signalling pathway 
than patients without PIK3CA mutations [143]. An overview of small 
molecule inhibitors of the PI3K/AKT signalling pathway that are 
currently used in clinical trials are shown in Fig. (3) and Fig (4), 
indicating their corresponding point of action and their chemical 
structure, respectively. 
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Fig. (3). Overview of small molecule inhibitors targeting the PI3K/AKT signalling 
pathway. The components EGFR, PI3K, AKT and mTOR are considered as potential 
therapeutic targeting sites in the pathway. 
 
EGFR Inhibitors 
EGFR mutation and amplification represent the most prominent genetic 
alterations in malignant brain tumors and identified this RTK as a 
suitable target for the treatment of this type of tumor. The use of small 
molecule inhibitors that target the EGFR generated great excitement in 
the first instance. Currently, the EGFR tyrosine kinase inhibitors 
gefitinib and erlotinib are being tested in a number of clinical trials [95, 
144-153]. Although these drugs were well tolerated by patients, clinical 
responses have been disappointing and rarely durable. Combinatorial 
treatments of EGFR inhibitors with chemotherapy and/or radiotherapy 
have yielded better, although still modest results. An overview of 
ongoing clinical trials in the different types of brain tumors is 
summarized in Table 2 (information in this table has been retrieved 
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from [154]). The poor responses to EGFR inhibition can be partly 
explained, by the fact that mutations in PTEN or in PIK3CA effectively 
uncouple EGFR from PI3K/AKT signalling. This hypothesis is 
supported by a few studies. Work by Mellinghoff et al. analyzed the 
response of 49 patients with recurrent malignant gliomas to EGFR 
inhibition in correlation with the expression of EGFR, its constitutively 
active mutant EGFRvIII and PTEN. This study demonstrated that 
expression of EGFRvIII sensitized tumors to EGFR inhibitors, only if 
PTEN was intact [155]. Similar results were obtained in an animal 
xenograft model, which showed that erlotinib-sensitive glioblastoma 
xenografts shared the following molecular characteristics: wild-type 
PTEN and increased EGFR expression [156]. A subsequent study 
performed in a cohort of 41 glioma patients found that response to 
erlotinib was associated with high EGFR expression levels and low 
phosphorylation levels of AKT [146]. None of the patients whose 
tumors had high levels of activated AKT responded to erlotinib. 
Further studies by Fan et al. showed that EGFR signalling through 
PI3K, in particular through mTOR, is critical for mediating the tumor 
cell response to EGFR inhibitors [157]. Together, these findings 
highlight the importance of an intact PI3K regulation in the 
responsiveness of tumors to EGFR inhibitors. Targeting signalling 
components downstream of EGFR might therefore offer a more 
efficient strategy to inhibit cell survival. 
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Fig. (4). Chemical structures of small molecule inhibitors targeting the PI3K/AKT 
signalling pathway. Structures were obtained from [174, 188, 206-207, 213, 220, 227-
233]. 
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Table 2. Ongoing clinical trials in brain tumors. Information about clinical 
trials has been retrieved from [154]. 
 
EGFR inhibitors in clinical trials 
Drug Targets Patient group 
Pha
se 
State Trial ID Ref. 
Erlotinib 
EGFR GBM II completed NCT00337883  
EGFR 
Glioblastoma,  
other solid tumors 
I completed NCT00030498 [148] 
EGFR GBM I, II completed NCT00045110 [149] 
EGFR 
GBM, Anaplastic Astrocyt
oma, Anaplastic Oligodend
roglioma, Glioblastoma, 
Gliosarcoma,  
Mixed Glioma 
I recruiting NCT01103375  
EGFR GBM II unknown NCT00086879  
EGFR GBM I unknown NCT00227032  
EGFR 
GBM, Anaplastic 
Astrocytoma 
I, II recruiting NCT00301418  
EGFR GBM II unknown NCT00054496  
Gefitinib 
EGFR GBM II completed NCT00250887  
EGFR GBM II completed NCT00014170 [153] 
EGFR GBM II completed NCT00016991 [151] 
EGFR malignant CNS tumors II completed NCT00025675 [152] 
Nimotuzumab EGFR GBM II completed NCT00561873  
BIBW 2992 HER2 
brain tumors,  
metastasis in brain 
II completed NCT00875433  
Lapatinib 
HER2 GBM II completed NCT00099060  
HER2 Glioblastoma, Gliosarcoma I, II completed NCT00103129  
Combination therapy 
Erlotinib + 
bevacizumab 
EGFR + 
VEGF 
Glioblastoma, Gliosarcoma II ongoing NCT00671970  
Erlotinib + 
radiation 
EGFR low-, high-grade glioma I, II ongoing NCT00124657  
Erlotinib + 
sorafenib 
EGFR +  
Raf-1, 
VEGFR, 
PDGFR 
GBM II completed NCT00445588  
Erlotinib + 
temozolomide
, radiation 
EGFR GBM II ongoing NCT00274833  
EGFR Glioblastoma, Gliosarcoma II ongoing NCT00039494  
EGFR Glioblastoma, Gliosarcoma II unknown NCT00187486  
Erlotinib + 
bevacizumab, 
radiation, 
temozolomide 
EGFR + 
VEGF 
Glioblastoma, Gliosarcoma II recruiting NCT00720356  
Erlotinib + 
dasatinib 
EGFR +  
SCR, ABL 
GBM I unknown NCT00609999  
Gefitinib + 
irinotecan 
EGFR 
Medulloblastoma, 
Glioblastoma 
I recruiting NCT00132158  
Gefitinib + 
radiation 
EGFR GBM II completed NCT00238797 [234] 
EGFR GBM I, II unknown NCT00052208  
Gefitinib + EGFR malignant primary glioma I completed NCT00027625  
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temozolomide 
Cetuximab + 
temozolomide
, radiation 
EGFR malignant glioma I, II unknown NCT00311857  
Cetuximab + 
bevazicumab, 
irinotecan 
EGFR +  
VEGF 
malignant glioma II completed NCT00463073  
Nimotuzumab 
+ 
temozolomide
, radiation 
EGFR GBM III ongoing NCT00753246  
BIBW 2992 + 
temozolomide
, radiation 
HER2 Glioblastoma I recruiting NCT00977431  
BIBW 2992 + 
temozolomide 
HER2 GBM II ongoing NCT00727506  
Panitumab + 
Irinotecan 
EGFR GBM II recruiting NCT01017653  
mTOR inhibitors in clinical trials 
Drug Targets Patient group 
Pha
se 
State Trial ID Ref. 
AP23573 mTORC1 
Glioblastoma,  
malignant CNS tumors 
I completed NCT00087451  
CCI-779 
(Temsirolimu
s) 
mTORC1 GBM II completed NCT00016328 [163] 
mTORC1 GBM I, II completed NCT00022724 [162] 
RAD-001 
(Everolimus) 
mTORC1 GBM, Astrocytoma II 
terminate
d 
NCT00515086  
Rapamycin 
(Sirolimus) 
mTORC1 GBM I, II ongoing NCT00509431  
mTORC1 GBM I, II completed NCT00047073 [167] 
Combination therapy 
CCI-779 + 
doxorubicin 
mTORC1 
Glioblastoma,  
malignant solid tumors 
I ongoing NCT00703625  
mTORC1 
Glioblastoma,  
malignant solid tumors 
I ongoing NCT00703170  
CCI-779 +  
erlotinib 
mTORC1 + 
EGFR 
Glioblastoma, Gliosarcoma I, II ongoing NCT00335764  
CCI-779 + 
vandetanib 
mTORC1 GBM I ongoing NCT00112736  
CCI-779 +  
radiation 
mTORC1 Glioblastoma II recruiting NCT01019434  
CCI-779 +  
sorafenib 
mTORC1 GBM I, II recruiting NCT00329719  
CCI-779 + 
temozolomide 
mTORC1 brain tumors I completed NCT00784914  
CCI-779 + 
temozolomide
, radiation 
mTORC1 GBM I ongoing NCT00316849  
RAD-001 + 
radiation 
mTORC1 GBM I, II recruiting NCT01062399  
RAD-001 + 
temozolomide 
mTORC1 GBM I ongoing NCT00387400  
RAD-001 + mTORC1 Glioblastoma I, II recruiting NCT00553150 [235] 
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temozolomide
, radiation 
RAD-001 + 
temozolomide
, radiation, 
bevacitumab 
mTORC1 + 
VEGF 
Glioblastoma II ongoing NCT00805961  
RAD-001 +  
AEE788 
mTORC1 + 
EGFR, 
VEGFR 
GBM I, II unknown NCT00107237  
RAD-001 +  
gefitinib 
mTORC1 + 
EGFR 
GBM I, II unknown NCT00085566  
RAD-001 +  
gleevec, 
hydroxyurea 
mTORC1 + 
PDGFR,  
BCR-Abl 
Glioblastoma, Gliosarcoma I unknown NCT00613132  
Rapamycin + 
erlotinib 
mTORC1 + 
EGFR 
Glioblastoma, Gliosarcoma II completed NCT00672243  
Rapamycin + 
vandetanib 
mTORC1 + 
VEGFR2 
GBM I recruiting NCT00821080  
PI3K inhibitors in clinical trials 
Drug Targets Patient group 
Pha
se 
State Trial ID Ref. 
PX-866 pan PI3K Glioblastoma II recruiting NCT01259869  
BKM120 pan-PI3K Glioblastoma II recruiting NCT01339052  
XL-147 pan-PI3K Glioblastoma I recruiting NCT01240460  
PKI-179 
PI3K, class 
IA 
malignant solid tumors I 
terminate
d 
NCT00997360  
PKI-587 
PI3K, class 
IA 
mTORC1 
mTORC2 
Glioblastoma I recruiting NCT00940498  
Combination therapy 
XL-765 + 
temozolomide 
PI3K, class 
IA 
mTORC1 
mTORC2 
Glioblastoma I recruiting NCT00704080  
BKM120 + 
bevacizumab 
pan-PI3K, 
VEGF 
GBM I/II 
not yet 
recruiting 
NCT01349660  
AKT inhibitors in clinical trials 
Drug Targets Patient group 
Pha
se 
State Trial ID Ref. 
Perifosine AKT malignant glioma II ongoing NCT00590954  
Combination therapy 
Perifosine +  
CCI-779 
AKT + 
mTORC1 
GBM I, II recruiting NCT01051557  
Perifosine +  
CCI-779 
AKT + 
mTORC1 
medulloblastoma, pediatric 
solid tumors 
I recruiting NCT01049841  
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mTOR Inhibitors 
The most extensively used drugs that target mTOR are rapamycin 
(sirolimus) and its analogs, CCI-779 (temsirolimus) and RAD-001 
(everolimus). Numerous studies have demonstrated the efficacy of 
mTOR inhibitors in in vitro and in vivo models (reviewed in [158-
159]). Unfortunately, clinical studies could not reproduce the 
promising results of these drugs in laboratory models in the treatment 
of glioma patients [160-163]. Considering that cancer cells favor the 
accumulation of multiple genetic alterations, several resistance 
mechanisms may be present. Therefore, single agent treatments are 
unlikely to have an impact on overall tumor progression. For example, 
it has been found that rapamycin leads to an activation of ERK1/2 and 
MEK1/2 in glioblastoma, while the combined inhibition of MEK1/2 
and mTOR leads to significantly suppressed cell proliferation 
compared to mTOR inhibition alone. These observations suggest that 
the limited benefit of rapamycin and its analogs can be explained by a 
feedback between mTOR and MAPK signalling [164]. The failure of 
EGFR inhibitors to impact on mTOR signalling in glioma suggested a 
rationale to combine inhibitors of EGFR and mTOR. Preclinical studies 
confirmed this hypothesis providing evidence that inhibitors of EGFR 
and mTOR had synergistic anti-tumor effects in glioblastoma [160, 
165]. One of the first completed clinical trials reported by Reardon et 
al. aimed at investigating the anti-tumor effects of gefitinib and 
sirolimus in patients with recurrent malignant glioma. While only 6% 
of the patients achieved a partial response, 38% achieved stable disease 
[166]. Similar results were reported by Doherty et al. The 
combinatorial treatment of gefitinib or erlotinib with sirolimus led to a 
partial response in 19% of the patients and a six-month progression-
free survival of 25% [161]. This combinational approach was only 
efficient in a subgroup of patients, highlighting the importance of 
patient stratification based on molecular characteristics of the tumor. 
A subsequent phase I clinical trial aimed at analyzing responses of 
glioblastoma patients to rapamycin treatment in dependence of the 
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molecular features of the tumors [167]. Rapamycin was able to 
significantly inhibit mTOR activity within tumors in a subset of 
patients and this correlated with reduced proliferation. Surprisingly, in 
half of the patients rapamycin led to a shorter time to tumor 
progression, which correlated with increased levels of phosphorylated 
AKT. This effect can be in part explained because mTOR inhibition by 
rapamycin not only leads to inactivation of mTORC1 dependent cell 
growth signalling, but also suppresses negative feedback loops, that 
attenuate PI3K signalling in response to mTORC1 activation. Among 
them, activation of S6K by mTORC1 initiates a feedback mechanism 
by which S6K directly phosphorylates IRS1 causing its inactivation 
and consequently, decreasing AKT activation. Thus, rapamycin 
treatment results in mTORC1-mediated S6K inactivation and thereby 
loss of feedback inhibition that leads to reconstitution of AKT 
activation, explaining the observed increase in tumor cell survival 
[167-168]. Secondly, inhibition of mTORC1 by rapamycin does not 
efficiently induce dephosphorylation of 4E-BP1 in most cellular 
contexts [169]. Rapamycin does not have the same affinity for 
mTORC2 as for mTORC1 [170]. As mentioned above, mTORC2 
directly phosphorylates AKT promoting its activation. At low 
rapamycin concentrations, mTORC2 complexes stay uninhibited and 
may become hyperactive, contributing to AKT activation [171-172]. 
In order to overcome these limitations, a new generation of ATP-
competitive active site mTOR inhibitors is under development. 
Contrary to rapamycin and its analogs, which inhibit mTOR through 
allosteric interactions, active site mTOR inhibitors target the catalytic 
site of both mTORC1 and mTORC2 (reviewed in [158]). Several 
independent studies are currently proving the anti-proliferative 
capacities of the different active site mTOR inhibitors, with the 
expectation that targeting both mTOR complexes, downstream and 
upstream of AKT, will have a more dramatic effect on carcinogenesis. 
It has been published that active site mTOR inhibitors more potently 
inhibit cell growth, cell cycle progression and protein translation in 
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several cell lines compared to rapamycin and its analogues [171, 173-
176]. Furthermore, active site mTOR inhibitors strongly inhibit 4E-
BP1 phosphorylation. An exciting recent study showed that PP242, an 
active site mTOR inhibitor, has a strong anti-tumor effect in T-cell 
lymphomagenesis in vivo with no noticeable toxicity. This effect was 
mediated through inhibition of mTORC1-dependent 4EBP-eIF4E 
hyperactivation [177]. Although there are no published studies about 
the effects of ATP-competitive active site mTOR inhibitors in brain 
tumors yet, great expectations for their anti-proliferative potential have 
emerged from the successful results in other cancer types. 
A note-worthy disadvantage of active site mTOR inhibitors is that they 
do not overcome the problematic loss of feedback inhibition of AKT 
observed after rapamycin-mediated mTORC1 inhibition. Any type of 
inhibition of mTORC1 will disrupt the negative feedback mechanisms. 
Targeting specifically mTORC2 could thereby be a better approach, 
since it would not only directly block AKT phophorylation, moreover 
it would not perturb the mTORC1-dependent feedback loops. Although 
specific mTORC2 inhibitors do not exist yet, it is speculated that they 
could have good therapeutic responses [170]. 
Another promising approach to efficiently block abnormal activation of 
the PI3K/AKT pathway is targeting components upstream of mTOR. 
For example, simultaneous targeting of mTOR and AKT in 
glioblastoma cells has been shown to efficiently downregulate the 
PI3K signalling pathway activation. Furthermore, this combination 
resulted in decreased cell proliferation and increased cell death in in 
vivo and in vitro experiments, independent of the PTEN-status [178]. 
As will be discussed further below, a class of kinase inhibitors with 
dual specificity against PI3K and mTOR was shown to have strong 
anti-tumor effects in several cancer types, including brain tumors 
(reviewed in [179]). 
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AKT Inhibitors 
AKT is a central node in the complex network of signalling pathways 
[53] and its role has been extensively investigated in many cancer types 
[180]. In vivo studies have shown the importance of AKT signalling for 
glioblastoma maintenance in the context of activated Ras, as expression 
of AKT negatively correlated with increased survival of glioblastoma 
tumor-bearing mice [181]. Although there are few preclinical reports 
about the pharmacological targeting of AKT in brain tumors, there is 
evidence that inhibition of AKT has anti-proliferative and 
radiosensitizing effects [182-185]. In the glioma cell lines U87MG and 
U251, inhibition of AKT by KP-372-1 and KP-372-2 resulted in cell 
growth inhibition through the induction of apoptosis [182]. Consistent 
with this finding, AKT was shown to have a protective role in TRAIL-
induced apoptosis [183]. The small molecule AKT inhibitor A-443654 
recently showed strong anti-tumor effects in vivo and in vitro, it 
significantly extended survival rates in a rat intracranial model of 
glioblastoma compared to control animals [184]. The radiosensitizing 
potential of AKT inhibitors has been demonstrated by several studies 
[109, 186-187]. It was shown that ionizing radiation induced AKT 
activation in a group of glioblastoma cell lines. AKT inhibitors 
increased the radiosensitivity in these cells, suggesting that AKT is 
activated as part of a feedback mechanism mediating radioresistance 
[109]. 
One of the most prominent AKT inhibitor is probably perifosine, a 
lipid-based AKT inhibitor that interacts with the pleckstrin homology 
domain of AKT preventing its translocation to the plasma membrane. 
Perifosine is currently being tested in a series of clinical trials in 
different cancers (reviewed in [188-189]). Although perifosine was 
generally well-tolerated by patients, tumor response was variable 
between different cancer types. While in sarcoma and waldenstrom 
macroglobulinemia patients perifosine showed anti-tumor activity as 
single agent, the efficacy of perifosine in patients with other solid 
malignancies was rather modest. In  medulloblastoma and glioblastoma 
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cells perifosine was recently shown to inhibit cell growth by different 
independent preclinical studies [190-192]. In medulloblastoma cell 
lines, perifosine treatment led to suppression of AKT phosphorylation 
in a time-dependent and dose-dependent manner, ultimately resulting 
in cell death [191]. The combination of perifosine with sublethal doses 
of etoposide or irradiation showed additive effects in medulloblastoma 
cells. Perifosine also showed an impact on a glioblastoma xenograft 
model, where it substantially reduced phosphorylated AKT levels, 
inhibited tumor growth rate and had synergistic anti-proliferative effect 
in combination with temozolomide [190, 193]. Clinical studies are now 
recruiting glioblastoma patients for the treatment with perifosine as 
single agent and in combination with mTOR inhibitors, with the hope 
to reproduce the preclinical data (see Table 1). 
PI3K Inhibitors 
Early studies investigating the molecular targeting of PI3K in human 
brain tumors used the first generation of pan-PI3K inhibitors 
wortmannin and LY-294002. It was reported that PI3K inhibitors 
impair cell growth, cell migration and invasiveness in malignant 
astrocytoma, glioblastoma and medulloblastoma cell lines [106-107, 
194-197]. Furthermore, PI3K inhibition sensitized glioma cells to 
radiation-induced cytotoxicity and showed a synergistic effect with 
chemotherapeutic agents [196, 198-200]. Despite their efficacy as 
single agents, both LY-294002 and wortmannin are restricted to 
preclinical studies because of their toxic side effects, poor 
pharmacological properties and lack of selectivity [201-202]. However, 
they represent useful research tools that have improved our 
understanding of the role of PI3K in cancer biology and gave rise to the 
development of a new generation of PI3K inhibitors with better 
pharmacological properties and isoform-selectivity [203-205]. 
PWT-458 and PX-866, which are both pan-PI3K inhibitors, have 
emerged as potential therapeutic candidates because of their improved 
stabilities and reduced toxicities [206-207]. PWT-458 is a pegylated 
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derivate of wortmannin, which releases its active moiety 17-
hydroxywortmannin, upon in vivo cleveage of its polyethylenglycol 
backbone. The pharmacological effect of PWT-458 in solid tumors was 
analyzed in preclinical settings [207]. Treatment of nude mouse 
xenografts with PWT-458 resulted in complete loss of AKT (Ser473) 
phosphorylation, demonstrating its efficacy in blocking the PI3K/AKT 
signalling pathway in vivo. PWT-458 showed potential anti-tumor 
activity as single-agent in xenograft models of U87MG glioma, non-
small cell lung cancer and renal cell carcinoma. Additionally, in 
U87MG tumors, PWT-458 augmented the anti-tumoral efficacy of a 
suboptimal dose of paclitaxel. PX-866, another wortmannin derivate, 
showed potent inhibitory effects on the PI3K pathway in glioblastoma 
in vitro and in vivo [208-209]. PX-866 inhibited tumor growth in 
glioblastoma xenografts and increased the median survival time of the 
animals [208]. Combinations of PX-866 with BBR3610, a potent 
polynuclear platinum compound, resulted in synergistic cell growth 
inhibition in glioma cells in vitro and prolonged survival rates in an 
orthotopic xenograft model [209]. Because of its promising anti-tumor 
effects and its acceptable side effects shown in preclinical and clinical 
studies, PX-866 is presently entering Phase II clinical trials for the 
treatment of glioblastoma (see Table 2). 
One of the first reports using a pharmacological approach to define 
specific PI3K family members critical for cell proliferation in glioma 
identified PI3K p110α as the functionally most important isoform 
[210]. A panel of 10 structurally unrelated isoform-selective p110 
inhibitors was screened in six glioblastoma cell lines. Only inhibitors 
against PI3K p110α, PIK-90 and PI-103, induced a proliferative arrest. 
Despite the ability of inhibitors of PI3K p110β, p110δ and p110γ to 
block PI3K signalling through AKT phosphorylation, none of these 
compounds showed any inhibitory effects on cell growth. Remarkably, 
PI-103 was highly effective against glioma xenografts with no 
observable toxicities. The activity of PI-103 was ascribed to its ability 
to selectively block PI3K p110α and mTOR, suggesting that 
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combinational inhibition of PI3K p110α and mTOR is an effective 
therapy in malignant glioma. These results are consistent with a 
previous study that demonstrated that the cooperative blockade of PI3K 
and mTOR signalling impacts on autophagy in glioma cells [211]. 
Further work performed by Fan et al. showed that PI-103 significantly 
augmented the anti-proliferative effects of EGFR inhibition by erlotinib 
in PTEN mutant glioma cells [212]. This finding was of great 
importance, since previous studies reported that erlotinib was only able 
to block proliferation in PTEN wild-type, but not in PTEN mutant cells 
[155-156]. These results provide a noteworthy therapeutic rationale for 
targeting EGFR, PI3K p110α and mTOR in a combinational approach 
for the treatment of PTEN mutant tumors. 
A subsequent study sought to identify the radiosensitizing potential of 
PI3K p110 isoform-selective inhibitors [213]. In further support of the 
importance of PI3K p110α in glioblastoma biology, only inhibition of 
PI3K p110α by PIK-90 and especially by PI-103 resulted in 
sensitization of glioblastoma cells to radiotherapy. Combinations of PI-
103 with ionizing radiation led to a significant reduction of tumor 
growth rate in glioblastoma xenografts. PIK-108, a PI3K p110β 
inhibitor, failed to inhibit cell proliferation either alone or in 
combination with radiation, although it was able to reduce AKT 
phosphorylation. This study indicated that PI3K p110α plays a key role 
in the PI3K/AKT survival pathway, whereas PI3K p110β plays a more 
restricted role. Consistent with the aforementioned reports, this study 
supports the therapeutic potential of cooperatively targeting PI3K 
p110α and mTOR. Beside its radiosensitizing potential, PI-103 was 
demonstrated to sensitize glioblastoma cells to chemotherapy-induced 
cell death by the inhibition of DNA repair mediated by DNA-
dependent protein kinase [214]. This recently published study showed 
for the first time that PI-103 chemosensitized glioblastoma stem cells 
and primary cultured glioblastoma cells to doxorubicin treatment, 
underscoring its clinical relevance. Together, these reports provide a 
rationale to overcome chemo- and radioresitance in glioblastoma. In 
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order to investigate tumor responses to PI-103 and to find possible 
biomarkers for target inhibition, a recent study monitored the effects of 
PI-103 by magnetic resonance spectroscopy (MRS). Phosphocholine 
levels were significantly decreased after PI-103 treatment of PTEN null 
prostate cells and PIK3CA mutant colon carcinoma cells, which 
correlated with ChoKα expression. Hereby, MRS detectable changes in 
lipid biosynthesis were identified as potential biomarkers for PI-103 
mediated response [215]. 
In medulloblastoma, the PI3K isoform p110α was also shown to be the 
most important class IA PI3K isoform in the control of cell growth and 
survival [107]. Downregulation by RNA interference, as well as 
pharmacological inhibition of PI3K p110α led to a decrease in cell 
proliferation and augmented the effects of chemotherapy in a cell line 
model. None of the inhibitors against the other isoforms, PI3K p110β 
or p110δ, showed a comparable effect. Recently, the gene encoding 
class IB PI3K isoform p110γ, PIK3CG, has been found to be 
overexpressed in primary medulloblastoma tumor samples and cell 
lines. Furthermore, this isoform has been identified to contribute to 
cisplatin resistance, emerging as a novel target for combinatorial 
treatments in medulloblastoma [216]. In vivo studies in 
medulloblastoma xenografts showed that treatment with OSU03012 
(PDK1 inhibitor) reduced tumor size and augmented the anti-tumor 
effects of CCI-779 (mTOR inhibitor) [217]. These findings suggest that 
dual-targeting of the PI3K/mTOR axis could be a more promising 
approach than single agent treatment in medulloblastoma, as has been 
indicated previously in glioblastoma. 
It is not surprising that the dual targeting of PI3K and mTOR shows 
enhanced effects compared to single-agent treatment. As mentioned 
before, inhibitors of mTORC1 cause loss of feedback inhibition of 
PI3K activation in certain cell types, resulting in drug resistance. 
Consequently, inhibiting PI3K simultaneously with mTOR will block 
this feedback activation of PI3K and will therefore efficiently attenuate 
the PI3K/AKT/mTOR signalling cascade. In support of this notion, 
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dual PI3K-mTOR inhibitors are active site ATP-competitors, which 
target structurally related kinase domains of both PI3K and mTOR 
(reviewed in [179]). As previously discussed for active site mTOR 
inhibitors, this class of drugs demonstrated a more efficient inhibition 
of cell growth than rapamycin because of its ability to block the 
formation of both mTOR complexes, mTORC1 and mTORC2 [158]. 
The success achieved by dual targeting of PI3K and mTOR to inhibit 
tumor growth has generated great excitement for the production of new 
inhibitors. PKI-402, a potent dual inhibitor that targets class I PI3K, 
including PIK3CA mutants, and mTOR, showed impressive results in 
preclinical settings [218]. It showed anti-proliferative effects in many 
cell lines from breast, pancreas, non-small lung cancer and brain 
tumors. In vivo, PKI-402 reduced tumor volume in breast (MDA-MB-
361) xenografts and inhibited tumor growth in glioma (U87MG) and 
lung (A549) xenograft models. Importantly, PKI-402 showed minimal 
effects on AKT phosphorylation in normal tissue, offering a therapeutic 
advantage. 
In terms of a clinical perspective, a novel orally available dual PI3K-
mTOR inhibitor with favorable pharmaceutical properties was 
developed by Novartis [219-220]. The imidazoquinazoline NVP-
BEZ235 selectively inhibits class I PI3Ks, with higher affinity for 
p110α, p110δ and p110γ and mTOR. Several studies investigated the 
anti-tumor potential of NVP-BEZ235 in a wide range of human tumor 
cell lines and xenografts, including multiple myeloma, sarcoma, 
pancreatic cancer, breast cancer and prostate cancer [179, 218, 221-
224]. NVP-BEZ235 exhibited a broad anti-tumor activity and was well 
tolerated when administrated orally in in vivo studies. In addition, 
NVP-BEZ235 was shown to synergize with chemotherapeutic agents, 
such as doxorubicin. The potential therapeutic advantage of NVP-
BEZ235 is further emphasized by the fact that it also has antitumor 
effects in cells bearing PIK3CA mutations, PIK3R1 mutations, HER2 
amplifications and PTEN loss [179, 221, 224]. In brain tumors, NVP-
BEZ235 also demonstrated anti-tumor potential. Preclinical studies 
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showed that NVP-BEZ235 inhibits tumor growth in PTEN null 
glioblastoma xenografts as a single agent [220]. The results of the 
combination of NVP-BEZ235 with temozolomide were even more 
impressive, leading to regression of the tumors. Further studies on the 
mechanisms of action showed that NVP-BEZ235 suppressed glioma 
cell proliferation by efficiently inhibiting the activity of AKT and S6K, 
as well as the phosphorylation of ribosomal protein S6 and 4E-BP1 
[225]. NVP-BEZ235 induced G1 cell cycle arrest and autophagy in 
glioma cells. Moreover, this study showed that NVP-BEZ235 impacts 
on angiogenesis, since the expression of vascular endothelial growth 
factor was significantly decreased upon NVP-BEZ235 treatment. 
Because in vitro experiments could be reproduced in vivo in animal 
models with similar results, this report strongly suggests NVP-BEZ235 
as a candidate for the treatment of glioblastoma and other advanced 
cancers. Therefore, NVP-BEZ235 has entered phase I and II clinical 
trials in patients with malignant solid tumors. Based on the successful 
results obtained from targeting the PI3K/mTOR axis in preclinical 
studies, two further dual PI3K-mTOR inhibitors, PKI-587 and XL-765, 
have recently entered phase I clinical trials for the treatment of 
malignant gliomas. Both studies are currently recruiting patients (see 
Table 2). It had previously been reported from in vitro and in vivo 
studies that XL-765 shows favourable activity as monotherapy as well 
as in combination with temozolomide in a range of genetically diverse 
glioma xenografts [226]. 
In summary, inhibitors of the PI3K/AKT signalling pathway were 
shown to impair typical brain tumor cell properties, such as extensive 
cell proliferation, resistance to apoptosis, cell migration and 
invasiveness. It remains to be elucidated which kind of inhibitor is the 
most appropriate for a given cancer type. Identification of biomarkers 
to predict drug sensitivity would substantially facilitate the choice of a 
specific therapy to successfully treat defined groups of patients. For 
instance, tumors that are sensitive to EGFR inhibitors are PTEN wild 
type [155]. Those who present loss-of-function in PTEN display 
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resistance to EGFR inhibitors, because PI3K/AKT signalling is 
uncoupled from EGFR control [212]. For the latter type of tumors dual 
PI3K-mTOR inhibitors might be an alternative, as single agents or in 
combination with EGFR inhibitors. In cancers with PIK3CA mutations, 
isoform-specific inhibitors against PI3K p110α might be more 
effective. However, it cannot be ruled out that the non-targeted PI3K 
isoforms will compensate the lack of activity of the inhibited isoform. 
It is not clear yet whether non-selective pan-inhibitors offer better 
clinical benefits, because they may show additional toxicities due to 
broad inhibition of all isoforms. Moreover, it is plausible that single-
agent PI3K/AKT pathway inhibitors have limited efficacy, because of 
the presence of multiple genetic alterations and feedback mechanisms 
found in cancer cells. It is therefore not surprising that combinatorial 
approaches may result in more promising results. An improved 
understanding of the complexity of the signalling networks inside 
tumor cells and their mechanisms of adaptation to compensate the 
effects caused by different targeted therapies will hopefully guide the 
development of new strategies for the treatment of brain tumors in the 
future. 
 
FINAL CONSIDERATIONS AND PERSPECTIVES 
Despite aggressive treatment including surgical resection, followed by 
chemotherapy and/or radiotherapy, the survival rates of patients with 
grade IV brain tumors is still very low, e.g. one year for glioblastoma 
patients. Additionally, this intensive treatment can cause severe side 
effects. Components of the pro-survival PI3K/AKT signalling pathway 
have been shown to be commonly altered in these tumors and seem to 
play an important role in the pathogenesis of malignant brain tumors. 
Inhibitors specific for single components of the PI3K/AKT pathway 
are able to affect brain tumor cells in vitro and in vivo by reducing cell 
proliferation, cell migration and invasion properties. Further, these 
inhibitors represent a useful tool in discovering the molecular biology 
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of brain tumors. In clinical trials, however, single inhibitor therapy has 
not shown highly convincing results so far. This can at least in part be 
explained by the fact that in vitro and in vivo models can rarely 
represent the vast genetic heterogeneity of tumors occurring in patients. 
Due to this wide spectrum of mutations in tumors with the same origin, 
it is not surprising that patients respond differently to a given treatment. 
For instance, a recent study has characterized the genetic features of 
advanced tumors and shown that tumors bearing PIK3CA mutations 
but not mutations in KRAS or BRAF respond to therapy targeting the 
PI3K/AKT signalling pathway. Patients with tumors bearing mutations 
in BRAF and KRAS did not respond to PI3K/AKT targeted therapy, 
indicating the presence of resistance mechanisms against this treatment 
approach [143]. Sequencing cancer genome studies will therefore be 
helpful to better characterize the average number of driving mutations 
involved in tumor formation and to gain further insights into the 
complex ability of tumor cells to develop resistance mechanisms to 
different treatment strategies. For example, resistance to radiotherapy 
and chemotherapy is a very common problem in glioblastoma. 
Additionally, resistance to protein kinase inhibitors most frequently 
involves mutations in gatekeeper residue of the kinase, which controls 
access to the affinity pockets in which most of the inhibitors bind. The 
multiple mechanisms leading to acquired resistance are very complex 
and point out the need for further studies to discover mechanistic 
insights and feedback loops leading to drug resistance. It has generally 
been observed in the clinic that multi-targeting therapies have a more 
potent effect than single-agent therapies and thus probably represent 
the more promising approach for satisfying patient responses. These 
therapies can involve different strategies: targeting multiple 
components in the same pro-survival signalling pathway, targeting 
multiple components in different signalling pathways or combining 
specific inhibitors with other treatment strategies like chemotherapy 
(inducing DNA damage or abolishing DNA repair mechanisms) and 
radiotherapy (inducing DNA damage). However, it remains 
challenging to predict which combinations are the most accurate for the 
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treatment of certain subtypes of cancer. Further studies will lead to 
deeper insight into the exact molecular and cellular mechanisms of 
malignant brain tumors and will help to develop future treatment 
modalities, including the discovery of potential diagnostic markers and 
the achievement of personalized medicine. 
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ABBREVIATIONS 
4E-BP1 = Eukaryotic translation initiation factor 4E-binding protein 
1 
BAD = BCL2-associated death promoter 
EGF = Epidermal growth factor 
EGFR = Epidermal growth factor receptor 
FKHR = Forkhead box O1 
GBM = Glioblastoma multiforme 
GSK-3β = Glycogen synthase kinase 3 beta 
IGF-1R = Insulin-like growth factor 1 receptor 
IRS1 = Insulin receptor substrate 1 
IRS2 = Insulin receptor substrate 2 
iSH2  = Inter-Src homology 2 
MGMT = O
6
-methylguanine-DNA methyltransferase 
MRS = magnetic resonance spectroscopy 
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mTOR = Mammalian target of rapamycin 
mTORC1 = Mammalian target of rapamycin complex 1, mTOR  
complex with raptor 
mTORC2 = Mammalian target of rapamycin complex 2, mTOR 
complex with rictor 
nSH2  = N-terminal Src homology 2 
PDGFR = Platelet-derived growth factor receptor 
PDK1 = 3-phosphoinositide-dependent protein kinase 1 
PI3K = Phosphoinositide 3-kinase, phosphatidylinositol 3-kinase, 
PI 3-kinase 
PI = Phosphatidylinositol 
PIP = Phosphatidylinositol-5-monophosphate 
PIP2 = Phosphatidylinositol-4,5-bisphosphate 
PIP3 = Phosphatidylinositol-3,4,5-trisphosphate 
PTEN = Phosphatase and tensin homologue deleted on 
chromosome 10 
RTK = Receptor tyrosine kinase 
S6K = p70 ribosomal S6 kinase; ribosomal protein S6 kinase, 
70kDa, polypeptide 1 
SHH = Sonic hedgehog 
TCGA = The Cancer Genome Atlas 
TSC1 = Tuberous sclerosis complex 1 
TSC2 = Tuberous sclerosis complex 2 
VEGFR = Vascular endothelial growth factor receptor 
Vsp34 = Vacuolar protein-orting defective 34 
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